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Abstract 
Fabry (FD) and Gaucher (GD) disease are lysosomal storage disorders, caused by single 
enzyme deficiencies on the glycosphingolipid degradation pathway as a result of genetic 
mutations in the GLA and GBA genes respectively.  These result in a functional enzyme 
deficiency within the lysosome and accumulation of un-degraded substrate.  GD is 
characterised by a bleeding tendency and bone infarction.  Patients with FD suffer from a 
vasculopathy with strokes, proteinuric renal failure and cardiac conduction defects, but 
both disorders are highly heterogeneous.  Abnormal cytokine profiles and a pro-
inflammatory state have been found in both FD and GD, leading to the hypothesis that 
abnormalities at the blood-endothelial interface affecting coagulation and leucocyte 
adhesion contribute to the pathology of these disorders.   
This thesis demonstrates the importance of vascular manifestations in the presentation of 
both GD and FD with failure to identify the underlying cause of these manifestations 
resulting in delays between the onset of clinical manifestations and arrival at the correct 
diagnosis.  Abnormalities at the blood-endothelial interface identified in GD include up-
regulation of adhesion molecules on lymphocytes that may be of importance in the 
pathogenesis of bone disease, and increased thrombin generation in an endothelial cell 
model of GD.  In FD, whilst cardiac and renal manifestations occur at earlier onset and 
with greater severity in men, cerebrovascular disease seems to affect both sexes to a 
similar degree.  Monocytes from females with FD exhibit an age-dependent increase in 
adhesion mimicking the age-dependent increase in cardiac and renal disease seen in these 
patients but the mechanisms underlying cerebrovascular disease remain uncertain.  Initial 
investigations of platelet prothrombinase activity suggest this may be enhanced in FD.  
Further investigation of these abnormalities at the cellular level may shed new insights on, 
and open up new therapeutic options, for the management of the vascular complications 
of these disorders.  
  
5 
 
Table of Contents 
Declaration ......................................................................................................................... 2 
Acknowledgements ............................................................................................................ 3 
Abstract .............................................................................................................................. 4 
Table of Contents ............................................................................................................... 5 
Table of Figures ................................................................................................................. 8 
Table of Tables ................................................................................................................. 10 
List of Abbreviations........................................................................................................ 12 
Chapter 1 Introduction ................................................................................................ 18 
1.1 Glycosphingolipids ............................................................................................ 18 
1.2 Lysosomes ......................................................................................................... 21 
1.3 Clinical manifestations of GD and FD .............................................................. 28 
1.4 Diagnosing GD and FD ..................................................................................... 31 
1.5 Pathophysiology of GD and FD ........................................................................ 32 
1.6 Treatment of GD and FD ................................................................................... 38 
1.7 Altered blood-endothelial interactions in FD and GD ...................................... 42 
1.8 Leucocyte adhesion and transmigration ............................................................ 47 
1.9 Haemostasis ....................................................................................................... 51 
1.10 Aims of project .............................................................................................. 56 
Chapter 2 Methods ...................................................................................................... 59 
2.1 Patient and healthy control recruitment ............................................................. 59 
2.2 General cell culture methods & equipment ....................................................... 59 
2.3 Sample preparation ............................................................................................ 60 
2.4 Drugs and lipids stock solutions ........................................................................ 62 
2.5 Generation of lenitviral shRNA knockdown endothelial model ....................... 63 
6 
 
2.6 Flow cytometry .................................................................................................. 66 
2.7 Adhesion assays................................................................................................. 68 
2.8 Cell staining techniques ..................................................................................... 69 
2.9 Enzyme assays ................................................................................................... 70 
2.10 Western blot analysis ..................................................................................... 73 
2.11 Coagulation assays ......................................................................................... 76 
2.12 Statistics ......................................................................................................... 81 
Chapter 3 Bleeding features in the presentation of Gaucher disease .......................... 82 
3.1 Introduction ....................................................................................................... 82 
3.2 Purpose of this chapter ...................................................................................... 83 
3.3 Hypotheses ........................................................................................................ 83 
3.4 Methods ............................................................................................................. 84 
3.5 Results ............................................................................................................... 87 
3.6 Discussion........................................................................................................ 101 
3.7 Conclusions ..................................................................................................... 106 
Chapter 4 Vascular features of Fabry disease ........................................................... 108 
4.1 Introduction ..................................................................................................... 108 
4.2 Hypotheses ...................................................................................................... 110 
4.3 Methods ........................................................................................................... 110 
4.4 Results ............................................................................................................. 115 
4.5 Discussion........................................................................................................ 149 
4.6 Conclusions ..................................................................................................... 153 
Chapter 5 Cellular adhesion in Fabry and Gaucher .................................................. 155 
5.1 Introduction ..................................................................................................... 155 
5.2 Purpose of this chapter .................................................................................... 156 
7 
 
5.3 Hypotheses ...................................................................................................... 158 
5.4 Methods ........................................................................................................... 158 
5.5 Results ............................................................................................................. 169 
5.6 Discussion........................................................................................................ 194 
5.7 Conclusion ....................................................................................................... 198 
Chapter 6 Cellular support of coagulation in Fabry and Gaucher ............................ 199 
6.1 Introduction ..................................................................................................... 199 
6.2 Hypotheses ...................................................................................................... 202 
6.3 Methods and assay development ..................................................................... 202 
6.4 Results ............................................................................................................. 209 
6.5 Discussion........................................................................................................ 222 
6.6 Conclusions ..................................................................................................... 224 
Chapter 7 Discussion ................................................................................................ 226 
7.1 Vascular features in the clinical presentation of FD and GD .......................... 226 
7.2 Glycosphingolipids and enzyme defects: different effects in different cells? . 228 
7.3 Abnormalities in blood-endothelial interactions ............................................. 231 
7.4 Study limitations .............................................................................................. 234 
7.5 Further research avenues ................................................................................. 235 
7.6 Conclusions ..................................................................................................... 237 
Publications .................................................................................................................... 238 
Appendix 1 Ethical Approval......................................................................................... 240 
Appendix 2 Solutions & Buffers .................................................................................... 246 
Appendix 3 GM approval............................................................................................... 251 
Reference List ................................................................................................................ 252 
  
8 
 
Table of Figures 
Figure 1-1: Degradation pathway for glycosphingolipids.. ............................................. 22 
Figure 1-2: Trafficking pathways to and from the lysosome ........................................... 23 
Figure 1-3: Potential mechanisms of cellular dysfunction ............................................... 34 
Figure 1-4: Treatment of FD/GD.. ................................................................................... 39 
Figure 1-5: Potential vascular mechanisms of disease.. ................................................... 46 
Figure 2-1: Prothrombinase assay .................................................................................... 79 
Figure 3-1: RFH GD cohort overview. ............................................................................ 88 
Figure 3-2: Presentation of GD. ....................................................................................... 90 
Figure 3-3: Discriminating GD from other diagnoses. .................................................... 93 
Figure 3-4: Bleeding symptoms and severity .................................................................. 95 
Figure 3-5: Bleeding features in relation to platelet count and disease severity. ............. 96 
Figure 3-6:Relationship between bleeding scores, gammopathy & bone infarcts ........... 98 
Figure 3-7: Coagulation screen & FXI activity ............................................................. 100 
Figure 4-1: Location of GLA mutations within the FD cohort.   ................................... 117 
Figure 4-2: Age at symptom onset and delay from symptom onset to diagnosis. ......... 122 
Figure 4-3:  Changing pattern presentation of FD index cases. ..................................... 125 
Figure 4-4: Disease manifestations of males diagnosed on family screening: .............. 131 
Figure 4-5: Presentation of females diagnosed on family screening. ............................ 134 
Figure 4-6: Prevalence of critical organ complications ................................................. 136 
Figure 4-7: Relationship between critical organ dysfunction and age. .......................... 138 
Figure 4-8: Prevalence of other organ involvement in FD patients with stroke/TIA .... 139 
Figure 4-9: Relationship between enzyme activity, disease severity & mutation type. 141 
Figure 4-10: Relationship between stroke, mutation type and enzyme activity. ........... 144 
Figure 4-11: Vascular risk factors and the FIPI prognostic score .................................. 146 
Figure 4-12: Relationship between FVIII and disease manifestations........................... 148 
Figure 5-1: Development of monocyte adhesion assay.. ............................................... 160 
Figure 5-2: shRNA sequences.. ...................................................................................... 164 
Figure 5-3: Confirmation of envelope and packaging vectors. ...................................... 165 
Figure 5-4: GFP expression & puromycin toxicity. ....................................................... 166 
Figure 5-5: Development of RAW to EAhy functional adhesion assay. ....................... 168 
9 
 
Figure 5-6: Adhesion of monocytes to tissue culture plastic. ........................................ 170 
Figure 5-7: Relationship between age and adhesion. ..................................................... 171 
Figure 5-8: Relationship between disease severity and adhesion.. ................................ 174 
Figure 5-9: Relationship between age and organ function in FD. ................................. 175 
Figure 5-10: Relationship between adhesion and GD complications.  . ........................ 176 
Figure 5-11: Expression of CD11a, CD11b & CD11c. ................................................. 178 
Figure 5-12: Expression of CD49d, CD54 (ICAM-1) & CD36. ................................... 179 
Figure 5-13: Expression of CD102 (ICAM-2) & CD50 (ICAM-3) ............................... 180 
Figure 5-14: CD62L expression.. ................................................................................... 181 
Figure 5-15: Endothelial characteristics of EAhy cells.................................................. 184 
Figure 5-16: Effect of TNFα on expression of adhesion molecules. ............................. 185 
Figure 5-17: Toxicity of inhibitors on EA.hy 926 cells. ................................................ 186 
Figure 5-18: Effect of pharmacological inhibitors on GBA and GLA activity ............. 187 
Figure 5-19: Effect of shRNA knockdown. ................................................................... 189 
Figure 5-20: Effect of enzyme inhibition on endothelial adhesion.. .............................. 191 
Figure 5-21: Effect of glycosphingolipids on adhesion ................................................. 192 
Figure 5-22: Effect of lipid-loading RAW on their adhesion to EAhy cells. ................ 193 
Figure 6-1: Development of tissue factor procoagulant activity .................................... 204 
Figure 6-2: The prothrombinase assay.. ......................................................................... 205 
Figure 6-3: Effect of TNFα and cell concentration on thrombin generation. ................ 208 
Figure 6-4: Monocytes and tissue factor.. ...................................................................... 210 
Figure 6-5: Platelet parameters of PRP.. ........................................................................ 213 
Figure 6-6: Thrombin generation of PRP....................................................................... 214 
Figure 6-7: Platelet prothrombinase activity. ................................................................. 215 
Figure 6-8: Thrombin generation – GD endothelial cell model.. ................................... 218 
Figure 6-9: Thrombin generation – FD endothelial cell model. .................................... 219 
  
10 
 
Table of Tables 
Table 1-1: Examples of lysosomal storage disorders ....................................................... 27 
Table 1-2: Clinical features of GD ................................................................................... 29 
Table 1-3: Clinical features and pathophysiology of FD ................................................. 30 
Table 1-4: Lipid abnormalities in GD and FD ................................................................. 33 
Table 1-5: Cytokines and their effects. . .......................................................................... 36 
Table 1-6: Cytokine abnormalities in GD and FD ........................................................... 37 
Table 1-7: Effect of cytokines & glycosphingolipids on adhesion & haemostasis.......... 45 
Table 1-8: Adhesion receptors involved in leucocyte-endothelial adhesion ................... 47 
Table 1-9: Adhesion abnormalities in FD ........................................................................ 50 
Table 1-10: Procoagulant abnormalities in FD ................................................................ 53 
Table 1-11: Coagulation abnormalities in GD ................................................................. 55 
Table 2-1: Antibodies used in flow cytometry ................................................................. 67 
Table 2-2 Antibody panels for D0 monocyte adhesion ................................................... 67 
Table 2-3: Layout of enzyme assays ................................................................................ 72 
Table 2-4: Antibodies used for Western blotting ............................................................. 75 
Table 3-1: Potential mechanisms of coagulopathy in coagulopathy in GD ..................... 82 
Table 3-2: Zimran severity score ..................................................................................... 84 
Table 3-3: Bone marrow burden score ............................................................................. 85 
Table 3-4: Condensed MCMDM-1 VWD bleeding score ............................................... 86 
Table 3-5: Primary presenting features of GD ................................................................. 91 
Table 4-1: FOS-MSSI Severity Score for FD ................................................................ 112 
Table 4-2: Fabry International Prognostic Index (FIPI) ................................................ 113 
Table 4-3: Recurrent mutations in FD ........................................................................... 116 
Table 4-4: Age and cause of death ................................................................................. 118 
Table 4-5: Presenting symptoms and age at diagnosis of index cases ........................... 120 
Table 4-6: Initial symptoms/ disease manifestations in index cases .............................. 121 
Table 4-7: Alternative diagnoses given prior to diagnosis of Fabry disease ................. 124 
Table 4-8: Vascular complications in male index cases ................................................ 126 
Table 4-9: Vascular complications in female index cases ............................................. 127 
Table 4-10: Vascular complications in males diagnosed on family screening .............. 128 
11 
 
Table 4-11: Vascular complications in females diagnosed on family screening ........... 132 
Table 4-12: Relationship between enzyme activity, severity & mutation type ............. 142 
Table 5-1: Adhesion molecules assessed ....................................................................... 161 
Table 5-2: Results of BLAST search for targets of the shRNA sequences ................... 163 
Table 5-3: Patients/controls recruited to monocyte adhesion studies ............................ 169 
Table 5-4: Relationship between adhesion ratio and clinical FD parameters ................ 172 
Table 5-5: MFI of adhesion molecules on leukocytes (mean ±SD) ............................... 177 
Table 5-6: Summary of changes in adhesion molecule expression ............................... 183 
Table 6-1: Monocyte tissue factor expression and activity ............................................ 209 
Table 6-2: Patients recruited to platelet studies and platelet parameters  ...................... 211 
Table 6-3: PRP thrombin generation parameters  .......................................................... 211 
Table 6-4: Prothrombinase assay results ........................................................................ 212 
Table 6-5: Endothelial cell thrombin generation - Gaucher cell model ......................... 217 
Table 6-6: Fabry endothelial cell model thrombin generation ....................................... 221 
  
12 
 
List of Abbreviations 
ACE  Angiotensin converting enzyme 
acLDL  Acetylated low density lipoprotein 
AHS  Autologous human serum 
APC  Activated protein C 
APTT  Activated partial thromboplastin time 
AT  Anti-thrombin 
ATCC  American Tissue Culture Collection 
ATP  Adenosine triphosphate 
BD  Becton Dickinson 
BMB  Bone marrow burden score 
BSA  Bovine serum albumin 
CBE  Conduritol β epoxide 
CO2  Carbon dioxide 
COX2  Cyclo-oxygenase 2 
CME  Clathrin mediated endocytosis 
CR3  Complement receptor 3 
DGJ  1-deoxygalactonorijimycin 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  Dimethyl sulfoxide 
13 
 
eNOS  Endothelial nitric oxide synthase 
ECG  Electrocardiogram 
EDTA  Ethylenediaminetetraacetic acid 
EPCR  Endothelial protein C receptor 
ER   Endoplasmic reticulum 
ERAD  Endoplasmic reticulum associated degradation 
ERT  Enzyme replacement therapy 
ESRF  End stage renal failure 
FBS   Fetal bovine serum 
FD   Fabry disease 
FITC  Fluorescein isothiocyanate 
FV(a)  Factor V (activated) 
FVIII  Factor VIII 
FX(a)  Factor X (activated) 
FXI  Factor XI 
Gal   Galactose 
GalNAc  N-acetylgalactosamine 
GalT2  β-1-4-galactosyltransferase 
Gb3   Globotriaosylceramide 
GBA  Glucocerebrosidase 
14 
 
GD   Gaucher disease 
GFP  Green fluorescent protein 
GFR  Glomerular filtration rate 
GI  Gastrointestinal 
GLA  Alpha-galactosidase 
Glc   Glucose 
GlcNAc  N-acetylglucosamine 
GluC   Glucosylceramide 
GSP  Glucosylsphingosine 
HDL  High density lipoprotein 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSP  Heat shock protein 
HUVEC Human umbilical vein cells 
ICAM  Intercellular adhesion molecule 
ICH  Institute of Child Health (UCL) 
IFNγ   Interferon gamma 
IBS  Irritable bowel syndrome 
ICD  Implantable cardiac defibrillator 
IL  Interleukin 
LacC   Lactosylceramide 
15 
 
LDL  Low density lipoprotein 
LFA-1  Lymphocyte function-associated antigen 1 
Lp(a)  Lipoprotein a 
LSD  Lysosomal storage disorder 
LysoGb3 Globotriaosylsphingosine 
LVH  Left ventricular hypertrophy 
LVMI  Left ventricular mass index 
M  Molar 
M6P  Mannose-6-phosphate 
Man   Mannose 
mM  Millimolar 
MFI  Median fluorescent intensity 
MPR  Mannose-6-phosphate receptor 
MPV  Mean platelet volume 
MRI  Magnetic resonance imaging 
mRNA  Messenger ribonucleic acid 
MSSI  Mainz severity score index 
MTT  Thiazolyl blue tetrazolium bromide 
NaCl  Sodium chloride 
NaOH  Sodium hydroxide 
16 
 
PAI  Plasminogen activator inhibitor 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PC  Protein C 
PE  Phycoerythrin 
PerCP  Peridinin-chlorophyll-protein complex 
PHS  Pooled human serum 
PPM  Permanent pacemaker 
PRP  Platelet rich plasma 
PT  Prothrombin time 
RFH  Royal Free Hospital 
RPMI  Roswell Park Memorial Institute medium 
PS  Protein S 
S1P  Sphingosine-1-phosphate 
SOB  Shortness of breath 
SRT  Substrate reduction therapy 
SSI  Severity score index (Zimran severity score – Gaucher disease) 
TAFI  Thrombin activatable fibrinolysis inhibitor 
TAT  Thrombin-anti-thrombin complex 
TCP  Tissue culture plastic 
17 
 
TF  Tissue factor 
TFPI  Tissue factor pathway inhibitor 
TGFβ  Transforming growth factor beta-1 
TIA  Transient ischaemic attack 
TM  Thrombomodulin 
TNFα   Tumour necrosis factor alpha 
tPA  Tissue plasminogen activator 
UDP  Uridine 5-disphosphate 
UPR  Unfolded protein response 
WPB  Weibel Palade bodies 
VCAM Vascular cell adhesion molecule 
VEGF  Vascular endothelial growth factor 
VLDL  Very low density lipoprotein 
VT  Ventricular tachycardia 
VWD  Von Willebrand disease 
VWF  Von Willebrand factor 
WML  White matter lesion 
  
18 
 
Chapter 1 Introduction 
Fabry disease (FD) and Gaucher disease (GD) are lysosomal storage disorders, caused by 
inherited deficiency of specific hydrolases required for the degradation of 
glycosphingolipids in the lysosome.  GD was first described by Phillipe Gaucher in 18821, 
denoting the presence of distinctive abnormal cells in a female with splenomegaly.  Over 
subsequent decades a clinical syndrome characterised by abnormal macrophages in the 
reticuloendothelial system causing hepatosplenomegaly, peripheral blood cytopenias, 
bone disease and, in some cases, neurological involvement, was given the eponymous 
name, Gaucher disease.  In 1898, William Anderson2 and Johannes Fabry3 independently 
described a widespread rash, angiokeratoma corporis diffusum and FD is now recognised 
as a multi-system disorder complicated by renal failure, cardiomyopathy and stroke.  It 
was not until the 1960s that the underlying enzyme deficiencies were identified: 
glucocerebrosidase (GBA) in GD4 and alpha galactosidase A (GLA) in FD5.  This 
discovery led to the development of specific therapies in the form of enzyme replacement, 
licensed first for GD in 1991 and then for FD in 2001.   
Despite these advances much still remains unknown about these disorders and in particular 
the mechanisms by which the presence of mutant enzyme results in the clinical 
manifestations. Although at first glance GD and FD may seem clinically disparate 
disorders, abnormalities involving interactions between blood constituents and the vessel 
wall have been implicated in the disease processes of both. This thesis investigates the 
role of vascular pathology in GD and FD, examining the prevalence of vascular 
manifestations in the patient cohort at the Royal Free Hospital, their relation to other 
disease manifestations and through laboratory investigation of blood-endothelial 
interactions. This chapter provides an overview of GD and FD and reviews the evidence 
base for vascular abnormalities in these disorders before outlining an investigative 
approach to further explore this area.   
1.1 Glycosphingolipids 
Glycosphingolipids comprise one or more sugar residues linked to the 1-hydroxyl group 
of ceramide by a β linkage.  Along with cholesterol, they are key components of 
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eukaryotic cell membranes, where they are thought to segregate into discrete 
microdomains termed lipid rafts6.  The ABO blood group determinants are complex 
glycosphingolipids and cell membrane glycosphingolipids have functional roles within 
the innate immune system; for example, globotriaosylceramide (Gb3) specifically binds 
the verotoxins of E.coli and Shiga toxin, whilst lactosylceramide (LacC) forms 
microdomains on the plasma membrane of neutrophils and macrophages which recognise, 
engulf and eliminate pathogens. Some glycosphingolipids, including LacC and 
sphingosine-1-phosphate (S1P) also function as bioactive signalling molecules.  
Regulated turnover of glycosphingolipids is therefore important for normal cellular 
functioning. 
1.1.1 Glycosphingolipid synthesis 
Glycosphingolipids needed to meet a cell’s requirements can either be synthesised de novo 
or recycled from the catabolism of other glycosphingolipids.  These catabolic reactions 
are more rapid and energy efficient than de novo synthesis and are stimulated by cytokines 
including tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ)7.  De novo 
synthesis of glycosphingolipids starts with synthesis of ceramide, a long chain amino 
alcohol (sphingosine) acylated with a fatty acid, within the endoplasmic reticulum (ER)8.  
Ceramides are then usually transported to the Golgi where they are converted rapidly to 
glycosphingolipids by step-wise addition of monosaccharide residues through the action 
of glycosyltransferases9.   
Galactosylceramide (Galβ1-1’Cer) and glucosylceramide (Glcβ1-1’Cer, GluC) are the 
initial glycosphingolipids formed and are synthesised by direct transfer of the 
carbohydrate moiety from a sugar nucleotide (e.g. uridine 5-diphosphate (UDP)-glucose) 
to ceramide.  Galactosylceramide is the principle glycosphingolipid in brain tissue.  GluC, 
the main lipid which accumulates in GD, is found predominately in peripheral tissues but 
is also present at low levels in the brain.  GluC is the precursor of lactosylceramide (LacC) 
and hence most of the complex neutral glycolipids and gangliosides.  LacC (Galβ1-4-
Glcβ1Cer) is synthesised by the addition of a galactose to GluC, catalysed by β-1-4-
galactosyltransferases (GalT2).  LacC is also regenerated by the catabolism of many of 
the lipids for which it is a biosynthetic precursor.  In human endothelial cells, TNFα 
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activates GalT2, resulting in increased LacC10. More complex glycosphingolipids are 
formed by the step-wise addition of further monosaccharides to the terminal end of the 
oligosaccharide chain: glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc) or mannose (Man).  Further addition of a galactose residue 
to lactosylceramide yields globotriaosylceramide (Gb3), the predominant lipid which 
accumulates in FD. 
Bioactive small molecules from sphingosine and ceramide 
As well as forming the backbone of sphingolipids, ceramide and sphingosine, and their 
phosphorylated derivatives also function as bioactive small molecules.  Ceramide and 
sphingosine-1-phosphate (S1P) are interconvertible via sphingosine as an intermediate 
and the balance of ceramide and S1P is highly biologically important11. Ceramide has 
anti-proliferative and pro-apoptotic effects whilst S1P is pro-proliferative.  
S1P is synthesised from sphingosine by two sphingosine kinases 1 and 2 (SphK1 and 
SphK2).  Binding of S1P to specific G-protein coupled receptors, activates a number of 
cell signalling pathways with downstream effects including activation of endothelial nitric 
oxide synthase (eNOS) stimulating nitric oxide production12, angiogenesis13 and up-
regulation of cyclooxygenase-214.   
Non-acylated derivatives 
Deacylated derivatives of glycopshingolipids are thought to arise either subsequent to 
deacylation reactions or by synthesis on a ceramide backbone.  These lysosphingolipids 
are water soluble as opposed to their water-insoluble acylated counterparts.   
Glucosylsphingosine (GluS) accumulates in GD15;16 and globotriaosylsphingosine 
(lysoGb3) accumulates in FD17.  
1.1.2 Glycosphingolipid degradation 
Glycosphingolipids for degradation are transported to the lysosome, predominately via 
the endocytic pathway and broken down by specific hydrolases.  Similarly to their 
synthesis, their degradation is by step-wise removal of the terminal monosaccharide from 
the end of the oligosaccharide chain (Figure 1-1).  Glycosphingolipids with less than four 
sugar residues are only degraded in the presence of sphingolipid activator proteins 
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(saposins)18.  Saposins A, B, C and D are derived by proteolytic processing from a single 
precursor prosaposin; saposin B is required by GLA and saposin C by GBA.  
1.2 Lysosomes 
Lysosomes are intracytoplasmic membrane bound organelles whose primary function is 
the degradation and recycling of macromolecules, both of intracellular and extracellular 
origin.  Discovered by Christian De Duve19, lysosomes have a lipid bilayer, cholesterol-
poor membrane, lined internally with a thick glycocalyx to prevent its degradation by 
lysosomal enzymes.  Lysosomes have an internal acidic pH, maintained by an ATP-
dependent proton pump, at which lysosomal hydrolases are optimally functional.   
Macromolecules are delivered to lysosomes by complex pathways including 
autophagocytic pathways (for intracellular material) and endocytic pathways (for 
extracellular material).  Inside the lysosome, macromolecules are degraded in a step-wise 
manner with specific enzymes for each macromolecule catalysing each step.  The 
breakdown products are then released from the lysosome either to the cytosol by diffusion 
or transporter proteins or to the extracellular space by exocytosis.  Salvage of simple 
macromolecules, not yet fully degraded to their core components, and their transport back 
to the Golgi apparatus additionally allows efficient production of more complex 
macromolecules to meet the cells requirements without the need for energy expensive de 
novo synthesis.    Egress of molecules from the lysosome involves multiple lysosomal 
proteins that act as transporters including cystinosin, sialin, cobalamin transporter and 
NPC1 protein.  Lysosomal exocytosis, involving the fusion of lysosomal vesicles with the 
plasma membrane, enables repair of the plasma membrane and release of lyososomal 
enzymes and breakdown products into the extracellular space, e.g. enabling degradation 
of the extracellular matrix.  
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Figure 1-1: Degradation pathway for glycosphingolipids.  Blue = lipids,; green = enzymes, red = disease caused by enzyme deficiency. 
Gal = galactose; glu = glucose; NAMA = N-acetyl neurominic acid; p = phosphate; GalNAc = N-acetylgalactosamine20. 
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Figure 1-2: Trafficking pathways to and from the lysosome 
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1.2.1 Trafficking of material for degradation to lysosomes 
A number of pathways are involved in the delivery of material to lysosomes including 
endocytosis, phagocytosis and autophagy (see Figure 1-2). 
Endocytosis 
Capture of extracellular material and integral membrane proteins occurs via specific 
endocytic mechanisms, with the precise mechanism depending on the nature of the 
material.  Clathrin-mediated endocytosis (CME) occurs when clathrin-coated pits on the 
plasmalemma internalise membrane receptor-ligand complexes into vesicles.    Clathrin-
independent endocytosis most often occurs at flask-like invaginations along the 
plasmalemma called caveolae – long-lived plasma membrane microdomains composed of 
caveolins, cholesterol, sphingolipids, GPI-anchored proteins and various receptor proteins. 
Early endosomes can be recruited back to the plasmalemma or to other organelles as 
sorting/recycling endosomes, allowing for the recycling and re-insertion of cell surface 
receptors, delivery of signalling ligands throughout the cell and internalisation of cell 
membrane components to be re-organised. Endosome to lysosome maturation involves a 
progressive decrease of the internal pH to about 5 in a mature lysosome generated 
primarily by the vacuolar-H+ ATPase. 
Autophagy 
Intracellular materials reach the lysosome through autophagocytic pathways which target 
material including organelles for degradation.  Autophagy occurs at a basal level and is 
also activated by a broad range of cellular stressors and mediates degradation of protein 
aggregates, oxidised lipids, damaged organelles and intracellular pathogens.  There are 
three distinct sub-types: microautophagy, chaperone-mediated autophagy and 
macroautophagy. 
Microautophagy involves direct engulfment of cytosolic material by the lysosome, either 
by direct invagination of the lysosomal membrane or projected arm-like extensions that 
sequester material into intralysosomal vesicles. 
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Chaperone-mediated autophagy is selective for soluble monomeric proteins containing a 
binding motif for heat shock protein 70 (HSP70) which, with co-chaperones, then 
promotes protein unfolding and translocation across the lysosomal membrane via the 
lysosomal membrane protein LAMP2A21. 
When macroautophagy is stimulated, double-membrane bound vesicles known as 
autophagosomes form to engulf cytosolic material.  This material, including dysfunctional 
organelles and oligomerised proteins is selectively recognised by chaperone complexes 
and adapter molecules including heat shock proteins, ubiquitin and p62/SQSTMI which 
allow for specific uptake of theses substrates within autophagosomes22.  Autophagosomes 
then fuse with lysosomes.  The enveloped material and its enveloping membrane are 
degraded by lysosomal hydrolases. 
1.2.2 Lysosomal enzyme synthesis and trafficking to lysosomes 
Soluble lysosomal enzymes are synthesised as precursor polypeptides and contain a 20-
25 amino acid N-terminal sequence which directs their co-translational translocation into 
the lumen of the ER.  Within the ER, the signal peptide is cleaved and the nascent protein 
undergoes glycosylation of selected asparagine residues (N-linked glycosylation).  These 
residues play a key role in protein folding and quality control mechanisms which are 
important for onward transport of the protein to the Golgi apparatus. 
Protein folding occurs within the ER: hydrophobic residues mainly face the interior of the 
protein whilst polar residues mainly occur on the external surface.  Protein mis-folding 
with exposure of hydrophobic residues on the external surface of the protein results in 
formation of protein aggregates.  Molecular chaperones within the ER inhibit formation 
of aggregates by binding exposed hydrophobic residues.  Persistently mis-folded proteins 
are targeted for degradation by the ER-associated pathways (ERAD), of which the 
ubiquitin-proteasome system is a key component. The lysosomal enzymes are then 
transported from the ER to the cis-Golgi via a vesicular transport mechanism.   
Targeting of lysosomal proteins from Golgi to the lysosomes 
Lysosomal enzymes are targeted to lysosomes via a number of different pathways.  
Historically, the main mechanism for most lysosomal enzymes, including GLA, was 
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thought to be mediated by a mannose-6-phosphate (M6P) modification that occurs in the 
late Golgi compartment, catalysed by GlcNAc-1-phosphotransferase.  There are two types 
of transmembrane mannose-6-phosphate receptors: cation-dependent (CD-MPR) and 
cation-independent (CI-MPR) which shuttle between trans-Golgi and late endosomes and 
target enzyme to lysosomes.  Both MPR are also present on the plasma membrane but 
only CI-MPR endocytoses M6P containing ligands, enabling uptake of enzymes with the 
M6P modification in the extracellular space to be taken up by surrounding cells.   
MPR bind M6P-containing proteins in the Golgi apparatus and these complexes exit the 
Golgi in clathrin-coated vesicles which fuse with endosomes.  The lower pH in the 
endosomes results in dissociation of the protein-receptor complex and release of the 
protein into the endosomal lumen from where they are transported onwards to the 
lysosome. The MPR recycles back to the Golgi. 
More recently, it has been discovered that some lysosomal enzymes are targeted to the 
lysosome by MPR-independent mechanisms.  Sortilin, a transmembrane glycoprotein, has 
been shown to traffic a number of lysosomal enzymes which also use the MPR mechanism 
including GLA23.  Glucocerebrosidase is not targeted via the MPR mechanism but is 
instead targeted via the integral lysosomal membrane protein LIMP224.  
Under normal conditions, 5-20% of many lysosomal enzymes escape the M6P trafficking 
pathway and are secreted from the cell.  These enzymes can then be taken up by MPR on 
distant cells, termed “secretion-recapture”. GLA undergoes secretion-recapture25, GBA 
does not. 
1.2.3 Lysosomal storage disorders 
Lysosomal storage disorders (LSDs) comprise a group of over fifty monogenic disorders 
affecting lysosomal function.  The majority of LSDs are the result of deficiency of a 
soluble lysosomal hydrolase but others results from a defect in an activator protein, 
membrane protein or part of a transport pathway (see Table 1-1). Rarely, GD may arise 
due to a mutation in the prosaposin gene encoding saposin C. 
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Table 1-1: Examples of lysosomal storage disorders 
Role Gene Protein Function Disease 
Lysosomal 
hydrolases 
GBA1 Glucocerebrosidase Hydrolysis of terminal β-
linked glucose residue 
from glucosylceramide 
Gaucher disease 
GLA Alpha 
galactosidase A 
Hydrolysis of terminal α-
linked galactose from 
glycosphingolipids 
Fabry disease 
Activator 
proteins 
PSAP Prosaposin, cleaved 
to saposins A, B, C 
& D 
Saposin C: activator of 
glucoceridosidase 
Gaucher disease 
(Saposin C) 
GM2A GM2 activator 
protein 
Activator protein for 
degradation of GM2 by 
hexosaminidase A 
GM2 
gangliosidosis 
(AB variant) 
Membrane ion 
channels 
MCOLN1 Mucolipin I  Ion channel involved in 
calcium signalling during 
lysosomal membrane 
fusion 
Mucolipidosis 
type IV 
CLCN7 CIC-7, chloride ion 
channel 
Contributes to lysosomal 
acidification 
Osteopetrosis 
Membrane 
transporters 
LAMP2A Lysosome- 
associated 
membrane 
glycoprotein 2 
Mediates chaperone 
mediated autophagy by 
binding cytosolic protein 
substrate on the lysosomal 
membrane so they can be 
internalised and degraded 
Danon disease 
NPC1 Neimann-Pick C1 
protein 
Exports cholesterol from 
endolysosomal 
compartment 
Neiman-Pick C 
Enzymes 
involved in post-
translational 
modifications 
SUMF1 Sulfatase-
modifying factor 1 
Oxidises a cysteine 
residue in the active site of 
sulfatases, required for 
function 
Multiple 
sulfatase 
deficiency 
GNPTAB & 
GNPTG 
N-
acetylglucosamine-
1-
phosphotransferase 
Formation of mannose-6-
phosphate residues on 
lysosomal enzymes in 
Golgi 
Mucolipidosis 
II/III 
 
Whilst often viewed as orders of excess due to the accumulation of un-degraded substrates, 
LSDs may also be viewed as deficiency disorders where critical components required for 
multiple metabolic pathways are reduced in supply as well as a state of over-abundance 
of un-degraded material26.  
Except for FD, Danon and Hunter’s disease which are X-linked, the LSDs are autosomal 
recessively inherited.   Individually rare, their overall estimated live birth prevalence 
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overall is 1 in 750027.  Within each disorder, there is wide-phenotypic variation ranging 
from a severe, infantile-onset form to more attenuated adult onset phenotype.  FD is 
unusual in that there is no infantile-onset form.  GD has traditionally been divided into 
three sub-types depending on the presence or absence of neurological features. Type 1 GD 
(GD1) is characterised by a lack of central nervous system involvement and accounts for 
95% of GD amongst Caucasians28.  Type 2 GD is an infantile onset severe neuronopathic 
form and type 3 GD has more attenuated neurological features; GD1 is the subject of this 
thesis and the other types of GD are not discussed further.  
1.3 Clinical manifestations of GD and FD 
GD and FD are both multi-system disorders and are highly heterogeneous in their clinical 
manifestations, even amongst patients with the same genotype.  Both may present at any 
time from early childhood to old age and, unlike the majority of LSDs, the clinical 
manifestations are systemic rather than neurodegenerative.  Both are rare disorders with 
an estimated prevalence of 1:50 00 – 1:100 000 for GD and 1: 117 00 in FD27, although 
newborn screening studies have suggested a much higher prevalence of GLA mutations29.  
Both are pan-ethnic but there is a particularly high carrier rate of GD amongst Ashkenazi 
Jews in whom the estimated carrier rate is 1:1230.  There is no known ethnic predisposition 
for FD.  
1.3.1 Gaucher disease 
GD primarily affects cells of the reticuloendothelial system resulting in 
heaptosplenomegaly, bone disease and decreased peripheral blood counts, often 
associated with a bleeding diathesis.  Polyclonal gammopathies are common at 
presentation and in the longer term there is an increased risk of multiple myeloma31. The 
clinical manifestations and their potential causes are outlined in Table 1-2.  In 
symptomatic patients, presenting features range from mild thrombocytopenia to massive 
splenomegaly and avascular necrosis of the hips32. In addition, the diagnosis may be 
fortuitous following the incidental detection of abnormal blood counts or splenomegaly 
on investigations performed for other reasons (e.g. insurance medicals, antenatal care). 
Whilst GD is a progressive  disorder in most patients33, the disease can be stable over 
many years particularly amongst Ashkenazi Jewish populations34. Differences between 
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observed and expected numbers of cases in Ashkenazi Jewish populations suggest that in 
some patients the disease is so mild that it remains asymptomatic and undiagnosed30. 
 Table 1-2: Clinical features of GD 
Domain Clinical features Potential mechanisms 
Thrombocytopenia 
& coagulopathy 
Thrombocytopenia (may be 
incidental finding) 
Bleeding, especially bruising 
Increased risk post-operative 
bleeding or post-partum 
haemorrhage 
Thrombocytopenia: Hypersplenism; Bone 
marrow infiltration; Impaired megakaryopoiesis 
Bleeding diathesis: ↓synthesis/ ↑consumption 
coagulation factors 
Defective platelet activation/ adhesion/ 
membrane function. Increased fibrinolysis 
Anaemia Fatigue 
Anaemia (may be incidental 
finding) 
Hypersplenism 
Hepcidin dysregulation 
Impaired erythropoiesis 
Haemolysis – membrane abnormality or 
autoimmune 
Concomitant B12 deficiency 
Splenomegaly Early satiety 
Abdominal pain, Distension/ 
abdominal mass 
May be incidental finding 
Infiltration by Gaucher cells 
Inflammation  
Bone disease Bone pain, infarcts, avascular 
necrosis Osteopenia/ osteoporosis 
Bone remodelling, lytic and 
sclerotic lesions 
Imbalance between osteoclast and osteoblast 
activity 
Infiltration by Gaucher cells 
Gammopathies & 
malignancy 
Gammopathy: polyclonal and 
monoclonal 
Multiple myeloma 
Other malignancies 
Chronic pro-inflammatory microenvironment 
stimulating clonal evolution 
Up-regulation of pro-proliferative cell signalling 
pathways by glycosphingolipids 
 
1.3.2 Fabry disease 
The classical presentation of FD is with onset of burning pain, particularly in the hands 
and feet (acroparasthesia) and the distinctive rash, angiokeratoma, in childhood or 
adolescence, often accompanied by gastrointestinal upset including pain and altered bowel 
habit; median age of symptom onset is 9-10 years in males and 13-23 years in females35;36.  
Involvement of critical organ systems including the kidneys, heart and brain ensues over 
subsequent decades and is life-limiting with a median life expectancy of 50 years in 
males37 and 70 years in females38.   Given its X-linked nature, for many years women 
were thought to be carriers rather than sufferers of FD.  It is now clear that the majority 
of women with FD develop similar clinical features to those seen in males38, although 
often milder and are best considered affected heterozygotes39.  The mechanisms by which 
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females can develop clinical manifestations despite sometimes normal enzyme levels 
remains an enigma40.  Lyonisation with inadequate cross-correction between cells has 
been hypothesised but is unlikely to provide a complete explanation41.  
Table 1-3: Clinical features and pathophysiology of FD 
Domain Clinical features Potential mechanisms 
Skin Angiokeratoma 
Decreased/ absent sweating 
Increased VEGF production 
Lipid accumulation in dermal 
microvasculature 
Neurological Neuropathic pain (acroparasthesia) 
Stroke/TIA/ white matter lesions 
Tortuous vessels 
Microvascular thrombosis and altered 
cerebral blood flow regulation due to 
lipid accumulation in endothelium and 
smooth muscle 
Renal Proteinuria 
Chronic renal failure 
Mesangial widening and glomerular 
sclerosis resulting in tubular dysfunction 
Gb3 deposition in podocytes with 
thickening of basement membrane 
Cardiac Arrhythmias (conduction defects, atrial 
and ventricular) 
Cardiac hypertrophy 
Valvular disease 
Energy depletion due to inefficient ATP 
utilisation by sarcomeres 
Activation pro-proliferative pathways 
Ischaemia and fibrosis in conduction 
system 
Gastrointestinal Abdominal pain 
Diarrhoea/constipation 
Lipid deposition in the ganglions of the 
mesenteric plexus 
Opthalmological Cornea verticillata (corneal deposits) 
Vessel tortuosity 
Lipid deposition in corneal epithelial 
basement membrane 
Audiovestibular Tinnitus, vertigo 
Sensorineural hearing loss 
Gb3 deposition in the vestibular and 
cochlear nerves 
 
The main clinical features and potential underlying mechanisms of FD are shown in Table 
1-3.  They are highly heterogeneous in the time of onset, severity and range of organ 
involvement both within and between different families. Although the classic phenotype 
of FD is of multi-organ involvement manifesting as pain and angiokeratoma followed by 
development of cardiac, renal and cerebrovascular complications in adulthood, cases of 
FD with predominant renal or cardiac manifestations diagnosed later in life, often with 
relatively high residual enzyme activity, have been described42;43.  Whether these 
comprise a true distinct phenotype or part of an increasingly broad spectrum of 
manifestations of FD remains unanswered. 
31 
 
1.4 Diagnosing GD and FD 
The cornerstone of diagnosis in both GD and males with FD is demonstration of low 
enzyme activity.  In both cases, this biochemical assay can be performed on leukocytes or 
cultured skin fibroblasts44.  GLA is secreted at high levels into the plasma and therefore 
in FD, measurement of enzyme activity can also be performed on plasma, but this is not 
the case for GD.  In females with FD, enzyme activities are usually reduced45 but can fall 
within the normal range and genetic analysis is required to confirm or refute the diagnosis.   
Demonstration of a pathogenic mutation in the GLA gene is required for diagnosis of FD.  
In FD, mutations are usually private, limited to a single or small number of families and 
are distributed along the length of the gene.  Over 300 mutations have been described46, 
most commonly missense mutations, but also nonsense and rearrangements.  Deciding 
whether or not a previously unreported mutation is pathogenic (i.e. disease causing) can 
be difficult and bioinformatic tools and in vitro expression studies are useful tools in this 
process47, but may still be inconclusive.  Screening studies of newborns or higher-
prevalence groups (e.g. cryptogenic stroke) have resulted in the identification of a high 
number of mutations of uncertain pathogenic significance48. 
In GD, mutational analysis of the GBA gene is recommended for patient counselling but 
is not required for diagnosis.  In GD, four mutations in the GBA gene, located at 1q22.1, 
account for >90% of within the Askenazi Jewish population: L444P, N370S, 84GG and 
IVS2+1G49.  Amongst non-Ashkenazi patients there is a much wider range of genotypes 
with almost 300 mutations reported50, although many patients are compound 
heterozygotes with the N370S or L444P mutation. Although genotype-phenotype 
correlations are imperfect they do provide some prognostic information with the presence 
of at least one N370S allele being considered protective against the neurological 
manifestations seen in GD151. 
In both GD and FD, the diagnosis might be suggested by the presence of characteristic 
storage cells on biopsy specimens.  In GD, patients are often diagnosed following the 
identification of characteristic Gaucher cells – enlarged, lipid laden macrophages with 
weakly basophilic fibrillar cytoplasmic inclusions - on bone marrow biopsies performed 
for investigation of splenomegaly and/or low blood counts.  In FD, storage material is 
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visible as “zebra-like” bodies on electron microscopy52, usually on renal biopsies 
performed for investigation of proteinuria/ renal failure but occasionally on 
endomyocardial biopsies.   The presence of storage material in either scenario is not 
sufficient for diagnosis – in GD pseudo-Gaucher cells are found in many haematological 
disorders including chronic myeloid leukaemia53 and haemoglobinopathies.  Chloroquine 
use can give rise to histological features identical to FD54 and therefore for both  disorders 
enzyme activity and/or mutational analysis must be performed.  
1.5 Pathophysiology of GD and FD 
Although the specific enzyme deficiency and the presence of glycosphingolipid 
accumulation in GD and FD were identified over half a century ago, relatively little 
remains known about the mechanisms by which a mutation in the encoding gene results 
in the clinical manifestations of the disease.  Much research has focussed on the 
consequences of impaired lipid degradation on lysosomal and cellular function.  More 
recently, a potential role for the mutant protein itself in pathogenesis of these disorders 
has been proposed.  Studies of the effects of cellular dysfunction at the wider 
microenvironment and organ level have been limited in part by difficulties in developing 
animal models of GD and FD which re-capitulate the disease manifestations seen in 
humans. 
1.5.1 Glycosphingolipid accumulation & cellular metabolism 
In both GD and FD, failure of the mutant enzyme to degrade their glycosphingolipid 
substrate results in accumulation of un-degraded substrate within the lysosomes.  Within 
GD, glucosylceramide is the predominant lipid stored but glucosylsphingosine, also 
accumulates.  In FD, Gb3 and its deacylated derivative accumulate, but in both disorders 
other abnormalities of glycosphingolipids also occur (see Table 1-4).  In GD, storage 
occurs predominantly within macrophages, whilst in FD, storage has been noted in many 
cell types including endothelial cells, podocytes and cardiomyocytes.  Whilst storage of 
undegraded lipid is the histological hallmark of both disorders, storage lipids comprises 
<2% of the weight of enlarged spleens in GD or hearts in FD 55, suggesting pathological 
mechanisms beyond simple storage.  
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Table 1-4: Lipid abnormalities in GD and FD 
Lipid GD GD GD GD FD FD FD 
GluC ↑ ↑  ↑ ↓ →  
GluS  ↑ ↑ ↑    
LacC    ↑ → →  
Gb3 →    ↑ ↑  
LysoGb3      ↑  
GM3 ↑   ↑    
S1P       ↑ 
Ceramide →     →  
Reference 56 15 57 16 58 17 59 
 
Determining the effects of storage on cellular function and whether storage per se is a 
fundamental cause of cellular dysfunction is an important, but largely unanswered 
question. Potential mechanisms of cellular dysfunction are illustrated in Figure 1-3, 
whereby glycosphingolipid accumulation results in alterations in key cellular functions 
including signalling pathways, oxidative pathways and intracellular trafficking.   
Accumulated lipids in both GD and FD can have direct effects on cellular functioning 
including calcium homeostasis, cellular proliferation and free radical formation.  Excess 
glucosylsphingosine has been postulated to have a role in the pathogenesis of both bone 
disease60 and haematological malignancies61 in GD. In FD, lysoGb3 has been shown to 
have a pro-proliferative effect on myocytes17 and to result in increased production of the 
cytokine transforming growth factor beta-1 (TGFβ1), which is involved in the control of 
cell proliferation, by podocytes62. In addition, increased S1P in FD has been implicated in 
the development of cardiac hypertrophy59.   
Altered mitochondrial function and increased production of free radicals has been found 
in both FD and GD. Impairment of the mitochondrial respiratory chain  enzymes has been 
found in FD63 and  whilst Gb3 accumulation results in oxidative stress and up-regulation 
of adhesion molecules within the endothelium64.  In GD, pharmacological inhibition of 
GBA resulted in mitochondrial dysfunction and increased free radical formation in a 
dopaminergic cells line65.  Glucosylceramide has shown to increase mitochondrial 
mitochondrial respiration in the liver and brain66.
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Figure 1-3: Potential mechanisms of cellular dysfunction
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1.5.2 Abnormalities in lysosomal trafficking pathways 
Enzyme deficiency can result in broader abnormalities of the lysosomal system, 
particularly affecting trafficking pathways to the lysosome: endocytosis and 
autophagocytosis.  Addition of lactosylceramide to cells with different lipidoses results in 
accumulation of lactosylceramide in the endosomal system, rather than transport to the 
Golgi which occurs in normal cells67. There is also evidence of accumulation of M6P 
receptors in the late endosomal system within Neimann-Pick type C68.  In Neimann-Pick, 
endocytic dysfunction results in impaired  recycling of membrane receptors and altered 
cell membrane composition69; whether this occurs in other glycosphingolipidoses has not 
been investigated. 
Accumulation of autophagosomes has been noted in a number of LSDs70;71 leading to 
accumulation of protein aggregates and abnormal mitochondria72.  Abnormalities of 
autophagy, with impaired autophagosome maturation have been found in FD73 and  
neuronopathic GD71.  Increased synthesis of the phospholipid phosphatidylcholine, a 
component of cell membranes74 and increased levels of other lysosomal enzymes (e.g. 
cathespins)75 in GD suggest attempts by the lysosomal system to compensate for the 
effects of enzyme deficiency.  
1.5.3 Missense mutations and the unfolded protein response 
Correct folding of both GBA and GLA in the ER is required for onwards transport to the 
Golgi and then the lysosome.  Mis-sense mutations which cause mis-folding of the enzyme 
result in retention of the mis-folded enzyme in the ER and its subsequent degradation by 
ERAD. If this pathway is saturated, mis-folded proteins accumulate within the ER, 
activating the unfolded protein response (UPR) – a signalling pathway that has been 
implicated in a range of metabolic and neurodegenerative diseases76.  This process has 
been suggested to underlie the increased risk of Parkinson’s disease in GD77; its potential 
role in other disease manifestations in GD or FD is undetermined. 
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1.5.4 Altered inflammatory responses and the microenvironment 
Histological studies from patient biopsy specimens and of animal models have suggested 
that altered responses to inflammation play an important role in organ pathology in both 
GD60;78 and FD79.  Cytokines play a key role in intercellular signalling and in the 
regulation of inflammatory reactions and have been found to be abnormal in both GD and 
FD.  Key cytokines investigated and their functions are outlined in Table 1-5 and studies 
revealing abnormalities in their expression in Table 1-6. 
Table 1-5: Cytokines and their effects. NK (natural killer), IFNγ (interferon gamma), 
IL (interleukin). 
Cytokine Produced by Effects on inflammation 
TNFα Macrophages, NK cells, T 
cells 
Promotes inflammation, endothelial activation 
IFNγ T cells, NK cells Macrophage activation 
IL1α Macrophages, neutrophils, 
endothelial cells 
Pro-inflammatory, stimulates TNFα production 
IL1β Macrophages Proinflammatory, induces COX2 
IL6 T cells, macrophages, 
osteoblasts 
Inhibits production TNFα, IL-1; activates and stimulates 
production IL1 receptor antagonist and IL10 
IL8 Monocytes, macrophages, 
endothelial cells 
Mobilises and activates neutrophils 
IL10 Monocytes, T cells Anti-inflammatory: down-regulates pro-inflammatory cytokine 
synthesis 
IL13 T cells Anti-inflammatory: down-regulates macrophage activity 
inhibiting production of pro-inflammatory cytokines 
 
Initial investigations of cytokines in  sphingolipidoses showed increased production of 
IL1 by murine macrophages incubated with GluC80. Histological studies of GD spleens 
have shown that Gaucher cells themselves most closely resemble anti-inflammatory 
alternatively activated macrophages, but are surrounded by leukocytes strongly 
expressing pro-inflammatory IL1β81.  Studies in both GD and FD have yielded sometimes 
conflicting results but support dysregulation of inflammation with an overall pro-
inflammatory tendency.  Increased levels of TNFα, IL1β and IL6 have been found in both 
GD and FD and additionally increased levels of IL8 have been found in some studies of 
GD.  
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Table 1-6: Cytokine abnormalities in GD and FD 
  TNFα IFNγ IL1α IL-1β IL-6 IL8 IL-10 IL13 Ref 
GD Plasma ↑        82 
GD Plasma →   → ↑  →  83 
GD Plasma →    → ↑   84 
GD PBMC 
mRNA 
↑   ↑ → →   85 
GD Serum ↑   ↑ → →   86 
GD Serum → → → → → ↑ → → 87 
FD  Plasma     ↑ (F 
only) 
   88 
FD Plasma ↑    ↑    89 
FD PBMC 
mRNA 
↑ → → ↑ →    90 
FD PBMC 
supernatant 
→ →  ↑ ↑   → 90 
FD Dendritic 
cells 
↑   ↑ →    90 
FD Monocytes →   ↑ ↑    90 
FD Plasma →    ↓    91 
 
1.5.5 Heterogeneity and genetic polymorphisms 
It is likely that the clinical sequelae of GD and FD are consequent on the aberrant 
activation of a number of different cellular signalling pathways and that other modifiers 
of these pathways, whether genetic or acquired, play a role in determining the severity and 
organ distribution of clinical features that manifest in individual patients. In the search for 
disease modifiers, polymorphism studies have been performed on genes encoding 
cytokines in both GD and FD and additionally on genes involved in coagulation and nitric 
oxide synthesis in FD. 
In FD, the polymorphisms G174C in IL6 and G894T in endothelial nitric oxide synthase 
and the FV Leiden mutation (G1691A) have been associated with cerebral white matter 
lesions92.  A further study also showed that homozygosity for the IL6 G174C 
polymorphism, which is associated with increased IL6 levels, was associated with 
increased disease severity and cerebrovascular events93, an association with also exists for 
stroke in the general population94.  Conversely, within GD, homozygosity for the IL6 
G174C polymorphism has been associated with milder bone disease95.  A polymorphism 
in the IL10 gene has also been associated with neurological disease in FD96.   
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1.6 Treatment of GD and FD 
Following diagnosis, patients require a comprehensive assessment to establish the extent 
of organ involvement and determine optimum treatment.  In the UK this is undertaken at 
designated specialist centres which were commissioned in 2005, of which the Royal Free 
Hospital is one.  In GD, radiological assessment of the skeleton, often using magnetic 
resonance imaging (MRI), assessment of liver and spleen volumes and bone densitometry 
as well as measurement of the blood count and immunoglobulin levels are undertaken.  In 
FD assessments cover the critical organ systems: renal (quantification of proteinuria, 
measurement of the glomerular filtration rate (GFR)), cardiac (electrocardiogram and 
echocardiogram) and neurological (pain assessment and cerebral MRI). 
Until the 1990s, treatment of LSDs was limited to supportive care, primarily in the form 
of blood transfusions and orthopaedic surgery for GD and renal and cardiac therapies for 
FD.  This scenario changed with the introduction of intravenous enzyme replacement 
therapy (ERT), initially for GD in 1991 and subsequently for FD in 2001.  Assisted by the 
financial incentives of orphan drug legislation, further therapies have been developed for 
both disorders targeted either at increasing intracellular enzyme levels or reducing 
glycosphingolipid products (see Figure 1-4).
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Figure 1-4: Treatment of FD/GD. Treatment strategies involve either increasing intracellular enzyme levels or reducing the amount of 
substrate requiring degradation.
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1.6.1 Enzyme replacement therapy 
Although the discovery of the enzymatic defects in the 1960s raised the conceptual 
possibility of ERT, it was not until the early 1990s that this became a reality for GD, the 
first LSD for which ERT became available.   Initial attempts at infusion of placental-
derived enzyme resulted predominant uptake by hepatocytes in the liver, rather than 
reticuloendothelial cells.  Discovery of the macrophage mannose receptor enabled 
targeting of the enzyme to macrophages, the predominant site of disease, by modifications 
to oligosaccharide chains97.  A pivotal study in twelve non-splenectomised patients 
showed improvement in liver and spleen volumes and blood counts and led to the licensing 
of the product alglucerase (Ceredase, Genzyme) in 199198.  Subsequently three 
recombinant products have become available: imiglucerase (Cerezyme, Genzyme), 
velaglucerase alfa (VPRIV, Shire) and taliglucerase (Elyso, Protalix) alfa.  All have 
demonstrated efficacy in haematological and visceral parameters.  Improvements in bone 
disease have been more difficult to demonstrate over the relatively short time course of 
clinical trials and the effect of ERT on other complications including multiple myeloma 
is uncertain. 
Two recombinant enzyme therapies were developed contemporaneously for FD: 
agalsidase alfa (Replagal, Shire Human Genetic Therapies) and agalsidase beta 
(Fabrazyme, Genzyme), which were both licensed in the EU in 2001.  Establishing the 
efficacy of these therapies is challenging – the clinical features of FD develop insidiously 
over many years and are highly heterogeneous making identification of clinically relevant 
end points applicable to a broad number of patients and achievable over the relatively 
short time frame of a clinical trial difficult.    Initial trials demonstrated clearance of stored 
lipids from endothelial cells and improvement in pain over a six month time period99;100.  
Stabilisation of mild-moderate renal impairment101 and reductions in left ventricular mass 
102 have been demonstrated but there is a paucity of data on the effect of ERT on major 
clinical events including stroke, arrhythmias and death103.  Patients receiving ERT may 
still experience clinical events: 5/58 (9%) developed strokes104 in a 54 month follow up 
study; progression of white matter lesions on MRI has also been reported105.   
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The main side effects of all ERT products is immunogenicity – reported rates of antibody 
production vary between products, but differences in assay design and sensitivity make 
direct comparison difficult.  Antibodies are predominately IgG and severe allergic 
reactions or anaphylaxis are rare106, facilitating home infusion for both GD and FD.  The 
impact of antibody formation on therapeutic responses has not been studied in detail in 
either disorder. 
1.6.2 Substrate reduction therapy 
Discovery that certain iminosugars can selectively inhibit the biosynthesis of 
glycosphingolipids led to the concept of reduction of the amount of substrate to a level at 
which the patient’s own residual enzyme activity is able to fully degrade it.  Miglustat was 
originally developed as an α-glucosidase inhibitor with potential anti-viral activity, but 
was found to inhibit glucosylceramide synthase at micromolar concentrations107.  In 
clinical trials in has been demonstrated to improve haematological and visceral 
parameters108 over 24 months, but direct switching of patients from ERT to miglustat may 
be associated with deterioration in haematological parameters109. Diarrhoea is a common 
side effect and development of paraesthesia has also occurred.  A second substrate 
reduction therapy, eliglustat tartrate (Genz 112638, Genzyme) is a PDMP-based analogue 
which inhibits glucosylceramide synthase at nanomolar concentrations110.  Results from 
phase II trials demonstrate improvement in haematological and visceral parameters 
comparable to those seen with ERT111 and phase III trials are expected to report shortly.  
Phase I trials of SRT for FD have been completed (Genz 682452, NCT01674036) and 
phase II trials are expected imminently. 
1.6.3 Chaperone therapy 
Many pathogenic mutations in the GBA1 and GLA genes result in protein mis-folding in 
the ER and premature degradation.  Pharmacological chaperones are small molecules 
which bind to proteins in the ER stabilising them and helping them to achieve their correct 
conformation and exit the ER to the Golgi.  Initial proof of principle for this approach was 
demonstrated by administration of galactose, a reversible competitive inhibitor of GLA, 
to a male patient with FD resulting in increased enzyme activity and improvement of 
cardiac function over a two year period112.  1-deoxygalactonojirimycin (DGJ, migalastat 
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hydrochloride, Amicus Therapies) is a competitive inhibitor of GLA which increased 
GLA activity in multiple cell types in patients with mis-folding mutations in a phase II 
trial113 and is currently undergoing phase III evaluation. 
In GD, isofagomine (Plicera, Amicus Therapeutics) showed good in vitro efficacy114, but 
only showed clinically meaningful improvements in 1/18 patients in a phase II trial115. 
High throughput screening studies identified ambroxol, an expectorant, as a potential 
chaperone116 and initial clinical data is promising117 but further evaluation is required.   
1.7 Altered blood-endothelial interactions in FD and GD 
Abnormalities in interactions between blood constituents and the vessel wall have been 
implicated in the clinical manifestations of both GD and FD.  Two key interactions 
between the endothelium and blood are haemostasis, the formation and degradation of 
fibrin clots and their regulation, and leucocyte adhesion, a key part of inflammatory 
responses involving the adherence of leucocytes to the endothelium and their 
extravasation into tissues (see Figure 1-5).  Abnormalities in both these processes have 
been implicated in the pathogenesis of some of the clinical manifestations of both GD and 
FD. 
1.7.1 Gaucher disease 
In GD there is an increased risk of bleeding which may be the presenting feature of GD 
or give rise to complications during interventions in patients with known GD (e.g. 
childbirth or orthopaedic surgery).  Whilst this has often been ascribed to 
thrombocytopenia, bleeding events can occur in patients with relatively normal platelet 
counts118 suggest abnormalities in coagulation processes beyond numerical 
thrombocytopenia.  Identification of concurrent abnormalities in procoagulant, 
anticoagulant and fibrinolytic pathways has led to the hypothesis of a state of chronic 
disseminated intravascular coagulation that may contribute to bone infarcts as well as 
bleeding risk119. 
There is an increased incidence of both polyclonal and monoclonal gammopathies120;121 
with an increased risk of multiple myeloma, estimated to be 5.9122 to 51.5 times that of 
the normal population31. Immune dysregulation within the bone marrow 
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microenvironment is thought to underlie these processes with Gaucher cells secreting 
cytokines which result in chemotaxis of leukocytes to the bone marrow.  
1.7.2 Fabry disease 
FD has often been considered a vasculopathy, contributing particularly to the development 
of cerebrovascular complications.  Whilst stroke is recognised as a complication of 
classical FD, it may occur in the absence of cardiac or renal FD complications123. It may 
also be the presenting feature of FD and recent screening studies have identified an 
incidence of FD of 0.5-3.9% in patients with stroke124;125.  Multiple mechanisms are 
thought to contribute to vascular disease including endothelial activation, altered vascular 
tone and a procoagulant state126;127, processes which have also been implicated in the 
development of renal and cardiac complications.  
1.7.3 Clinical importance 
Better understanding of these clinical manifestations and the pathogenic processes 
underlying them is important for improving diagnosis, prognosis and enabling better 
informed management decisions.  Both GD and FD are rare disorders, with patients often 
reporting long delays and circuitous routes between symptom onset and diagnosis.  
Understanding how patients present and identification of features which could raise 
suspicion of the correct diagnosis may help improve the diagnostic pathway.  Within GD, 
patients often require operative interventions (e.g. joint replacements) or are potentially at 
increased risk of bleeding during childbirth. Better understanding of the bleeding risk and 
the processes underlying it will enable more informed management decisions to be 
undertaken. 
In FD vascular events including cardiac arrhythmias and cerebrovascular events may have 
life-changing or life-limiting consequences.   These complications may occur without 
warning and currently there is little evidence base on which to be able to predict the risk 
of occurrence.  Understanding the underlying processes and risk factors for vascular 
events would be useful for predicting prognosis, which may be particularly beneficial 
when deciding whether to institute therapy or whether genetic testing, particularly in 
females, should be undertaken.  It may also better inform decisions as to whether to 
institute supportive therapies, (e.g. anti-platelet agents) to reduce risk. 
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1.7.4 Potential underlying mechanisms 
Localised thrombus formation in the vessel lumen and leucocyte adhesion and 
extravasation are normally tightly controlled and orchestrated, predominately by pro- 
and anti-inflammatory cytokines (see Table 1-7).  Abnormal activation or regulation of 
these processes may contribute to the clinical manifestations GD and FD (see Figure 
1-5); in addition altered levels of glycosphingolipids may impact on these signalling 
pathways.  
Altered composition of cell membranes as a result of glycosphingolipid accumulation may 
effect processes that occur on the cell membrane, including those involving coagulation 
enzyme complexes.  Incorporation of Gb3, LacC or GluC into phospholipid vesicles 
enhances inactivation of FV by the anticoagulant pathway128, possibly by altering lipid 
raft formation.  
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Table 1-7: Effect of cytokines & glycosphingolipids on adhesion & haemostasis 
Molecule Effect on cellular adhesion Effect on coagulation 
TNFα Up-regulation of adhesion molecules incl. 
ICAM-1, VCAM-1129 and E-selectin.    
Up-regulation of tissue factor130 
IFNγ Up-regulation ICAM1 and VCAM1 Increases TF and PAI expression in 
mouse models131 
IL1α Promotes expression adhesion molecules 
 
Increases EC TF expression and reduces 
activation of PC by thrombin-
thrombomodulin comple132. Induces 
thrombin formation and activates 
fibrinolysis in baboons133 
IL1β Promotes expression adhesion molecules  
IL6 Up-regulation adhesion molecules Activates coagulation but not 
fibrinolysis134 and induces TF 
expression 
IL8 Up-regulation adhesion molecules required 
for firm adhesion of monocytes to EC135 
Produced by HUVEC and mononuclear 
cells in response to FXa136 
IL10 Down-regulates IFNγ induced expression 
of adhesion molecules137 
Inhibits activation of coagulation and 
fibrinolysis138 
IL13 Induces expression of VCAM1 but not 
ICAM1 or E selectin on HUVEC139 
 
LacC Up-regulation of Mac1 (CR3) on 
neutrophils140 and ICAM-110 and PECAM-
1 on endothelium141  
Enhanced inactivation of FVa by protein 
C128 
S1P Increases ICAM1, VCAM1 and E selectin 
expression on HUVEC142 
Exocytosis of WP bodies, releasing 
VWF143 
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Figure 1-5: Potential vascular mechanisms of disease.  Potential sites of abnormalities between the endothelium and blood components 
resulting in vascular manifestations of GD and FD.
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1.8 Leucocyte adhesion and transmigration 
The recruitment of activated leucocytes from the bloodstream to sites of inflammation 
is mediated by cell adhesion molecules expressed on leucocytes and the local 
endothelium (see Table 1-8).  There are four key steps in this process: rolling, firm 
adhesion, extravasation and migration, regulated by processes which control activation 
or de novo synthesis of these receptors. 
Table 1-8: Adhesion receptors involved in leucocyte-endothelial adhesion 
Family Role Name Tissue distribution Ligand 
Selectins Bind carbohydrates. 
Initiate leukocyte-
endothelial interaction. 
Mediate cell margination 
& slow rolling 
P-selectin 
(PADGEM, 
CD62P) 
Activated 
endothelium & 
platelets 
PSGL-1, sialyl-
Lewisx 
E-selectin 
(ELAM-1, 
CD62E) 
Activated 
endothelium 
Sialyl-Lewisx 
L-selectin 
(LECAM-1, 
CD62L) 
Lymphocytes, 
monocytes, NK 
cells 
CD34, GlyCAM 
Integrins Bind to cell-adhesion 
molecules and 
extracellular matrix. 
Strong adhesion.  Ligands 
predominately for 
immunoglobulin 
superfamily receptors and 
complement 
CD11a:CD18 
(LFA-1, α1β2) 
Monocytes, T cells, 
macrophages, 
neutrophils, 
dendritic cells 
ICAM-1, ICAM-
2, ICAM-3, 
ICAM-4 
CD11b:CD18 
(CR3, Mac-1, 
αMβ2) 
Neutrophils, 
monocytes, 
macrophages 
ICAM-1, iC3b, 
fibrinogen, FX 
CD11c:CD18 
(CR4, p150.95, 
αXβ2) 
Dendritic cells, 
macrophages, 
neutrophils 
iC3b, fibrinogen 
CD49d:CD29 
(VLA-4, α4β1) 
Monocytes, 
macrophages 
Fibronectin, 
VCAM-1 
Immuno-
globulin 
super-
family 
Important for firm 
adhesion and leukocyte 
transmigration 
Ligand for integrins 
ICAM-1 (CD54) Activated 
endothelium, 
leukocytes 
LFA-1, Mac-1 
ICAM-2 
(CD102) 
Resting 
endothelium, 
dendritic cells, 
leukocytes 
LFA-1 
ICAM-3 (CD50) Leukocytes LFA-1, αDβ2 
VCAM-1 
(CD106) 
Activated 
endothelium 
VLA-4 
PECAM (CD31) Activated 
leukocytes, 
endothelial cell-cell 
junctions 
CD31 
Scavenger 
receptors 
Bind polyanionic ligands 
e.g. oxidised or acylated 
lipids 
SRBI (CD36, 
Platelet GPIV, 
GPIIIb) 
Platelets, 
monocytes, 
endothelium. 
oxLDL, acLDL, 
LDL, HDL, 
collagen 
Rolling 
Selectins are they key molecules mediating rolling.  They are membrane glycoproteins 
which bind specific carbohydrate moieties and are found on both leucocytes and 
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endothelial cells as well as platelets.  Pre-formed P selectin is stored in Weibel-Palade 
bodies (WPB) of endothelial cells and appears on the endothelial surface within 
minutes of exposure to inflammatory mediators (e.g. C5a or histamine)144.  TNFα and 
IL-1 also induce WPB exocytosis and additionally induce synthesis of E selectin, 
which appears on the endothelial surface within 2 hours145.  Interactions between 
selectins and carbohydrates allow leucocytes to reversibly adhere to the endothelium, 
slowly rolling along the surface of the activated endothelium.  This slow rolling 
permits the stronger firm adhesion interactions to occur; should these not occur then 
the leucocytes detach. Binding to selectins results in leucocyte arrest exposing them to 
chemokines and other stimuli in the endothelial microenvironment. 
Firm adhesion 
Firm adhesion involves interaction between integrins on leucocytes and endothelial 
ICAMs, with ICAM-1 and VCAM-1 thought to be the key mediators on the endothelial 
surface.    Integrins are heterodimers, consisting of an α and β subunit; lymphocyte 
function-associated antigen 1 (LFA-1), complement receptor 3 (CR3) and complement 
receptor 4 (CR4) share a common β subunit (β2, CD18).  Normally leukocytes only 
adhere very weakly to the surface of endothelial cells as integrins exist on the cell 
surface predominately in an inactive conformation.  Cytokines bound to proteoglycans 
on the surface of endothelial cells bind receptors on leucocytes triggering a calcium-
dependent conformational change in the integrins: from a bent, compact form to an 
extended conformation146.  Interactions between inflammation, coagulation and 
leucocyte adhesion are exemplified by CR3 which, in its activated conformation, also 
serves as a ligand for iC3b, coagulation factor X and fibrinogen.  The main ligands of 
CR4 are C3b and fibrinogen. Leucocyte integrin mediated adhesion is cation 
dependent. 
ICAM-1 is constitutively expressed at low levels on endothelial cells and leukocytes 
but expression is up-regulated by stimulation (e.g. TNFα or IL-1).  ICAM-2 is 
constitutively expressed at high levels on endothelial cells and does not increase upon 
cell stimulation.  VCAM-1 is not expressed on basal endothelial cells and is 
synthesised upon stimulation e.g. with TNFα or IL-1. 
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Extravasation and migration 
Leukocyte extravasation also involves LFA-1 and CR3 as well as further adhesive 
interactions involving PECAM which is expressed both on the leukocyte and at the 
intercellular junctions of endothelial cells.  These interactions enable leucocytes to 
squeeze between the endothelial cells.  They then move through the basement 
membrane (diapedesis) with the aid of enzymes that break down the extracellular 
matrix proteins of the basement membrane.  Migration through tissues to sites of 
inflammation occurs along chemokine gradients (e.g. IL-8). 
Activators and regulators of leucocyte-endothelial adhesion 
Up-regulation of adhesion activity can occur by three mechanisms (1) release of pre-
formed stores; (2) conformational change/ increased functional activity and (3) de 
novo synthesis.  Inflammatory mediators of this process are released by macrophages 
and include lipid mediators of inflammation (prostaglandins, leukotrienes and platelet-
activating factor (PAF)) – rapidly produced by macrophages through enzymatic 
pathways that degrade membrane phospholipids.  Their actions are followed by those 
of the chemokines and cytokines that are synthesised and secreted by macrophages in 
response to pathogens e.g. TNFα and IL1β, which activate endothelial cells.  This 
localises adhesion to sites near inflammation.  In unstimulated monocytes and 
granulocytes about 60% of CD11b and CD11c is located in peroxidase negative 
granules; stimulation by cytokines or chemotactic stimuli results in mobilisation of 
these stores, resulting in mRNA synthesis-independent up-regulation of adhesion 
molecules on the cell surface147. 
Scavenger receptors 
Scavenger receptors are structurally heterologous cell surface receptors which are able 
to bind a wide range of polyanionic ligands, including oxidised and acetylated 
lipoproteins.  CD36, a class B scavenger receptor, is expressed on monocytes, platelets 
and some endothelial cells. In addition to modified low density lipoproteins, CD36 
also binds native lipoproteins: HDL, LDL and VHDL148 and is thought to play a role 
in foam cell formation.  Scavenger receptors have been implicated in the pathogenesis 
of atherosclerosis, diabetes and cardiomyopathies149.  
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1.8.1 Cellular adhesion in FD & GD 
In FD, studies have examined both cellular expression of adhesion molecules and 
levels of soluble adhesion molecules in the plasma (see Table 1-9).  Levels of soluble 
adhesion molecules have been shown to correlate with cell surface expression150 but 
do not indicate the source of these – leucocytes, endothelium or both.   
Table 1-9: Adhesion abnormalities in FD 
Study 
population 
Sample Intervention ICAM-
1 
VCAM-1 P selectin  E selectin Ref. 
Immortalised 
cells from 
FD pt 
Dermal 
microvascular 
endothelial 
Gb3 loading ↑  ↑  ↑  64 
GB3 loading + 
TNFα 
↑ →  → 
ERT ↓ →  → 
Healthy 
donor 
primary cells 
Microvascular 
(MiVEC) & 
macrovascular 
(MaVEC) 
endothelial 
cells 
Gb3 loading → ↑ (MiVEC) 
→ 
(MaVEC) 
  151 
GLA silencing → →   
25 male FD, 
15 controls 
Plasma/serum Not on ERT ↑ ↑ ↑ → 152 
12 male FD, 
15 controls 
Plasma/serum Not on ERT → ↑ → → 153 
 
Studies have shown an increase in both VCAM-1 and ICAM-1, the key molecules 
involved in firm adhesion, as well as on some occasions increases in selectins.  
Increased expression of adhesion molecules in dermal microvascular cells from a 
patient with the R112H mutation was also accompanied by increased generation of 
reactive oxygen species which were implicated in the pathogenesis64. 
Immunophenotyping of monocytes from untreated male FD patients showed increased 
expression of CD11b and CD18, the two subunits of CR3, but no difference in 
expression of CD62L or CD49d152.  Expression of PECAM-1 has also been found to 
be increased on leukocytes from a mixed population of treated and untreated male 
patients154. 
Studies of leucocyte adhesion in GD have been more limited.  Analysis of chemotaxis 
of monocytes and neutrophils from GD1 patients has shown reduced neutrophil 
chemotaxis in 2/7 patients and reduced monocyte chemotaxis in 2/4 patients, 
associated with impaired phagocytosis155.  A larger study involving 67 GD patients 
and 62 controls showed increased leucocyte and erythrocyte adhesion to a glass slide 
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surface156. Erythrocyte but not leukocyte adhesion was correlated with the presence of 
gammopathies and both were correlated with levels of complement C3. A recent study 
of erythrocytes157 from 22 untreated GD patients showed increased erythrocyte 
adhesion to microvascular endothelial cells associated with increased expression of 
laminin α5, but without any increased expression of CD36 or CD49d on 
immunophenotyping.  Additionally, a mouse model of neuronopathic GD, with 
reduced enzyme activity only in neural cells has found increased mRNA levels of 
VCAM-1 and ICAM-1 in the grey matter of the GD mice compared to controls, 
associated with up-regulation of TNFα78. 
1.9 Haemostasis 
Haemostasis describes the processes whereby blood clot formation occurs at the site 
of a vessel injury resulting in sealing the break in the vessel wall.  It is tightly regulated 
both in location and timing and encompasses a number of processes including: platelet 
adhesion and activation; activation of coagulation enzymes to form a stable fibrin clot; 
termination of clot formation by anti-coagulant pathways and clot dissolution by 
fibrinolytic pathways as well as alterations in vascular tone.  Abnormalities in any of 
these processes can result in either bleeding or inappropriate thrombus formation. 
Platelet plug formation 
Platelets play a central role in haemostasis with functions including adhesion to the 
subendothelial matrix, platelet to platelet adhesion (aggregation), secretion of the 
contents of platelet granules and by providing a phospholipid surface for the assembly 
of coagulation factors enzyme complexes (procoagulant response).  The initial step in 
all these processes is platelet activation with activators including thrombin158 and 
collagen (potent agonists) and ADP and epinephrine (weak agonists).  Tissue factor is 
a key activator of platelets, acting through the protease-activated receptors PAR-1 and 
PAR-4159.  Following activation, platelets undergo conformational changes that 
facilitate their adhesion to the subendothelial matrix, primarily mediated by von 
Willebrand factor (VWF) via the GP1b/IX/V receptor, with additional adhesion to 
collagen.  Formation of a stable clot involves cross-linking of platelets with VWF and 
fibrin via the integrin GPIIb/IIIa.  The platelet procoagulant response involves the 
exposure of procoagulant phospholipids, primarily phosphatidylserine, on the outer 
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membrane of the platelet surface, on which coagulation factor complexes are then able 
to assemble. 
The coagulation cascade and fibrin clot formation 
A firm fibrin clot is formed as the end product of a series of enzymatic reaction 
catalysed by complexes of coagulation factors on the platelet surface.  As with platelets, 
tissue factor is also the primary activator of thrombin formation in vivo160.  Tissue 
factor (TF) may arise either due to exposure of the vascular adventitia following 
vascular damage or as the result of expression in endothelial cells or monocytes 
following activation by pro-inflammatory cytokines.  TF forms a complex with FVIIa 
and binds FX, activating it to produce a small amount of FXa161.  This FXa combines 
with FVa, primarily from platelet alpha granules, to form the prothrombinase complex 
which activates prothrombin to thrombin (initiation phase).  Thrombin has a number 
of actions one of which is activation of FVIII, FXI and FV, resulting in increased 
formation of FXa by the tenase complex (FIXa and FVIIIa) and subsequently thrombin 
(amplification phase).  Thrombin also converts fibrinogen to fibrin; fibrin forms 
polymers which are then cross-linked by FXIII to form a stable clot.   
Termination of coagulation 
To ensure localised and limited clot formation, anti-coagulant pathways exist to 
terminate the enzymatic reactions of the coagulation cascade.  Anti-thrombin (AT) is 
a circulating protease inhibitor that inhibits the enzymes of the coagulation cascade, 
especially thrombin and FXa by forming irreversible complexes with them162. Tissue 
factor pathway inhibitor (TFPI) also circulates in the plasma but at far lower 
concentrations than AT and inhibits FX activation by binding to FVIIa-TF complexes 
and FXa163. 
The protein C-protein S pathway is activated by thrombin which binds to 
thrombomodulin (TM) on the surface of endothelial cells.  This binding induces a 
conformational change in thrombin enabling it to activate protein C (PC).  This 
activation of PC is enhanced by an endothelial receptor for PC (EPCR)164.  Activated 
PC associates with protein S on the phospholipid surface and proteolytically activates 
FVa and FVIIIa.  A mis-sense mutation at position 506 in FV, switching arginine to 
glutamine, termed the FV Leiden mutation, reduces its susceptibility to inactivation by 
PC165. 
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Fibrinolysis 
To restore normal vessel flow in the lumen, the clot must be degraded by a process 
known as fibrinolysis, mediated by the enzyme plasmin which cleaves fibrin polymers 
resulting in fibrin degradation products, of which D-dimers are a major component.  
Plasminogen binds to fibrin and is activated by tissue plasminogen activator (tPA), 
predominantly produced by the endothelium166.  This process is regulated by 
plasminogen activator inhibitor 1 (PAI-1) which inhibits tPA and α2-antiplasmin 
which inhibits plasmin.  Additional control of this process is provided by thrombin-
activatable fibrinolysis inhibitor (TAFI) which is activated by the thrombin-TM 
complex and can bind to fibrin protecting it from degradation by plasmin. 
1.9.1 Coagulation abnormalities in Fabry and Gaucher 
Fabry disease 
A number of plasma studies have been performed on FD patients looking for evidence 
of a procoagulant tendency (see Table 1-10). Increased soluble tissue factor has been 
correlated with disease severity and renal function in male patients88.  The PC anti-
coagulant pathway is the most investigated. Presence of the FV Leiden mutation in 
addition to a GLA mutation has been associated with increased fibrin deposition in a 
Fabry mouse model167 and the presence of cerebrovascular disease92 and poor renal 
outcomes168 in FD patients. Additionally, detection of a lupus anticoagulant, which is 
associated with increased thrombotic events, in 33% of patients in one study169, 
suggests an additional procoagulant mechanism. 
Table 1-10: Procoagulant abnormalities in FD 
No pt 25 M 12 M 17M, 19F 4M, 5F 
TF   ↑ (M) (↑) 
VWF →  →  
PC    → 
PS    → 
TM ↓ →   
TAT   ↑ (F)  
TFPI    ↓ 
PAI ↑    
Α2AP   →  
tPA →  →  
Ref 152 153 88 170 
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Only limited studies have been performed on platelets in FD. Enhanced platelet 
aggregation to weak agonists has been reported in one study 171 with increased levels 
of β thromboglobulin, released from platelet α granules, found in this and a further 
study88, although platelet factor 4 levels (also released from α granules) were normal. 
Increased levels of homocysteine, associated with increased risk of vascular events, 
have also been reported in two studies153;170  
Coagulation abnormalities in GD: 
Abnormalities of all aspects of coagulation have been described in GD but whilst 
bleeding problems are known to occur in patients, the lack of information regarding 
bleeding symptoms in most studies makes the clinical significance of these 
abnormalities difficult to interpret.  The presence of bleeding at relatively high platelet 
counts led to further investigation of platelet function, although the presence of 
thrombocytopenia at presentation can present technical challenges.  Platelet 
aggregation has been found to be abnormal in 22-50% of patients172-174, predominately 
to low dose agonists, with some improvement noted following ERT.   The mechanisms 
underlying the aggregation abnormalities are unknown.  Although it has been 
hypothesised that glucocerebrosides in the plasma adsorb to the platelet membrane 
impairing function175, incubation of normal platelets with glucosylceramide for three 
hours did not result in impaired aggregation172, suggesting that, at least over this short 
time period, excess glucosylceramide did not affect aggregation.  
Abnormalities of platelet membrane function have also been described.  Assessment 
of platelet adhesion using a cone-plate analyser (Impact-R) revealed reduced adhesion 
in GD compared to controls, even in patients receiving ERT118.  Mixing studies 
suggested that this was due to an intrinsic platelet defect with reduced adhesion being 
associated with the presence of mucosal bleeding.  Abnormal platelet adhesion has 
also been described in two splenectomised GD patients where increased ristocetin 
induced platelet aggregation was found despite normal glycoprotein 1b and von 
Willebrand activity, resulting in a diagnosis of “pseudo-pseudo-Bernard-Soulier” 
syndrome175. 
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Table 1-11: Coagulation abnormalities in GD: percentage of patients with 
coagulation protein abnormalities 
No. 
patients 
30 9 11 15 5 21 10 28 
↑PT 42 11 - 47 80 - 100 81 
↑APTT 38 55 100 53 100 - 60 - 
↓FII 50 11 - - 20 - 20 - 
↓FV 87 22 18 23 100 - 30 27 
↓FVII 33 - 9 8 0 - 50 - 
↓FVIII 10 11 27 15 60 - 30 27 
↓FIX 3 0 73 31 20 - 20 14 
↓FX 57 - 9 8 20 - 10 - 
↓FXI 27 33 - 0 40 - 0 36 
↓FXII 30 - - 15 25 - 10 27 
↓PC 26 - - - - 10 - - 
↓PS 11 - - - - - - - 
↓AT 3 - - - - 0 - - 
↑D dimer 68 - - - - 76 - - 
↑TAT 46 - - - - 43 - - 
Reference 119 176 177 174 178 179 180 181 
 
Multiple studies have reported the presence of a prolonged prothrombin time (PT) 
and/or activated partial thromboplastin time (APTT).  Measurement of coagulation 
factor activity has revealed decreased activity of multiple coagulation factors, with 
sometimes multiple deficiencies in the same patient, albeit mostly mild (see Table 
1-11).  Two studies which re-measured factor activity following ERT noted 
improvements in a number of patients 174;180.  Although reduced FXI activity has been 
hypothesised to be the result of co-inheritance of mutations in the F11 gene due to the 
high carrier rate of both disorders in the Ashkenazi Jewish population182, the presence 
of multiple factor deficiencies suggests a more global process affecting synthesis, 
consumption or both. 
Variable coagulation factor activity in some patients led to the hypothesis of 
glycosphingolipid interference with phospholipids in coagulation factor activity 
assays176 although measurement of antigen levels showed that these correlate with 
measured activity119. The additional finding of decreased levels of anticoagulant 
proteins and increased products of fibrinolysis has led to the hypothesis of chronic 
activation of coagulation resulting in a consumptive coagulopathy 119;179.  Raised D-
dimer levels have been correlated with severity of bone disease183. 
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1.10 Aims of project 
This project explores the disease manifestations of FD and GD which are associated 
with abnormalities at the blood-endothelial interface, predominately bleeding events 
in GD and vascular complications in FD.  The first half of this project examines these 
disease manifestations in the presentation and complications of GD and FD within the 
large patient cohorts of the Lysosomal Storage Disorders Unit at the Royal Free 
Hospital.  It explores the role of these manifestations in the diagnosis of these disorders 
and offers insights into how the diagnostic process might be improved.  It explores the 
manifestations in relation of other clinical features of these disorders in order to 
explore potential common underlying mechanisms.  The second half of the project 
details laboratory investigation of cellular abnormalities in leukocyte-endothelial 
adhesion and cellular support of haemostasis using primary cell isolates from patients 
and through development of an endothelial cell model of disease to explore the 
contribution of cellular dysfunction to these processes. 
1.10.1 Hypotheses 
The central hypothesis of this thesis is that vascular events constitute an important part 
of the pathology of FD and GD and therefore furtherance of our understanding of these 
events, from both an epidemiological and pathophysiological stand point, will advance 
patient care.  Specific hypothesis tested are as follows: 
Chapter 3:  Bleeding features in the presentation of GD 
1.  Patients presenting with GD most commonly are diagnosed by haematologists 
by bone marrow biopsy.  Rationale: GD is rare and therefore not commonly considered 
in the differential diagnosis of thrombocytopenia/splenomegaly; consequently it is 
diagnosed when bone marrow biopsies are performed for other possible diagnoses 
2. Bleeding severity is associated with overall disease severity and the presence 
of gammopathies and bone infarcts. Rationale: the bleeding diathesis has been 
proposed to arise due to chronic activation of the coagulation system as a result of 
chronic inflammation 
3. FXI deficiency is a manifestation of GD rather than genetic co-inheritance and 
improves with ERT Rationale: the wide range of factor deficiencies described in prior 
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studies suggests a disease-related mechanism rather than inherited deficiencies of 
coagulation factors. 
Chapter 4: Vascular features of FD 
1. Patients presenting with FD may experience vascular events (e.g. stroke, 
arrhythmias) prior to diagnosis and experience long delays between those events and 
arrival at the correct diagnosis  Rationale: FD is rare and therefore not commonly 
considered in the differential diagnosis of vascular events such as stroke or atrial 
fibrillation 
2. Cerebrovascular events are not predicted by other disease manifestations, 
enzyme activity or more common cardiovascular risk factors Rationale: strokes have 
been reported in patients without other disease manifestations and in cohort of patients 
with cryptogenic stroke 
3. Abnormalities of plasma procoagulant and anticoagulant factors are associated 
with vascular manifestations of FD Rationale: von Willebrand factor and 
anticoagulant pathways are controlled primarily by the endothelium and these disease 
manifestations have been hypothesised to be due to endothelial dysfunction.  
Chapter 5: Cellular adhesion in FD and GD 
1. Increased expression of leukocyte adhesion molecules occurs in FD and GD and 
is associated with vascular manifestations in FD and the presence of bleeding and 
gammopathies in GD. Rationale: FD and GD are associated with a pro-
inflammatory state which results in up-regulation of adhesion molecules 
2. Lipid loading of endothelial cells, but not reduction in enzyme activity alone 
results in increased endothelial adhesion activity. Rationale: results to date suggest 
that Gb3 excess rather than GLA deficiency is responsible for endothelial 
dysfunction.  Glycosphingolipids LacC and S1P have been found to up-regulate 
adhesion molecule expression and other glycosphingolipids may also perform this 
function. 
Chapter 6: Cellular support of haemostasis in FD and GD 
1. Monocytes from FD and GD have increased tissue factor expression and are 
procoagulant. Rationale: tissue factor expression is induced by pro-inflammatory 
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cytokines.  FD is associated with a procoagulant state and laboratory studies in 
GD suggest that chronic activation of coagulation occurs. 
2. The platelet membrane in FD and GD has altered procoagulant capacity. 
Rationale: glycosphingolipid accumulation within lipid rafts in the platelet 
membrane may also membrane dynamics required for assembly of coagulation 
enzyme complexes (e.g. prothrombinase) 
3. The endothelium in FD is procoagulant and supports increased thrombin 
generation. Rationale: microvascular lesions occur in FD and have been 
hypothesised to be due to increased activation of coagulation. 
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Chapter 2 Methods 
Except where indicated, all experiments were performed by myself.  For solutions and 
buffers, where no supplier is listed these were made in house and full details of their 
production are listed in Appendix 2. All suppliers of materials were based in the UK. 
2.1 Patient and healthy control recruitment 
The study received ethical approval from the National Research Ethics Committee 
(NREC number: 12/LO/0271).   Patients and controls gave written consent for 
participation in the study.  Healthy controls were recruited from departmental members 
and unaffected relatives/partners accompanying patients to clinic.  The patient 
information leaflet and ethics approval can be found in Appendix 1. 
2.2 General cell culture methods & equipment  
All plate readings were performed on a BMG FluoSTAR Galaxy fluorimeter (BMG 
Lab Tech). 
2.2.1 Cell lines  
Tissue culture work was performed in a class II biosafety cabinet.  Cells were cultured 
in an incubator at 37°C, 5% CO2 (HERAcell 150, Kendro) 
The RAW 264.7 cell line was obtained from ATCC.  RAW264.7 is a semi-adherent 
murine monocyte-macrophage cell line, established from ascites of a tumour induced 
by intraperitoneal injection of Abselon Leukaemia Virus into a male mouse. RAW 
264.7 were cultured in R10 medium, consisting of RPMI 1640, supplemented with 
10% fetal bovine serum (FBS, Life Technologies), 10mM HEPES (Life Technologies), 
100 units/ml penicillin, 100µg/ml streptomycin (Life Technologies) and 2mM L-
glutamine (Life Technologies).  Cells were harvested from tissue culture plastic (TCP) 
using 0.02% EDTA (Sigma) supplemented with 1mg/ml of lidocaine (Sigma).  Cells 
were passaged every 3-4 days, split 1:3-1:5 and used up to 30 passages. 
The EA.hy 926 cell line was obtained from ATCC. It is a human umbilical vein 
endothelial cell (HUVEC) line established by the fusion of HUVEC with a 
thioguanine-resistant clone of the A549 adenocarcinoma cell line by exposure to 
polyethylene glycol184.  The EA.hy 926 cell line was cultured in high glucose (4.5g/L) 
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) supplemented 
with 10% FBS, 10mM HEPES, 100 units/ml penicillin, 100µg/ml streptomycin and 
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2mM L-glutamine.  Cells were harvested from TCP with 0.25% trypsin-EDTA 
solution (Sigma) and were passaged weekly, split 1:10-1:16 and used up to 30 passages. 
The HEK293T cell line was obtained from ATCC for use as a packaging cell line for 
the generation of lentiviral particles. It is a human embryonic kidney (HEK) cell line, 
derived from the HEK293 cell line into which the simian virus 40 (SV40) T cell 
antigen has been inserted.  The cells were cultured in high glucose DMEM 
supplemented with 10% FBS, 10mM HEPES, 100 units/ml penicillin, 100µg/ml 
streptomycin and 2mM L-glutamine.  Cells were harvested using 0.25% trypsin-
EDTA solution and passaged every 2-3 days, split 1:4.   
2.2.2 Cell counts and viability 
Cells were enumerated utilising a haematocytometer.  Cell viability was measured by 
Trypan blue (Sigma) dye exclusion and viability of cell lines maintained at >95%. 
2.2.3 MTT dye reduction assay 
Thiazolyl blue tetrazolium bromide (MTT) is a tetrazolium compound which is 
reduced by the mitochondrial dehydrogenases NADPH & NADH in metabolically 
active cells to a water-insoluble but DMSO soluble blue MTT-formazan crystals.  
Cells cultured in 96 well plates were exposed to drugs for 24-72 hours prior to the 
assay being performed.  MTT (Sigma Aldrich) was dissolved in appropriate medium 
DMEM at 5mg/ml. 10μl per well of MTT suspension was added and the plate 
incubated at 37°C for 2 hours.  The medium was carefully aspirated from the wells and 
100μl per well of DMSO (Sigma) added.  The plate was placed on a plate shaker at 
150rpm for 30 minutes, until the crystals were fully dissolved.  The resulting 
absorbance was read at 570nm.   
2.3 Sample preparation 
2.3.1 Separation of peripheral blood monocyte-enriched mononuclear cells 
A monocyte-enriched mononuclear cell fraction was isolated using an iodixanol 
flotation barrier to produce a monocyte enriched, platelet poor cell fraction. 54% 
iodixanol was prepared by the addition of 0.6 volumes of 8.5% NaCl solution to 5.4 
volumes of 60% iodixanol (Optiprep, Sigma).  An iodixanol gradient with a density of 
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1.074g/ml was prepared by the addition of 6.3 volumes of 60% iodixanol to 23.7 
volumes R10 medium. 
9ml of blood was collected into a sterile 15ml centrifuge tube containing 1ml of 3.2% 
sodium citrate solution and inverted to ensure adequate mixing.  2ml of 54% iodixanol 
was added to the citrated blood to increase its density to approximately 1.105g/ml.  
4ml of the increased density blood was added to each fresh 15ml Falcon tube and 
overlaid with 6ml of the 1.074 iodixanol gradient.  The gradient was overlaid with 
500μl of R10, to prevent the monocytic layer interfacing with air.  The sample was 
centrifuged at 700g for 30min at 4°C.  Following gradient centrifugation, the 
uppermost band, containing monocyte enriched mononuclear cells was removed with 
a sterile syringe and quill. The isolated cells were washed once in 8.5% NaCl and re-
suspended in 3ml of R10 medium. 
2.3.2 Preparation of human serum 
5ml of whole blood was collected into a 5ml Gold SST vacutainer (Becton Dickinson 
- BD) and allowed to clot for 30min at 4°C.  The samples were centrifuged at 2000g, 
5min, 4°C.  100μl serum was used to make heat inactivated autologous serum by 
heating at 56°C for 1 hour in a waterbath.  The remained was aliquotted and stored at 
-80°C until use. 
900μl of RPMI 1640, supplemented with HEPES, penicillin/streptomycin and L-
glutamine was added to 100μl serum to make 10% autologous medium for use in 
adhesion assays. 
2.3.3 Preparation of pooled human serum  
Healthy volunteers were bled into 5ml Gold SST vacutainers (BD).  The samples were 
clotted at 4°C for 30min and then centrifuged at 2000g, 5min, 4°C.  The serum was 
aspirated and serum from all samples pooled.  The serum was heat inactivated at 56°C 
in a waterbath for 1 hour.  The serum was then aliquoted and stored at -80C prior to 
use. 
2.3.4 Preparation of plasma  
Whole blood was collected in 2.7ml citrate vacutainers (BD).  For single spun plasma, 
vacutainers were centrifuged at 2500g, room temperature for 20minutes. The top 2/3 
of plasma was aspirated, aliquoted and stored at -80°C until use.  For triple spun 
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plasma, after the initial centrifugation step, the aspirated plasma was centrifuged a 
further time at 2500g, room temperature for 20 minutes then the top 2/3 plasma 
aspirated and centrifuged at 14000rpm for 3min using a mini-Eppendorf fixed 
centrifuge. Triple spun plasma was stored at -80°C until use. 
2.3.5 Preparation pooled human plasma 
Healthy volunteers were bled into 2.7ml citrate vacutainers and centrifuged at 3500g, 
room temperature for 20 minutes.  The top 2/3 plasma from each sample was collected 
and the samples were pooled.  The plasma was then prepared as for triple spun plasma 
above, aliquoted and stored at -80°C until use. 
2.3.6 Preparation of platelet rich plasma 
Blood was collected in 2.7ml citrate vacutainers and centrifuged at 160g, room 
temperature for 10 minutes. The platelet count was measured using a Sysmex XS-
1000i bench top analyser. 
2.4 Drugs and lipids stock solutions 
2.4.1 Enzyme inhibitors 
Amiodarone hydrochloride was obtained from the Royal Free Hospital Pharmacy as a 
sterile concentrate 50mg/ml in 3ml ampoules.  A 50mM stock solution was made by 
the addition of 1.65ml of sterile water to 3ml of amiodarone concentrate.  The solution 
was aliquotted and stored at -20°C 
A 50mM stock solution of chloroquine was made by dissolving 300mg of chloroquine 
hydrochloride (Sigma) in 11.63ml of sterile water.  The solution was sterile filtered, 
aliquotted and stored at -20°C. 
A 100mM stock solution of 1-deoxygalactonijorimycin (DGJ) was made by dissolving 
20mg of 1-deoxygalactonijorimycin hydrochloride (Carbosynth) in 1ml of sterile 
water.  The solution was aliquotted and stored at -20°C. 
A 100mM stock solution of conduritol β epoxide (CBE) was made by dissolving 5mg 
of conduritol β epoxide (Sigma) in 308μl of sterile water.  The solution was aliquoted 
and stored at -20°C. 
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2.4.2 Glycosphingolipids 
Stock concentrations of lipids were made by dissolving lipids in methanol.  Stocks 
were aliquoted and stored at -80°C. Stocks were all 1mM, except for sphingosine 
(10mM).  For globotriaosylceramide, hot methanol was used and the sample warmed 
prior to use to ensure the lipid was re-solubilised.  The following lipids were used: 
globotriaosylceramide (Gb3, Matreya LLC), globotrioasylsphingosine (lysoGb3, 
Matreya LLC), lactosylceramide (bovine buttermilk, Matreya LLC), glucosphingosine 
(plant, Santa Cruz Biotechnology), sphingosine (ENZO life sciences) and sphingosine-
1-phosphate (Sigma). 
2.4.3 Antibiotics 
A stock solution of 10mg/ml puromycin dihydrochloride (Sigma) in distilled water 
was made, aliquotted and stored at -20°C.  A stock solution of 100 mg/ml of ampicillin 
sodium (Sigma) was made in distilled water, aliquotted and stored at -20°C. 
2.5 Generation of lenitviral shRNA knockdown endothelial model 
An endothelial cell model of Fabry disease was created using small-hairpin RNA 
targeting the alpha galactosidase A mRNA sequence, delivered to cells using a 
replication incompetent lentiviral vector. An application was submitted to and 
approved by the UCL Safety Committee to conduct work involving genetically 
modified organisms (experiment number 1556 RF – see Appendix 3) and work was 
conducted in accordance with departmental guidelines. Plasmids were obtained from 
the UCL Cancer Institute shRNA library; the GIPZ plasmids are also available 
commercially from the Thermo Scientific Open Biosystems Human GIPZ shRNAmir 
lentiviral library. The shRNA sequences and vector maps are detailed in 5.4.3.  
2.5.1 Isolation of plasmid DNA 
Plasmids were supplied as bacterial stabs.  A small amount of bacteria was streaked 
on an Agar plate, supplemented with 100μg/ml of ampicillin, and incubated at 37°C 
overnight.  The following day, a single colony was picked with a pipette tip and 
transferred to 5ml of LB broth, containing 100μg/ml ampicillin.  The broth was 
cultured overnight at 37°C with 200rpm shaking. Plasmid DNA was isolated using a 
QIAprep® Spin Miniprep kit (Qiagen), following the manufacturer’s instructions. 
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2.5.2 Quantification of DNA 
The DNA was quantified spectrophotometrically using a Nanodrop 1000 (Thermo 
Scientific). 1.5μl of sample was placed on the pedestal and the DNA quantified based 
on absorbance of UV light.  The purity was ascertained from the ratio of the OD at 
260nm to 280nm.  Where higher than 250ng/μl, the DNA concentration was adjusted 
to 250ng/μl using molecular grade distilled water (Sigma). DNA was stored at -80°C 
until required. 
2.5.3 Confirmation of packaging vectors by restriction digest 
A restriction digest was performed of the packaging vectors (p8.91 and pMDG) to 
ensure the complete plasmid was present (Figure 5-3).  A single digest was also 
performed to linearise the DNA. 500ng of plasmid DNA was added to an Eppendorf 
followed by 1μl of the appropriate restriction endonuclease (EcoR1, Bgl II or BamH1, 
New England Biolabs) and 2μl of the correct buffer supplied with the endonucleases 
(New England Biolabs).  The reaction volume was made up to 20μl with distilled water 
and the incubated at 37°C for 30 minutes. 
A 1% agarose gel was made by dissolving 1g of agarose (Bioline) in 100ml of TBE 
buffer.  Once cooled slightly 5μl of 10mg/ml ethidium bromide (Sigma) was added in 
a fume hood and the gel poured into a template.  The set gel was transferred to the gel 
tank and the tank filled with 1% TBE buffer.  5μl of loading dye (Thermo Scientific) 
was added to each reaction mixture.  2.5μl of sample was added per well of the gel.  
5μl of Hyperladder I molecular weight marker (BioLine) was added to appropriate 
wells.  The gel was run at 100V for 75 minutes and the bands visualised under UV 
light (BioRad Gel Doc XR+). 
2.5.4 Sequence confirmation of shRNA segment of GIPZ plasmids 
Sequencing of the GIPZ plasmids was undertaken to ensure that the correct shRNA 
insert was present. The pGIPZ primer (Sigma) sequence is (5’ to 3’): 
GCATTAAAGCAGCGTATC. 250ng of plasmid DNA and 1μl of 10μM pGIPZ 
primer were added to a well of a 96 well sequencing plate (Life Technologies) and the 
volume made up to 8μl with 10mM Tris/0.01mM EDTA, pH 8.0 (Sigma).  The sample 
was denatured by heating to 98°C for 5 minutes on a thermal cycler (BioRad C1000).  
The sample was cooled on ice for 7 minutes prior to the addition of 2μl of BigDye v1.1 
(Life Technologies). The DNA was the amplified by polymerase chain reaction (PCR) 
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on the thermal cycler at 96°C for 20 seconds, 50°C for 5 seconds, 60°C for 120 seconds, 
for 40 cycles. The 10μl of reaction mixture was then transferred to a DyeEx clean-up 
plate (Qiagen) and centrifuged at 1000g for 3 minutes to remove the excess dye 
terminators.  The samples were then air dried at 70°C for 1 hour and then re-suspended 
in 10μl of HiDi-formamide (Life Technologies). 
The DNA was sequenced on an ABI 3500 automated sequencer (Life Technologies) 
using the standard run module. The sequences analysed using Mutation Surveyor 
Software v3.3 (SoftGenetics) and compared to the sequences supplied by the 
manufacturer. 
2.5.5 Lentiviral vector production 
Replication incompetent lentiviral particles containing the shRNA sequence of interest 
were generated using a third generation packaging system in HEK293T cells.  The 
three plasmids used comprised: 
1. P8.91: the packaging vector containing a minimal set of genes required to generate 
the virion structural proteins 
2. pMDG: vesicular stomatitis virus G protein envelope vector 
3. pGIPZ: shRNA vector containing the shRNA sequence of interest as well as puromycin 
resistance gene and GFP gene. 
On the day prior to transfection (D-1), HEK293T cells were seeded at sub-confluence 
on 10cm tissue culture treated plates and cultured overnight at 37°C. 
The following day (D0), 1μg of p8.91 DNA, 1μg of pMDG DNA and 1.5μg of pGIPZ 
DNA were mixed together in an Eppendorf.  In a separate Eppendorf 10μl of Fugene 
6 (Promega) was added to 200μl of Optimem (Invitrogen).  The DNA mixture was 
added to the Fugene/Optimem mix and left to stand at room temperature for 15 minutes.  
The medium on the HEK293T cells was changed with fresh pre-warmed medium and 
the DNA/Fugene/Optimem mix added to the plate.  The plate was incubated overnight. 
On D+1, the medium on the HEK293T plates was changed.  On D+2, the medium 
contain the virus particles was collected and passed through a 0.2μm sterile filter 
(Sartorius).  Fresh medium was added to the HEK293T plates and further virus 
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collected on D+3 and D+4. Virus was stored overnight at 4°C prior to use and surplus 
virus aliquoted and stored at -80°C. 
2.5.6 Infection of EA.hy 926 cells with lenitviral vector 
On D-1, EA.hy cells were seeded at 100 000 per well in 6 well plates (Corning) and 
cultured overnight.  On D0, the medium was changed to antibiotic and serum free 
DMEM. 1.5ml of virus was added per well. To increase the infection rate, 8μg/ml of 
hexadimethrine bromide (polybrene, Sigma) was added and the plate centrifuged for 
1 hour at 500g, room temperature prior to incubation overnight at 37°C.  On D+1, 
medium was replaced with fresh DMEM containing serum and antibiotics.  On D+2, 
successful viral infection was confirmed by visualisation of GFP expression under a 
fluorescent microscope (Nikon Eclipse TS100).  Puromycin selection of infected cells 
was commenced using a dose of puromycin pre-determined by MTT assay to result in 
death of uninfected cells over 3-6 days.  shRNA knockdown was confirmed by 
measurement of GLA enzyme activity and protein levels.  Cells cultures were 
maintained in puromycin containing medium. 
2.6 Flow cytometry 
2.6.1 General flow cytometry method 
Monoclonal antibodies were used as direct conjugates with fluorescein isothiocyanate 
(FITC), AlexaFluor® 488, phycoerythrin (PE), peridinin-chlorophyll-protein complex 
(PerCP) and allophycocyanin (APC).  1-10x105 cells per aliquot were incubated in the 
dark with the designated panel of antibodies for 30mins before being washed and re-
suspended in PBS.  Samples were acquired on a FACS Calibur (BD), with 5000-10 
000 events being recorded and analysed with CellQuest (BD) or FlowJo (Tree Star).  
  
67 
 
Table 2-1: Antibodies used in flow cytometry 
Target Species Ig class Product 
code 
Company Clone Conjugate Dilution 
CD11a Mouse IgG2a κ 555379 BD G43-25B FITC 1:10 
CD11b  Mouse IgG1κ 301306 Biolegend ICRF44 PE 1:10 
CD11c Mouse IgG1κ 301614 Biolegend 3.9 APC 1:10 
CD50 Mouse IgG2b κ 555958 BD TU41 FITC 1:10 
CD54 Mouse IgG1κ 353112 Biolegend HA58 APC 1:10 
CD102 Mouse IgG1κ 328506 Biolegend CBR-
IC2/2 
PE 1:10 
CD62L Mouse IgG1κ 304816 Biolegend DREG-56 AlexaFluor 
488 
1:20 
CD49d Mouse IgG1κ 304304 Biolegend 9F10 PE 1:10 
CD142  Mouse IgG1 FAB23391
G 
R&D 
systems 
323519 AlexaFluor 
488 
1:20 
CD36 Mouse IgG2aκ 336208 Biolegend 5-271 APC 1:10 
CD204 
(SR-AI) 
Mouse IgG2b FAB2708P R&D 
systems 
351615 PE 1:10 
CD14 Mouse IgG2b κ 345786 BD MφP9 PerCP 1:10 
CD14 Mouse IgG2b κ 345785 BD MφP9 PE  1:10 
CD3 Mouse IgG1κ 345766 BD SK7 PerCP 1:10  
2.6.2 Quantification of monocyte percentage by flow cytometry 
50μl of monocytic fraction isolated over an iodixanol gradient was placed in a round 
bottom tube (BD). 5μl of CD14 PE and 5μl of CD3 PerCP was added and the sample 
incubated in the dark for 30 minutes. The % of monocytic cells was ascertained from 
the percentage of CD14 positive cells within a gate set to include monocytes and 
lymphocytes based on their forward and side scatter properties, as detailed in section 
5.4.2. 
2.6.3 Flow cytometry of D0 monocytes for adhesion receptors and tissue factor 
50µl of the monocytic fraction was placed in each of 4 round bottomed tubes (BD) and 
the panels of antibodies added (see Table 2-2).  Further analysis was undertaken after 
data collection using FlowJo to determine the mean fluorescent intensity of the 
adhesion receptor in different mononuclear cell populations. 
Table 2-2 Antibody panels for D0 monocyte adhesion 
 Tube 1 Tube 2 Tube 3 Tube 4 
FITC/AlexaFluor 
®488 
CD11a CD50 CD62L CD142 
PE CD11b CD54  CD36 
APC CD11c CD102 CD49d CD204 
PerCP CD14 CD14 CD14 CD14 
 
68 
 
2.7 Adhesion assays 
2.7.1 Monocyte adhesion to tissue culture plastic 
The monocyte fraction isolated over an iodixanol gradient was adjusted to a 
concentration of 1x106 monocytes/ml. Cells were re-suspended in either 10% heat 
inactivated autologous serum 10% heat inactivated pooled human serum.  105 cells 
were added per well of a 96 well TCP plate (Corning) with or without addition of 5mM 
EDTA.  All conditions were performed in triplicate.  The plate was incubated at 37°C 
for 1 hour to allow the monocytes to adhere. 
The plate was washed three times with PBS to remove non-adherent cells.  100μl of 
100% methanol was added per well and the cells fixed overnight at 4°C.  The plate 
was washed once with PBS and 100μl per well of 20% Giemsa stain (Sigma) added.  
The plate was left one hour to stain, then washed three times with tap water.  The 
Giemsa was solubilised by adding 100μl per well of 100% methanol and placing the 
plate on a plate shaker for 30 minutes.  Absorbance was read at 570nm. The adherence 
of monocytes was reported as the ratio of the mean absorbance of the test sample to 
the mean absorbance of the pooled human serum. 
2.7.2 Adhesion of RAW cells to EAhy cells 
EA.hy cells were seeded at 40 000 per well (for 3 day cultures) or 20 000 per well (for 
7 day cultures) with additional drugs (lipids/ enzyme inhibitors) added where indicated, 
and cultured at 37°C.  For 7 day cultures, the medium was changed after 3 days. On 
the day of the adhesion assay, where indicated, EA.hy were stimulated with 
recombinant human tumour necrosis factor alpha (TNFα, Life Technologies) at the 
doses and durations indicated. 
RAW cells were harvested from tissue culture plastic using 0.02% EDTA 
supplemented with 1mg/ml of lidocaine the day prior to the adhesion assay.  They 
were then cultured overnight on 10cm bacteriological plastic petri-dishes to allow 
recovery of adhesion receptors.  For the adhesion assay, RAW were harvested using 
5mM EDTA and re-suspended at 1x106/ml in serum free medium.  5μl per ml of 
Vybrant ® DiI cell labelling solution (Life Technologies) was added and the cells 
incubated at 37°C for 5 minutes followed by 15 minutes at 4°C.  DiI is a fluorescent 
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lipophilic carbocyanine dye. The cells were then washed three times in serum-
containing DMEM and re-suspended at 2x106/ml. 
Medium was removed from the EA.hy plate and replaced with 100μl per well of DiI 
labelled RAW.  Under some conditions, 5μl per well of 100mM EDTA was also added. 
The plate was incubated at 37°C for 1 hour and then washed three times with PBS to 
remove non-adherent cells.  Fluorescence was measured at excitation 530nm, emission 
590nm. 
2.8 Cell staining techniques 
EA.hy cells for cell staining were grown on 13mm No1 glass coverslips (Scientific 
Laboratory Supplies). Coverslips were dipped in ethanol and flame sterilised over an 
electric Bunsen burner.  EA.hy cells were seeded 100 000 per well of a 24 well plate 
(Corning) and cultured for 7 days.  Prior to staining, coverslips were washed three 
times in PBS prior to fixation in methanol or 4% paraformaldehyde as indicated below. 
2.8.1 Giemsa staining 
The cells were fixed for 20 minutes in methanol then stained with 5% filtered Giemsa 
for 45 minutes.  The coverslips were rinsed in tap water and dried before being 
mounted face down in DPX Mountant (Sigma) on glass microscope slides (VWR 
International). 
2.8.2 Fluorescent staining for von Willebrand factor 
Cells were fixed in 4% paraformaldehyde for 20 minutes then washed twice with PBS.  
The cells were permeabilised with 0.1% Triton in PBS for 10 minutes, washed and 
blocked by incubating with 3% BSA in PBS for 1 hour at room temperature.  Primary 
antibody staining was performed with a 1:200 dilution of polyclonal rabbit anti-human 
VWF (A0082, Dako) and incubated for 1 hour at room temperature.  The coverslips 
were washed three times with PBS and secondary antibody staining performed with 
Texas Red conjugated goat anti-rabbit antibody (1:200 dilution, GeneTex) for 1 hour 
at room temperature.  The coverslips were washed three time in PBS then nuclear 
staining performed with 1:1000 dilution of 4’,6’-diamidino-2-phenylindole (DAPI, 
Life Technologies), 1 minute incubation.  The coverslip was washed and mounted face 
down on a glass slide in Prolong Gold mountant (Life Technologies). 
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2.8.3 Cellular uptake of DiI labelled acetylated LDL 
EA.hy cells were grown to confluence on glass coverslips in a 24 well plate. On the 
day of the assay, human DiI labelled acetylated LDL (Intracell) was made up in 
medium at a concentration of 10μg/ml.  The medium was aspirated from the wells and 
replaced with 300μl of DiI acLDL containing medium.  The cells were incubated at 
37°C for 4 hours.  The coverslips were removed from the 24 well plate, washed and 
fixed in 4% paraformaldehyde before being mounted in Prolong Gold mountant. 
2.8.4 Imaging 
Slides were imaged using a Nikon Eclipse TS100 microscope and Nikon DsFi1 camera.  
Imaging of fluorescently stained slides was performed on a Leica TCS SP5 confocal 
microscope with assistance of David Westmoreland, MRC Laboratory of Molecular 
Cell Biology, UCL. 
2.9 Enzyme assays 
2.9.1 Cell lysate preparation 
For cell lines, the medium was aspirated from confluent monolayers of cells in 96/24 
well plates 50/150μl ProtoJet Mammalian Cell lysis solution (Fermentas) added. The 
plate was placed on a plate shaker, 150rpm for 15 minutes, following which the cells 
were disrupted with a pipette tip to ensure fully lysed and the lysate collected into an 
Eppendorf. The sample was centrifuged at 13 000rpm for 15 min and the supernatant 
used in assays or stored at -80°C until required. 
For patient samples, 10ml blood was collected into a vaccutainer containing EDTA 
(BD).  5ml of Lymphoprep (Axis Shield) was added to the bottom of a 15ml centrifuge 
tube (Falcon) and overlaid with 10ml of whole blood.  The sample was centrifuged at 
650g, 4°C for 25 minutes, brake off.  The mononuclear layer was aspirated into a 1.7ml 
Eppendorf and centrifuged at 8000rpm, 2 minutes.  The supernatant was aspirated.  
The cell pellet was re-suspended in 1ml of red cell lysis solution and left for 5 minutes 
at room temperature.  The sample was centrifuged at 8000rpm, 2 minutes, the 
supernatant discarded and the pellet re-suspended in 1ml PBS.  After further 
centrifugation 8000rpm, 2 minutes, the PBS was discarded and the pellet stored at -
80°C.  On the day of enzyme assays/protein quantification the pellet was thawed and 
re-suspended in 800μl of Mammalian cell lysis solution. The sample was placed on a 
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plate shaker at 150rpm for 15 minutes and then centrifuged at 13 000rpm for 15 
minutes.  The supernatant was used for protein quantification or enzyme assays, 
usually after a 1:3 dilution in distilled water. 
2.9.2 Protein quantification 
Protein quantification was performed using a Bicinchoninic Acid (BCA) Protein 
Assay kit (Sigma).  This is based on the method of Lowry 185 and relies on the 
formation of a Cu2+-protein complex under alkaline conditions, with subsequent 
reduction of Cu2+ to Cu1+.  The amount of reduction is proportional to the amount of 
protein present.  BCA forms a purple-blue complex with Cu1+ under alkaline 
conditions with an absorbance of 560nm. 
The assay was performed in a 96 well plate.  A bovine serum albumin (BSA) standard 
supplied in the kit was used to construct a standard curve across the linear range of the 
assay (0-1000μg/ml).  25μl of test or standard samples were added to wells in duplicate.  
BCA working reagent was made up by mixing 1 part of 4% copper (II) sulphate 
pentahydrate solution with 50 parts of bicinchionic acid solution (bichionic acid, 
sodium carbonate, sodium tartrate and sodium bicarbonate in 0.1N NaOH, pH 11.25).  
200μl of working solution was added to each sample well and the plate incubated at 
37°C for 30 minutes.  Absorbance was read at 560nm and the test sample protein 
concentrations read off the standard curve. 
2.9.3 General method for enzyme activity measurement 
Assays were performed in 24 well plates (PlateMax 24, 4titude), laid out as 
summarised in Table 2-3. 150μl of substrate-inhibitor working solution was added to 
wells 3-5 and 15μl of sample of known protein concentration to wells 4 & 5.  The plate 
was incubated at 37°C for 1 hour.  After the incubation, 1000μl of 1M glycine stopping 
solution was added to wells 3-5. 200μl of 4-methylumbeliferone standard working 
solution was added to well 1 and 200μl of distilled water to well 2.  950μl of 1M 
glycine was added to wells 1&2 and 15μl of sample to wells 1-3.  The fluorescence 
was then measured at excitation 365nm, emission 450nm 
  
72 
 
.Table 2-3: Layout of enzyme assays 
Additions 1 2 3 4  5 
 Standard Standard 
blank 
Substrate 
blank 
Sample 
reaction 
Sample 
reaction 
Pre-
incubation 
Nil Nil 150µl 
substrate 
150µl 
substrate 
15µl sample 
150µl 
substrate 
15µl sample 
After 1hr 
incubation 
  1000µl 
Glycine 
1000µl 
glycine 
1000µl 
glycine 
After glycine 15µl sample 
200µl 
standard 
950µl glycine 
15µl sample  
200µl ddH2O 
950µl glycine 
15µl sample   
The enzyme activity (nmol/hr/mg protein) was then calculated by the equation: 
𝐸𝑛𝑧𝑦𝑚𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑥
1000
15
𝑥
1
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐 (
𝑚𝑔
𝑚𝑙 )
 
Where the fluorescence of the sample equals the average test reading of the sample (4 
& 5) minus the substrate blank (3) and the fluorescence of the standard = the standard 
reading (1) minus the standard blank (2). 
2.9.4 Preparation of substrate-inhibitor solutions 
At acid pH, alpha galactosidase A hydrolyses the substrate 4-methylumbelliferyl-α-
galactopyranoside to 4-methylumbelliferone and galactose.  Addition of an excess of 
α-N-acetyl galactosamine inhibits the activity of alpha galactosidase B.  A 8mM stock 
substrate solution was prepared by dissolving 250mg of 4-methylumbelliferone-α-D-
galactopyranoside (Sigma) in 74ml of Mcilvaine’s buffer.  This was aliquoted and 
stored at -20°C.  An inhibitor-substrate working solution was made by adding 500mg 
of N-acetyl-D-galactosamine (Sigma) to 11.3ml of stock substrate solution. 
At acid pH, alpha galactosidase B (N-acetyl-galactosaminidase) hydrolyses the 
substrate 4-methylumbelliferyl-N-acetyl-β-D-galactosaminidine to 4-
methylumbelliferone and N-acetyl-galactosamine. Substrate solution was made by 
dissolving 100mg of 4-methylumbelliferyl-N-acetyl-β-D-galactosaminidine (Sigma) 
in 264 ml of Mcilvaine’s buffer, pH 4.7.   
At acid pH, beta glucocerebrosidase hydrolyses the substrate 4-methylumbellifryl-β-
D-glucopyranoside to 4-methylumbelliferone and glucose.  Sodium taurocholate 
added to the substrate solution inhibits the activity of unrelated β-glucosidases.  The 
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substrate stock solution consists of 4.8mM 4-methylumbelliferyl-β-D-
glucopyranoside made by dissolving 250mg of 4-methylumbelliferyl-β-D-
glucopyranoside (Sigma) in 96ml of Mcilvaine’s buffer pH5.9. Sodium taurochlorate 
is then added to give a final solution of 4.8mM 4.8mM 4-methylumbelliferyl-β-D-
glucopyranoside, 1.5% sodium taurocholate (Sigma), pH 5.1. 
2.10 Western blot analysis 
Western blots were performed using the NuPage ® system (Life Technologies).  The 
primary antibodies used are listed in Table 2-4. 
2.10.1 Cell lysate preparation 
EA.hy cells for western blot analysis were seeded at 2x105 per well in 24 well plates 
and cultured for 3 days or 1x105 per well and cultured for 7 days.  For cell lysis, 
medium was aspirated from the wells and the cells washed in 1ml of warmed Hanks 
buffer.  Cell lysis solution was made by supplementing 1ml of whole cell lysis solution 
with 10μl of protease cocktail inhibitor (Sigma) and 10μl of 100mM 
phenylmethylsulfonyl fluoride (17.4mg/ml in DMSO).  Hanks buffer was aspirated 
from the wells and 100μl of cell lysis solution added per well.  The plate was left on 
ice for 10 minutes and then the cells disrupted with a pipette tip and the lysate 
transferred to an Eppendorf.  The samples were centrifuged at 14 000rpm, 10 minutes 
at 4°C.  The lysate was collected and stored at -80°C until analysis. 
2.10.2 Preparation of samples for loading onto gel 
Loading dye mix was made by adding 2.5 volumes of 1M DL-dithiothreitol to 7.5 
volumes of loading dye (NuPage, Invitrogen).  10μl of loading dye mix was added to 
20μl of sample.  Molecular weight markers for loading were made by adding 3μl of 
Novex ® Sharp Pre-stained Protein Standard (Life Technologies) to 17μl distilled 
water and adding 10μl of loading dye mix.  All samples for loading were then heated 
at 80°C for 10 minutes. 
2.10.3 Gel electrophoresis 
Running buffer was made by diluting 50ml of 20X NuPage ® MOPS SDS running 
buffer (Life Technologies) in 950ml of distilled water. A 12% Bis-Tris NuPage ® gel 
(Life Technologies) was washed with running buffer and then inserted into the gel tank.  
500μl of NuPage ® antioxidant (Life Technologies) was added to the centre well of 
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the tank and both the inner and outer wells filled with running buffer. Samples were 
loading using a Hamilton syringe.  The gel was run at 200V for 50 minutes. 
2.10.4 Transfer of proteins from gel to membrane 
Transfer buffer was made from 12.5ml of 20X transfer buffer, 25ml methanol, 200μl 
anti-oxidant and made up to 250ml with distilled water.  The gel was removed from 
the tank and cracked open using a gel spatula.  Buffer-soaked filter paper was applied 
to the back of the gel.  Hybond membrane (GE Healthcare) was applied to the front of 
the gel and covered with filter paper.  The gel-membrane sandwich was placed in the 
transfer cassette, encased with buffer-soaked sponges and placed in the gel tank.  The 
inner tank was filled with transfer buffer and the outer tank with tap water.  The transfer 
was run at 25V for 90 minutes. 
The gel-membrane sandwich was removed from the transfer cassette and the filter 
paper and gel discarded.  The membrane was stained for 30 seconds with Ponceau S 
(Sigma) to ensure transfer of the protein bands.  
2.10.5 Blocking and antibody staining 
The membrane was washed for 30-45 minutes in TBS-Tween on a plate shaker at 
80rpm, with 3-5 changes of wash solution.  The membrane was then placed in a roller 
bottle and 10ml of blocking solution supplemented with 500μl of FBS and 100μl of 
10% azide added.  The bottle was placed in a rotating oven at 21°C and blocked for 1 
hour.  After 1 hour, the primary antibodies were added at the appropriate dilution and 
the incubated overnight in the rotating oven. 
The following day, the membrane was removed and washed 5 times in TBS-Tween. 
The membrane was placed in a clean roller bottle and 10ml of blocking solution, 
supplemented with 500μl FBS added.  The appropriate HRP-conjugated secondary 
antibody was added and the membrane incubated for at least 2 hours in the rotating 
oven, prior to being washed 5 times in TBS-Tween. 
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Table 2-4: Antibodies used for Western blotting 
Antibody Species Target band size Manufacturer Dilution (μl per 
10ml) 
Alpha galactosidase A Rabbit 50kDa Santa Cruz (H-104) 10μl 
VCAM-1 Sheep 85kDa R&D systems 
(AF809) 
10μl of 100μg/ml 
ICAM-1 Sheep 90kDa R&D systems 
(AF720) 
5μl of 200μg/ml 
Hsp60 Mouse 60kDa Stressgen  3μl of 1:10 dilution 
PARP Mouse 113kDa (plus 
89kDa on 
cleavage) 
BD 3μl 
Aldolase Sheep 39kDa Abcam (ab182915) 3μl 
HRP-conjugated anti-
rabbit 
Goat N/A Dako 3μl 
HRP-conjugated anti-
sheep 
Goat N/A Dako 3μl 
HRP-conjugated anti-
mouse 
Rabbit N/A Dako 3μl 
 
2.10.6 Enhanced chemiluminescene visualisation of bands 
PierceTM enhanced chemiluminescent substrate (Thermo Scientific) was used for 
detection of horse radish peroxidase enzyme activity.  A 1:1 solution of reagent A and 
reagent B was made. The membrane was placed on a Perspex board and 1ml of ECL 
mixture added to membrane and incubated for 1 minute.  The membrane was wrapped 
in Saran wrap and exposure to X ray film (Fuji) for 2, 6, 20, 60, 180 and 600 seconds.  
The film was then developed manually by placing in developer for 1 minute followed 
by fixer for 1 minute and washing in tap water before drying. 
2.10.7 Staining with a house keeping antibody for normalisation 
Normalisation for protein content was performed using the housekeeping protein heat 
shock protein 60 (Hsp60).  After initial antibody staining, the membrane was washed 
5 times in TBS-Tween.  Further antibody staining was then performed by incubating 
the membrane overnight in blocking solution containing mouse anti-human Hsp60 
antibody.  The membrane was then washed and incubated for 2 hours with HRP 
conjugated rabbit anti-mouse secondary antibody. ECL was performed as above.  For 
a small number of later blots, aldolase was used for normalisation due to the 
unavailability of Hsp60. 
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2.10.8 Densitometry 
The density of the bands was measured using Quantity One 4.6.9 (BioRad).  The 
density of each band of protein of interest was then normalised to the density of the 
Hsp60 band for that sample. 
2.11 Coagulation assays 
2.11.1 Tissue factor procoagulant assay 
Monocytes isolated over an iodixanol gradient were re-suspended in TrisHCl-1% BSA 
buffer at 1x106 monocytes/ml. Pooled citrated plasma and 25mM calcium chloride 
were warmed to 37°C.  100μl of monocyte suspension and 100μl of pooled plasma 
were added per macrocuvette (Merlin Medical) and placed in a KC4 coagulometer 
(Amelung).  The plasma and monocytes were incubated together at 37°C for 120 
seconds.  100μl of 25mM calcium chloride was added and the time to clot formation 
measured.  For the construction of a standard curve, the monocytes were replaced by 
dilutions of Recombiplastin (DiaPharma). The assays were performed in triplicate and 
the tissue factor activity in arbitary units read off the standard curve. 
2.11.2 Platelet rich plasma thrombin generation 
Thrombin generation was performed using the Calibrated Automated Thrombogram 
(Thrombinoscope BV).  Use of a slow-reacting fluorogenic substrate for thrombin 
allows repeated measurement of thrombin generated over a prolonged period of time. 
A mathematical program in the CAT calculates the free thrombin generated from the 
raw thrombin generation data. Measurements were performed in duplicate. 
1pM tissue factor is made by diluting Innovin (Sysmex, UK) which is thought to have 
a tissue factor concentration of 6nM in HEPES buffer.  80μl of platelet rich plasma 
was added to 3 wells in an Immunolon 2HB round bottomed 96 well plate.  20μl of 
1pM tissue factor was added to the two test wells and 20μl of thrombin calibrator 
(Stago Diagnostica) added to the calibrator well.  The reaction mixture was incubated 
at 37°C for 10 minutes.  The reaction was started by the addition of 20μl per well of a 
calcium solution containing the fluorogenic substrate (FluCa, Stago Diagnostica) and 
the measurements commenced.  Readings were taken automatically every 20 seconds 
for 60 minutes.  
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2.11.3 Preparation of washed platelets 
Platelet rich plasma (PRP) was diluted 2:1 with Krebs Ringer buffer, pH 5.0 and 
centrifuged at 500g, room temperature for 10 minutes.  The platelet pellet was re-
suspended in Krebs Ringer buffer supplemented with glucose and was twice further.  
The platelet pellet was re-suspended in Tris-HCl-1% BSA buffer and the platelet count 
measured.  
2.11.4 Prothrombinase assay 
The conversion of prothrombin to thrombin is catalysed by the prothrombinase 
complex (FVa-FXa) in the presence of calcium ions, occurring on a phospholipid 
surface.  In this assay FVa and FXa are present in excess so that the phospholipid 
surface provided by the platelets is the rate limiting factor.  A schematic overview of 
the assay method is shown in Figure 2-1.  
A 300nM stock of FXa was made by diluting FXa (Haematologic Technologies) to a 
total volume of 7.25ml in TrisHCl-1%BSA.  A 600nM stock of FVa was made by 
diluting FVa (Haematologic Technologies) to a total volume of 496μl in TrisHCl-
1%BSA.  A 16μM stock of prothrombin was made by diluting prothrombin in a total 
volume of 1736μl in TrisHCl-1%BSA.  All coagulation factors were aliquoted and 
stored at -20°C.  A thrombin-specific chromogenic substrate, S2238 (Chromogenix), 
was re-constituted at 3mM in distilled water. 
Working solutions of FVa and FXa were made just before performing the assay by 
diluting the stock solution 1:10 in TrisHCl-1%BSA.  Washed platelets were re-
suspended at 100x109/L and 50x109/L in Tris-Hcl-1%BSA.  The assay reaction was 
performed in a water bath at 37°C.  158μl of platelet suspension (or dilutions of 
phospholipid standard, Bell and Alton Platelet Substitute, Diagnostic Reagents Ltd.) 
was placed in a cuvette in a waterbath and incubated for 3 minutes.  5μl of 0.11M 
calcium chloride was added and after a further minute 25μl of FVa and 25μl of FXa 
were added.  After a further minute, the reaction was started by the addition of 60μl of 
prothrombin.  5μl sub-sampling of the reaction mixture into 200μl of stopping buffer 
in a 96 well plate was performed at specified time points (0, 15, 30, 45, 60, 75, 90, 105, 
120, 150, 180, 240, 360, 480 and 600 seconds).   
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On completion of the prothrombinase reaction, 10μl of chromogenic substrate was 
added to each well of the 96 well plate.  After 3 minutes the reaction was stopped by 
the addition of 50μl of 50% acetic acid.  The absorbance was read on the plate reader 
at 405nM.
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Figure 2-1: Prothrombinase assay
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2.11.5 Measurement of plasma von Willebrand factor antigen level by ELISA 
Plasma von Willebrand factor (VWF) was measured by an in house enzyme-linked 
immunosorbant assay in the Royal Free Haemophilia Centre.  A 96 well ELISA plate 
(Immunolon 1, Dynatech Laboratories) was coated with the primary antibody the day 
before the assay. A 1:1000 dilution of rabbit anti-human von Willebrand antibody 
(A0082, Dako) in coating buffer was made and 100μl added per well.  The plate was 
stored overnight at 4°C. 
CRYOcheck normal reference plasma, with a known concentration of VWF (Precision 
Biologic) was used to construct a standard curve.  CRYOcheck was diluted 1:80 in 
dilution buffer and then a further range of dilutions made.  Test samples were diluted 
1:200 in dilution buffer. All samples were tested in duplicate.  The coated plate was 
washed times with wash buffer and the 100μl standard/sample added per well. The 
plate was incubated for 1 hour on a plate shaker.  The plate was washed three times 
with wash buffer. A 1:8000 dilution of tag antibody (HRP-conjugated rabbit anti-
human VWF, P0226, Dako) was made in dilution buffer.  100μl of tag antibody was 
added per well.  The plate was incubated for 1 hour on a plate shaker.  The plate was 
washed three times with wash buffer.  Substrate solution was made by adding 6mg of 
O-phenylene dihydrochloride (OPD, Sigma) and 7μl of 30% hydrogen peroxide 
(Sigma) to 15ml of substrate buffer.  100μl of substrate solution was added to each 
well and the plate incubated on the bench for 8-10 minutes.  The reaction was stopped 
by addition of 100μl of 0.5M sulphuric acid per well.  The absorbance was read on a 
plate reader at 492nm.   The VWF concentrations were read off the standard curve and 
the results multiplied by two, to account for the 1:200 dilution of the test samples.  
2.11.6 Coagulation assays performed by the haemophilia centre laboratory 
The following assays performed by the haemophilia centre laboratory biomedical 
science staff following the standard SOPs of the diagnostic laboratory and the methods 
employed are discussed in the relevant chapters: 
- Thrombophilic protein coagulation activity: FVIII, protein C, protein S, anti-thrombin 
and dilute Russell Viper venom test (see Chapter 4) 
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- Mutation analysis for FV Leiden (G1691A) and prothrombin gene mutation 
(G20210A) (see Chapter 3) 
- FXI activity and F11 gene sequencing (see Chapter 3) 
2.12 Statistics 
Statistical analyses were performed using Excel 2010 (Microscoft) and GraphPad 
Prism version 6.02 (GraphPad).  For comparisons between two groups, t-tests were 
used for normally distributed data and Mann Whitney U if the data was not normally 
distributed.  Linear regression analyses were performed to establish the relationship 
between two variables.  Except where otherwise stated a p value of <0.05 was 
considered significant. 
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Chapter 3 Bleeding features in the presentation of Gaucher disease 
3.1 Introduction 
Whilst the initial description of GD was of a patient with splenomegaly, GD affects 
the entire reticulo-endothelial system with disease manifestations including bone 
infarcts, peripheral blood cytopenias and a bleeding diathesis.  Whilst bleeding has 
been reported in patients with GD, the pattern and severity of bleeding symptoms is 
not well characterised.    
Both abnormalities of platelet function and coagulation factor deficiencies have been 
described and various hypotheses proposed as to the underlying mechanisms (see 
Table 3-1).   In addition interference of glycosphingolipids with the assays has also 
been proposed at as a cause for in vitro abnormalities119.  Improvements following 
ERT have been reported in both platelet aggregation abnormalities and coagulation 
factor activity. 
Table 3-1: Potential mechanisms of coagulopathy in coagulopathy in GD 
Platelets Coagulation factors 
Decreased production due to bone marrow 
infiltration 
Splenic sequestration 
Increased consumption 
Decreased production due to: 
Genetic abnormalities (e.g. in F11 gene). 
Hepatic impairment 
Increased consumption 
Adsorption by glucocerebrosides 
 
It is not known how prominent bleeding manifestations are in the presentation of GD.  
With the advent of effective specific therapy for GD and the suggestion that early 
initiation of therapy may reduce long term complications186, there is clear impetus to 
make a timely diagnosis.   Better understanding of the clinical features with which 
patients present may help with earlier identification and investigation of patients with 
possible GD.  The relationship between bleeding and other manifestations of GD has 
not been examined – it is not known whether bleeding symptoms are a marker of 
disease severity or whether they impact on the development of other disease features, 
in particular bone disease.  
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3.2 Purpose of this chapter 
This chapter explores the presenting features of GD in the Royal Free cohort of patients 
in order to identify specific patterns of clinical and laboratory abnormalities which 
may serve to raise suspicion of the diagnosis. The severity and nature of bleeding 
symptoms is examined and correlated with other disease manifestations to identify any 
common mechanisms.   Finally, the changes in deficiency of a specific coagulation 
factor in response to enzyme replacement therapy are described.  FXI is specifically 
discussed as this is the coagulation factor that was frequently found to be reduced in 
our cohort. The chapter consists of three sections:   
1. Description of the presenting features of patients in the cohort: 
a) Presenting features 
b) Diagnosing speciality and diagnostic test 
c) Identification of clinical and laboratory abnormalities commonly found at 
baseline 
2. Bleeding manifestations within the cohort and their relation to: 
a) Baseline platelet counts and coagulation abnormalities 
b) Overall disease severity, bone disease and gammopathies 
3. In patients with FXI deficiency at baseline: 
a) Effect of FXI on bleeding score/complications 
b) Changes in FXI levels following initiation of ERT 
3.3 Hypotheses 
1. Patients presenting with GD most commonly are diagnosed by haematologists 
by bone marrow biopsy.  Rationale: GD is rare and therefore not commonly considered 
in the differential diagnosis of thrombocytopenia/splenomegaly; consequently it is 
diagnosed when bone marrow biopsies are performed for other possible diagnoses 
2. Bleeding severity is associated with overall disease severity and the presence 
of gammopathies and bone infarcts. Rationale: the bleeding diathesis has been 
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proposed to arise due to chronic activation of the coagulation system as a result of 
chronic inflammation 
3. FXI deficiency arises as a manifestation of GD rather than genetic co-
inheritance and improves with ERT Rationale: the wide range of factor deficiencies 
described in prior studies suggests a disease-related mechanism rather than inherited 
deficiencies of coagulation factors. 
3.4 Methods 
3.4.1 Historical case notes review 
Patients with GD have been seen at the Royal Free since 1974, with the centre being 
designated a national specialist centre in 1997. A retrospective case note review was 
undertaken to establish key features regarding the time course from symptom onset to 
diagnosis, the diagnosing speciality and diagnostic tests.  The primary presenting 
feature was defined as the main clinical feature which, on investigation, led to the 
diagnosis of GD.  Bleeding manifestations and baseline laboratory abnormalities were 
recorded.  Laboratory abnormalities were defined as being outwith the normal range 
for the laboratory at the time the test was performed.  The cohort included patients 
managed at the Royal Free GD clinic up until May 2012. 
3.4.2 Disease severity scoring 
The severity of GD was scored using the Zimran severity score index (SSI) based on 
patients’ baseline characteristics 34, see Table 3-2. 
Table 3-2: Zimran severity score 
Domain Feature Score 
Cytopenia Unsplenectomised 
If splenectomised: 
Leukopenia 
Anaemia 
Thrombocytopenia 
1 
 
1 
1 
1 
Splenomegaly None 
Mild 
Moderate 
Massive 
Splenectomised 
0 
1 
2 
3 
3 
Hepatomegaly None 
Mild 
Moderate 
Massive 
0 
1 
2 
3 
Liver function tests Normal 0 
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Some abnormal 
All abnormal 
1 
2 
Clinical signs liver disease  4 
CNS involvement  20 
Other organ involvement (e.g. 
lung) 
 4 
Bone – objective No signs/symptoms 
Xray or scan signs 
0 
1 
Bone – subjective No pain 
Mild/occasional pain 
Chronic pain 
0 
2 
3 
Bone – fractures None 
Post traumatic 
Avascular necrosis or 
pathological 
0 
2 
5 
 
3.4.3 Assessment of bone disease 
Historical assessment of bone disease was with plain film radiographs, which are able 
to identify many abnormalities including avascular necrosis, infarcts and bone 
remodelling.  Over the last two decades, the use of MRI imaging to assess bone disease 
has been employed.  This is more sensitive in detecting bone abnormalities and also 
enables semi-quantitative assessment of the degree and site of bone involvement, using 
the bone marrow burden (BMB) scoring system to be undertaken187, with a higher 
score signifying more severe bone involvement (see Table 3-3).  All MRIs were 
reviewed by a radiologist specialising in GD and the BMB scores reported as part of 
routine clinical care. 
Table 3-3: Bone marrow burden score 
Domain Abnormality Score 
MRI signal intensity: T2 
images (spine and femora) 
relative to subcutaneous fat 
Hyperintense 
Slightly hyperintense 
Isotense 
Slightly hypointense 
Hypointense 
Mixed type 
2 
1 
0 
1 
2 
3 
MRI signal intensity: T1 
images (spine and femora). 
Relative to subcutaneous fate 
Slightly hyperintense or 
isotense 
Slightly hypointense 
Hypointense 
0 
1 
2 
Sites of involvement (femora)  Diaphysis 
Proximal epiphysis/apophysis 
Distal epiphysis 
1 
2 
3 
Sites of involvement (spine) Patchy 
Diffuse 
Absence of fat in basivertebral 
vein region 
1 
2 
1 
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3.4.4 Bleeding severity score 
The condensed MCMDM-1 VWD bleeding states questionnaire188 was used to obtain 
a standardised bleeding history in an interview between the patient and the investigator 
(see Table 3-4).  It was originally developed to aid in the diagnosis of von Willebrand 
disease (VWD); 100 healthy controls had a mean bleeding score of 0.16 (±2SD -3.2-
+3.6) and therefore an abnormal bleeding score was defined as ≥4188.  
Table 3-4: Condensed MCMDM-1 VWD bleeding score 
Domain -1 0 1 2 3 4 
Epistaxis  No or 
trivial 
(<5 
min) 
>5-<10 
minutes 
Consultation 
only 
Packing/ 
cauterisation/a
nti-
fibrinolytics 
Blood 
transfusion/ 
factor 
replacemen
t/ 
desmopress
in  
Cutaneous  No or 
trivial 
(<1cm) 
>1cm and 
no trauma 
Consultation 
only 
  
Bleeding 
from minor 
wounds 
 No or 
trivial 
(<5min) 
>5 min Consultation 
only 
Surgical 
haemostasis 
Transfusion
/ factors/ 
DDAVP 
Oral cavity  No Reported at 
least once 
Consultation 
only 
Surgical 
haemostasis/ 
antifibrinolytic
s 
Transfusion
/ factors/ 
DDAVP 
GI bleeding  No Associated 
with ulcer/ 
portal 
hypertensi
on/ 
haemarrhoi
ds 
Spontaneous Surgical 
haemostasis/ 
transfusion/ 
DDAVP/ 
factors/ 
antifibrinolytic
s 
 
Tooth 
extraction 
No 
bleeding 
in at least 
2 
extractio
ns 
Not 
done or 
nil in 1 
extracti
on 
In <25% 
procedures 
In >25% 
procedures, 
no 
intervention 
Resuturing or 
packing 
Blood 
transfusion/ 
factors/ 
DDAVP 
Surgery No 
bleeding 
in at least 
2 
surgeries 
Not 
done or 
nil in 1 
surgery 
In <25% 
surgery 
In >25% 
surgery, no 
intervention 
Surgical 
haemostasis or 
antifibrinolytic
s 
Transfusion
/ factors/ 
DDAVP 
Menorrhagi
a 
 No Consultatio
n only 
Antifibrinolyt
ics or pill use 
Curretage or 
iron therapy 
Transfusion
/ factors/ 
DDAVP/ 
hysterecto
my 
Post partum 
haemorrhag
e 
No 
bleeding 
in at least 
2 
No 
deliveri
es or no 
Consultatio
n only 
Curettage/ 
iron therapy/ 
anti-
fibrinolytics 
Transfusion/ 
factors/ 
DDAVP 
Hysterecto
my 
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deliverie
s 
bleedin
g in 1 
Muscle 
haematoma 
 Never Post 
trauma, no 
therapy 
Spontaneous, 
no therapy 
Requiring 
DDAVP or 
factors 
Requiring 
transfusion 
or surgery 
Haemarthro
sis 
 Never Post 
trauma, no 
therapy 
Spontaneous, 
no therapy 
Requiring 
DDAVP or 
factors 
Requiring 
transfusion 
or surgery 
CNS 
bleeding 
 Ever   Subdural, any 
intervention 
Intracerebr
al, any 
interventio
n 
 
3.4.5 FXI activity and mutation analysis 
Patients who had been previously identified as FXI deficient, either due to 
investigation of a prolonged APTT at baseline or investigation of bleeding symptoms 
were identified and baseline FXI levels recorded.  A follow up sample was collected 
and FXI activity measured by automated one-stage ATPP-based activity assay using 
an ACL TOP analyser (Instrumentation Laboratories) by the biomedical staff of the 
haemophilia centre laboratory (Royal Free Hospital).  In patients found to have a FXI 
level below the normal range on follow up, sequencing of the 15 exons of the F11 gene 
was performed (Ms G Mellars, chief BMS, Genetic Laboratory, Haemophilia Centre, 
Royal Free Hospital). 
3.5 Results 
3.5.1 Overview of GD cohort 
The cohort consisted of 86 patients: 49 males (57%) and 37 females (43%).  45 (52%) 
of these patients were referred at the time of diagnosis, 29 (34%) had a known 
diagnosis of GD but were not receiving ERT at the time of referral and 12 (14%) were 
already receiving ERT and transferred care either due to geographical reasons or 
following the designation of specialist centres in 1997 (see Figure 3-1).  Although 
ERT has been available since 1991, there are still patients diagnosed with GD in the 
pre-ERT era being referred for specialist review.  Sixty-eight patients (79%) had at 
least on N370S mutation with compound heterozygosity for the N370S with another 
(non-N370S or L444P) mutation being the commonest mutation type.  
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Figure 3-1: RFH cohort overview. A: Referrals to RFH: 2-4 new diagnoses are seen 
each year; despite the availability of ERT since 1991 there are still patients with known 
diagnoses being referred on for treatment, suggesting that awareness of therapy is 
incomplete.  B: genotypes of the cohort. 
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3.5.2 Presentation of Gaucher disease 
The key symptom, investigation of which led to the diagnosis of GD, was considered 
the presenting feature. Symptoms related to splenomegaly and bleeding were the 
commonest presenting features (see Table 3-5 and Figure 3-2).  Bleeding most 
commonly consisted of excessive bruising, but two patients presented with post-
operative bleeding (following a hip replacement and gingivectomy).  Symptoms 
related to splenomegaly included abdominal pain, early satiety and distension or a 
palpable mass.  Bone pain was the third commonest presentation, primarily with hip 
pain; this was associated with avascular necrosis in two cases and one patient presented 
with a pathological fracture and was found to have a concurrent diagnosis of multiple 
myeloma.  In 16 patients (18.6%) the diagnosis arose following investigation of 
abnormalities (predominately thrombocytopenia and splenomegaly) detected 
opportunistically during routine antenatal care, routine examinations (e.g. insurance 
medicals) or unrelated medical problems (e.g. road traffic accidents).   
GD has an increased prevalence in the Ashkenazi Jewish population and carrier 
screening for this and other high prevalence disorders (e.g. Tay-Sachs) is offered to 
this community by some charities (e.g. Jewish Genetic Disorders UK).  Two patients 
were diagnosed with GD by this method.  An additional eight were diagnosed 
following the diagnosis in an affected sibling or after being born to two known 
carrier/affected parents. 
  
90 
 
 
Figure 3-2: Presentation of GD.  A: Primary presenting symptom. B: Diagnosing 
speciality. C; Initial diagnostic test.  D: Time from symptom onset to diagnosis. 
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Table 3-5: Primary presenting features of GD 
Category Feature No. (%) 
Symptomatic Abdominal pain/distension 16 (18.6) 
Bruising/ bleeding 16 (18.6) 
Bone pain 12 (14) 
Fatigue 5 (5.8) 
Growth failure 2 (2.3) 
Jaundice 2 (2.3) 
Pathological fracture 1 (1.2) 
Incidental Thrombocytopenia/splenomegaly in pregnancy 4 (4.6) 
Incidental abnormal FBC 6 (7) 
Incidental splenomegaly 5 (5.8) 
Incidental abnormal liver function tests 1 (1.2) 
Screening Affected sibling/ parents 8 (9.3) 
High-risk community 2 (2.3) 
Unknown  6 (7) 
 
Diagnosing speciality and diagnostic test 
Consistent with the common presentations of bruising and splenomegaly, 79% of 
patients were diagnosed by haematologists (including haemostasis specialists in 4%) 
(see Figure 3-2).  Despite bone pain being a common primary presenting feature, 
patients were rarely diagnosed by orthopaedic surgeons or rheumatologists.  One 
patient was diagnosed by a clinical biochemist following investigation of marked 
hypertriglyceridaemia, having presented to their GP with debilitating fatigue. 
Bone marrow biopsy was the primary diagnostic test and was performed in 58 (68%) 
of patients with the diagnosis being made less commonly following other tissue 
biopsies: liver 8 (9%), splenectomy 1 (1%) and bone (1%). Despite the availability of 
peripheral blood leucocyte enzyme assays since 1970189, enzyme assays were only 
used as the primary test in 8 patients (9%) outside the context of family or Jewish 
community screening. 
Time from symptom onset to diagnosis 
The median age at diagnosis was 26 years (range 0-76).  The median time from onset 
of symptoms attributable to GD to diagnosis was 2 years (range <0.5-27 years).  The 
time from symptom onset to diagnosis has not changed significantly with the advent 
of specialist services and ERT: prior to 1997, the median time to diagnosis was 1.5 
years (range 0.5-27) and after 1997 3.0 years (range 0.5-27), p = 0.27).  The shorter 
times from symptom onset to diagnosis in those diagnosed prior to 1975 is likely to 
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due to the fact that those with long diagnostic delays during this period would have 
been diagnosed at an older age and may be already deceased. 
Most delays were due to non-investigation rather than mis-diagnosis.  In the eight 
patients with delays of 10 or more years, three had a long history of hip pain with one 
being diagnosed with Perthes disease age 13 and the other two were diagnosed with 
avascular necrosis of the hip in their 30s.  Two had a history of significant bleeding 
requiring surgical intervention post dental extraction and tonsillectomy, both aged 7 
and another was had been diagnosed with “chronic immune thrombocytopenia purpura” 
on the basis of chronic thrombocytopenia.   The other two patients had long histories 
of persistent abdominal pain and splenomegaly dating back to childhood. 
3.5.3 Clinical and laboratory abnormalities at the time of presentation 
Full blood counts were analysed in non-splenectomised patients referred either at the 
time of diagnosis or prior to enzyme replacement therapy (N = 64), see Figure 3-3.  
Mean haemoglobin was 12.3g/dl (range 6.6-16.3), mean white cell count 4.84x109/L 
(range 1.97-11.28) and mean platelet count 90x109/L (range 30-255).  Mean neutrophil 
count was 3.0x109/L (range 1.2-8.41) and mean lymphocyte count 1.48x109/L (range 
0.6-4.56). 
The forty five patients who were referred for assessment at the time of initial diagnosis 
had a more complete clinical and laboratory assessment performed and these were 
analysed in order to identify key features, which if present in combination, should raise 
suspicion of GD amongst clinicians (see Figure 3-3).  Splenomegaly, either palpable 
or on ultrasound assessment, (87%), hepatomegaly (44%) and bruising (40%) were the 
commonest clinical features.  Bone pain was reported by 36% with 11% already having 
avascular necrosis of the hip at the time of diagnosis.  Blood tests performed at 
diagnosis included: full blood count, coagulation screen, liver function tests, 
immunoglobulins, serum protein electrophoresis, ferritin and serum angiotensin 
converting enzyme (ACE).  A raised serum ACE (97%), hyperferritinaemia (87%), 
thrombocytopenia (82%) and low HDL cholesterol (75%) were the commonest 
laboratory abnormalities.  43% had a prolonged APTT at baseline. 
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Figure 3-3: Discriminating GD from other diagnoses. 
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3.5.4 Bleeding symptoms in Gaucher disease 
54% of patients had documented bleeding symptoms at presentation.  These were 
predominately bruising (45%) but post-operative bleeding (including post-dental 
extraction) was reported in 8%.  Bleeding scores were obtained in 40 GD patients (15 
females, 25 males) and 47 (33 females, 15 males) healthy controls.  The median 
bleeding score in healthy controls was 0 whilst the median bleeding score in GD 
patients was 3.  19 (47.5%) of GD patients had a score ≥4, whilst only 1 control (2.1%) 
did. 
No controls or GD patients reported any gastrointestinal, central nervous system, joint 
or muscle bleeds.  Bleeding symptoms in controls were confined to epistaxis, 
menorrhagia, post partum haemorrhages and, in one control, a bleeding wound (see 
Figure 3-4), consistent with findings from previous studies188.  In contrast, in GD 
patients bleeding symptoms occurred across the spectrum of mucocutaenous bleeding 
symptoms and were more severe than in controls.  Dental extraction and post-surgical 
bleeding often required surgical intervention or, in one case, transfusion.  One patient 
had a hysterectomy to control post-partum haemorrhage and had also had other severe 
bleeding events, including post dental extraction resulting in a total score of 15. 
 Bleeding symptoms and platelet count 
The relationship between the baseline platelet count and bleeding symptoms, both 
historical recorded symptoms and bleeding scores was examined (see Figure 3-5).  
The median platelet count in patients with bleeding symptoms was not significantly 
lower than in those without (77 x109/L (range 34-225) vs. 103 x109/L (range 37-189), 
p=0.13. The median platelet count in those with post-operative bleeding was 61x109/L 
(range 41-92).  Only two patients with epistaxis and one patient with post-operative 
bleeding had a platelet count <50 x109/L. 
Similarly, there was no relationship between bleeding score and platelet count.  The 
median platelet count in those with a bleeding score <4 was 87x109/L (range 37-241) 
compared to 64x109/L (range 38-159) in those with a score ≥4 (p = 0.33).  Three 
patients were excluded from this analysis as there was no pre-splenectomy platelet 
count available. 
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Figure 3-4: Bleeding symptoms and severity. A: bleeding symptoms established 
from historical case notes review. B: MCMD1 bleeding scores in GD patients and 
controls. C: bleeding score subsets Gaucher patients.  D: bleeding score subsets 
controls. 
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Figure 3-5: Bleeding features in relation to platelet count and disease severity 
(ISS).  A: Baseline platelet count and bleeding symptoms – historical cohort. B: 
baseline platelet count and bleeding score; C: baseline severity and bleeding symptoms 
– historical cohort; D: baseline severity and bleeding score. 
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Bleeding symptoms and disease severity 
There was no difference in the baseline SSI severity score between GD patients with 
and without bleeding symptoms (median 6, range 1-12 vs. median 5.5, range 2-16; p 
= 0.62), see Figure 3-5. The median score in those with post-operative bleeding was 
7 (range 3-12).   
Amongst those patients with bleeding scores, there was similarly no relationship 
between baseline severity and bleeding score.  The median SSI of those with a bleeding 
score <4 was 5 (range 1-23), whilst the median SSI of those with a bleeding score ≥4 
was 6 (range 3-13), p = 0.92. 
There was no difference in bleeding scores between patients who had a gammopathy, 
either a diagnosis or long term follow up (see Figure 3-6).  Median bleeding score was 
higher in those with bone infarcts at baseline (4 in infarcts, vs. 2 without infarcts) and 
follow up (4 vs. 2.5) but these differences were not statistically significant (p = 0.74 
and 0.54 respectively). 
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Figure 3-6:Relationship between bleeding scores and gammopathies at baseline (A) 
and follow up (B) and bone infarcts at baseline (C) and follow up (D). 
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3.5.5 Coagulation abnormalities and FXI deficiency in Gaucher disease 
As indicated above, an abnormal APTT was found in 43% of patients from the 
historical cohort.  The APTT was considered prolonged if the coagulation time was 
longer than that of the normal range of the laboratory at the time of testing.  The normal 
ranges varied over time due to changes in methodology, particularly reagents. Of the 
patients with a prolonged baseline APTT, the APTT has normalised in all except two 
patients, one of whom had recently commenced ERT.  17% of patients had a prolonged 
PT, in conjunction with a raised APTT, all of which normalised with ERT (see Figure 
3-7).  The bleeding scores of patients with and without a prolonged APTT at baseline 
are shown in Figure 3-7.  The median bleeding score of patients with a prolonged 
APTT was 4 compared to 2 for those without; this is of borderline significance (p = 
0.064).  10/18 (55.5%) of patients with a prolonged APTT at baseline had a bleeding 
score ≥4 compared to 9/22 (40.9%) of patients with a normal baseline coagulation 
screen. 
Despite the prevalence of bleeding symptoms and abnormal coagulation screens at 
presentation in patients with GD, systematic evaluation for a bleeding disorder had not 
been undertaken in patients.  Thus, identification of more specific haemostatic defect 
was, to a degree opportunistic.  Amongst the cohort, 17 patients who had been found 
to have FXI deficiency (reduced FXI coagulation factor activity) were identified from 
the case notes.  Five of these patients were seen at a haemophilia centre prior to the 
diagnosis, where they were found to have FXI deficiency.  Of these three were also 
found to have abnormal platelet aggregometry. Two were diagnosed with a “weak 
agonist receptor defect” and their thrombocytopenia ascribed to chronic immune 
thromobocytopenic purpura.  The other was further investigated and the diagnosis of 
GD made.   
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Figure 3-7: Coagulation screen & FXI activity in relation to bleeding scores & 
response to therapy. A: normalisation of PT and APTT following at least 1 year ERT. 
B:  relationship between bleeding scores and abnormal coagulation screens at baseline. 
C: Changes in FXI levels in those with FXI deficiency at baseline. D: relationship 
between bleeding scores and FXI deficiency at baseline.  
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FXI deficiency 
Of the seventeen patients with FXI deficiency at baseline, only two had no bleeding 
symptoms, one of whom was diagnosed on Jewish community screening and has not 
required therapy for their GD.  Of the other fifteen patients, four reported only bruising, 
three had additional menorrhagia, two epistaxis and six post-operative bleeding 
(including dental extraction).  Thirteen of these patients had a bleeding score 
ascertained.  The median bleeding score in those with FXI deficiency was 4 compared 
to 3 in those without (see Figure 3-7).  Baseline and follow up FXI levels were 
performed in 13 patients who had received ERT for a prolonged period (median 14.9 
years, range 9.2-19.6).  The median FXI level at baseline was 55 IU/dL (range 39-68; 
normal range for laboratory >70IU/dl) and the median FXI level at follow up was 
90IU/dL (range 47-110, p<0.0001).  Three patients still had low FXI levels.  
Mutational analysis of the F11 gene in two of these patients failed to reveal evidence 
of a genetic abnormality.  The third was unavailable for mutational analysis.  Of the 
four patients without follow-up FXI levels, three had recently commenced on ERT 
(within 1 year).  Mutational analysis of the F11 gene in these patients found no 
evidence of a F11 mutation.  The fourth patient is untreated and was not available for 
further evaluation. 
3.6 Discussion 
3.6.1 Presentation of GD: 
Patients most commonly presented with symptoms related to visceral or 
haematological involvement consistent with the findings of a previous study of 
patients from the USA and Australasia190.  Although bone pain was a common 
presenting complaint, the high incidence of additional splenomegaly or full blood 
count abnormalities, most likely results in ultimate diagnosis of these patients by 
haematologists.  Despite the availability of ERT and the development of national 
specialist services for GD in the UK, some patients continue to experience long delays 
between symptom onset and diagnosis, with little change over the past decades.  This 
is likely to be attributable to a number of factors including a lack of awareness of GD, 
the non-specific nature of presenting symptoms and the relative wellbeing of many 
patients leading to less impetus to make a concrete diagnosis.  
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GD often has an insidious onset and patients may develop extensive organ involvement 
with minimal overt symptomatology.  Investigation of 37 N370S homozygotes 
identified through a community carrier screening program found that although 65% 
were asymptomatic, 97% had splenomegaly, 14% had bone infarcts of MRI imaging, 
52% had osteopenia and 9% established osteoporosis191.  The presence of established 
avascular necrosis of the hip in 11% of patients in this study at diagnosis highlights 
the need for earlier diagnosis.  Once bone infarction has occurred it is irreversible and 
avascular necrosis of the hip ultimately results in joint replacement in most patients 
and therefore the aim should be to diagnose and institute therapy prior to the 
development of such irreversible complications. 
3.6.2 Diagnosing GD in the haematology clinic 
Given the rarity of GD, making the diagnosis requires a high index of suspicion in the 
consulted physician.  Thrombocytopenia and splenomegaly, whether symptomatic or 
incidental findings, are common reasons for referral to haematologists and both have 
wide differential diagnoses.  Amongst haematologists asked to give a differential 
diagnosis of a 42 year old with anaemia, thrombocytopenia, hepatosplenomegaly and 
bone pain, all classic features of GD, 65% selected leukaemia, 36% lymphoma and 
20% GD190 as part of their differential diagnosis.  A study of over 2000 patients with 
splenomegaly found a haematological cause in 57%, mostly commonly leukaemia or 
lymphoma; amongst those with a haematological diagnosis 87% had generalised 
lymphadenopathy and 85% a raised cell count (haemoglobin, platelets or white 
cells)192.  This is in contrast to our GD cohort where generalised lymphadenopathy not 
was documented and, in the absence of splenectomy, patients had reduced rather than 
raised cell counts.  The chronicity of the symptom onset and the only modest 
reductions in cell counts, without neutropenia should make differentiation from acute 
leukaemia relatively straightforward.  Chronic myeloid leukaemia may cause marked 
splenomegaly but a review of over 400 cases revealed only 4.5% of patients had a 
white cell count <4.5x109/L and 4.5% a platelet count <150x109/L193.  Whilst 
lymphoproliferative disorders may present with splenomegaly, the vast majority have 
an associated lymphocytosis194 rather than the lymphopenia seen in our GD cohort. 
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3.6.3 Bleeding symptoms in the diagnosis of GD 
Bleeding symptoms, most commonly bruising, are reported by over half of patients at 
diagnosis, a similar incidence to that found in an Israeli cohort118.  In addition to 
bruising, more significant bleeding can occur, with post dental and/or post-operative 
bleeding occurring in eight patients pre-diagnosis.  The condensed MCMDM-1 score 
was initially developed to assist in the diagnosis of VWD but had also been evaluated 
for its utility in the diagnosis of mild bleeding disorders195 and FXI deficiency196.  The 
commonest diagnoses in this study were mild platelet function defect, FXI deficiency 
and VWD – abnormalities which have all been reported in GD. 47.5% of GD in our 
study had a bleeding score ≥4, which has been shown to have a positive predictive 
value of 71% for the diagnosis of a mild bleeding disorder195.  It is therefore not 
surprising that some patients were reviewed by haemostasis specialists and diagnosed 
with mild factor deficiencies or platelet function defects without the true underlying 
diagnosis being discerned. 
Whilst GD is rare, it should be considered in patients presenting with bleeding 
symptoms, particularly if thrombocytopenia (even mild) or splenomegaly are also 
present, or if bleeding is disproportionate to the coagulation abnormalities present.  
Whilst bleeding symptoms have often been attributed to thrombocytopenia, within this 
cohort bleeding symptoms were out of proportion to the platelet count and there was 
no definite relationship between platelet count and bleeding symptoms.  Whilst a 
platelet count of 50x109/L is often deemed acceptable for major surgical procedures197, 
only one out of seven patients with post-operative bleeding had a platelet count 
<50x109/L, supporting the presence of defects in platelet function and/ or the 
coagulation proteins.   
FXI is of particular interest within haemostasis.  Unlike other coagulation factor 
deficiencies, the level of FXI does not predict clinical bleeding risk198 and the reasons 
for this are yet to be understood.  Both GD and hereditary F11 deficiency are common 
within the Ashkenazi Jewish population with carrier rates of 1 in 12 and 1 in 8 
respectively.  With the increasing availability of mutational analysis techniques, it 
should be possible to clarify patients who have inherited FXI deficiency and the 
diagnosis of GD should be considered in patients in whom no mutation is identified. 
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3.6.4 Role of laboratory abnormalities in the differential diagnosis of GD 
A history of bruising or bone pain or detection of splenomegaly on clinical 
examination should raise suspicion of the diagnosis of GD. In addition, in this study, 
four key laboratory parameters, beyond the full blood count, were identified which are 
abnormal at presentation in the majority of GD patients: raised serum ACE, polyclonal 
gammopathy, raised ferritin and low HDL cholesterol.  These assays are readily 
available in most routine hospital laboratories.   
ACE is a zinc-metallopeptidase which has a wide cellular distribution and is also 
secreted into plasma199.  Increased serum ACE is found in disorders involving 
activation of cells of the monocyte/macrophage lineage, particularly sarcoidosis200 and 
GD201.  In contrast, ACE levels are normal or decreased in haematological 
malignancies202 and thus may be a useful discriminatory test.   
Low HDL cholesterol levels in GD have been correlated with disease severity203;204 
and response to ERT. Whilst hypocholesterolaemia has also been found in 
myeloproliferative disorders, these should be readily distinguishable from GD by the 
presence of increased cell count and the blood film appearances. 
Hypergammaglobulinaemia is most commonly found in inflammatory disorders, 
particularly liver disease and connective tissue disease205 and it is notable that a 
number of patients were diagnosed by hepatologists, with a few presenting with 
abnormal liver function tests or jaundice secondary to hepatic involvement.  
Hyperferritinaemia, outside the context of iron overload, is also a feature of connective 
tissue disorders including Still’s disease and haemophagocytic lymphohistiocytosis 
(HLH).  HLH is characterised by dysregulated activation of the immune system and 
haemophagocytosis by macrophages.  It shares many laboratory features with GD 
including cytopenias, hyperferritinaemia, hypertriglyceridaemia  and a 
coagulopathy206 but usually presents with an acute severe febrile illness207.  One could 
hypothesise that these similarities arise due to overload of glucocerebrosidase 
following the increased delivery of glycosphingolipids to the lysosome that 
accompanies haemophagocytosis208. 
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3.6.5 Pathophysiology of bleeding manifestation of GD 
The presence of bleeding symptoms in GD has long been recognised, but the 
mechanisms underlying them and their relationship to other disease manifestations is 
less clear.  Whilst a number of case reports and studies have investigation platelet 
and/or coagulation abnormalities in GD (see Table 1-11) the results have been 
conflicting.  In addition the lack of characterisation of the bleeding phenotype beyond 
presence/absence of bleeding symptoms in these studies makes the clinical 
significance of any abnormalities difficult to interpret. Our study confirms that reduced 
levels of FXI are a disease manifestation of GD, rather than due to co-inheritance of 
F11 mutations and improve significantly with ERT. 
In our study we found no correlation between overall disease severity and bleeding 
symptoms or bone disease.  The findings of multiple abnormalities in the coagulation 
system in previous studies, with reductions in coagulation factors and increased 
products of fibrinolysis has led to the hypothesis that coagulation abnormalities are the 
result of chronic activation of the coagulation system119, with inflammation being the 
driver of that process.  Increased levels of pro-inflammatory cytokines have been 
reported in GD82-84, albeit, similarly to haemostatic assays, with conflicting results.  
Inflammatory processes have been implicated in many of the manifestations of GD, 
particularly gammopathies.  We, however, could find no difference in bleeding 
symptoms between patients with or without a gammopathy suggesting other factors 
are involved in this process.   
Coagulation factors are synthesised and, in many cases post-translationally modified 
in the liver and therefore infiltration of the liver by Gaucher cells may impair these 
functions even in the absence of overt hepatic dysfunction.  Similarly to GD, liver 
disease is associated with a raised serum ACE209, low HDL cholesterol, 
hyperferritinaemia and polyclonal gammopathy.  Indeed, liver dysfunction as well 
systemic macrophage activation may contribute to these abnormalities in GD.  It is 
therefore possible that low levels of coagulation factors as in part due to liver 
dysfunction, although why the abnormalities are so variable between studies is unclear.  
The liver is also involved in the synthesis of anticoagulant proteins (AT, PC and PS); 
these have been less well studies in GD.  In one study of 30 patients, AT was only low 
in one119, so it is likely that other mechanisms are involved.  
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Investigating the mechanisms underlying the bleeding diathesis is challenging, both 
due to the disorder itself and the nature and limitations of haemostatic assays.  GD is 
a rare disorder and therefore most centres will only see a handful of new cases per year, 
meaning that recruitment to studies needs to run over a prolonged period to achieve 
even double-digit recruitment.  As evidenced by the results for FXI levels in previous 
studies of coagulation factors and platelets174;178, abnormalities often normalise with 
enzyme replacement therapy meaning that studies ideally need to be done on patients 
at diagnosis.  In the absence of baseline pre-treatment data, studies on treated patients 
are likely to be difficult to interpret. 
The studies performed to date examine plasma coagulation factors and platelet 
function – predominately aggregometry, but adhesion function has also been measured 
using a cone plate analyser in one centre.  The conflicting results from these studies 
suggest that further investigations that purely examine these parameters may not be 
sufficient for gaining further mechanistic insights.  Further work should include more 
novel assays of both platelet function and haemostasis control, ideally using whole 
blood assays which more closely reflect the complex interactions that occur between 
circulating cells, plasma proteins and the vessel lining in haemostatic processes.  These 
assays would require fresh patient samples, an additional hurdle particularly for 
collaborative studies. 
3.7 Conclusions 
GD most commonly presents with symptoms related to splenomegaly, bleeding or 
bone pain.  Ultimately the diagnosis is made by haematologists in almost 80% of 
patients, usually after performing a bone marrow rather than an enzyme assay.  This, 
coupled with the oft long delays from initial symptoms suggest that increased 
awareness regarding GD is still required amongst these clinicians.  
Whilst bleeding symptoms are most commonly bruising, more severe bleeding 
episodes do occur including epistaxis and post-procedural bleeds (including surgical 
and dental) and may lead to patients’ presentation to specialist haemostasis clinics.   
The diagnosis should be considered especially in those with bleeding out of proportion 
to the laboratory abnormalities.  The mechanisms underlying the bleeding diathesis 
remain unclear and bleeding does not clearly correlate with other disease 
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manifestations.  Looking beyond plasma abnormalities, subsequent chapters examine 
the role of leucocytes and platelets in GD. 
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Chapter 4 Vascular features of Fabry disease 
4.1 Introduction 
The classic triad of clinical features of Fabry disease comprises pain (acroparasthesia), a 
rash (angiokeratoma) and sweating abnormalities beginning in childhood-adolescence 
with subsequent development of cardiac, renal and cerebrovascular complications 
resulting in a shortened life expectancy.  As an X-linked disorder, the historical focus of 
clinical studies (both mechanistic and therapeutic trials) has been on male patients; 
however, in recent years it has been demonstrated that many females with a GLA mutation 
develop clinical features of FD210.  Since the advent of ERT a large number of screening 
studies have been undertaken aiming to identify undiagnosed patients with FD who have 
renal, cardiac or cerebrovascular complications48.  This has resulted in the increasing 
recognition of a broader phenotypic spectrum of FD than that classically described. 
Evidence from cohort and registry studies of delays between symptom onset and diagnosis 
led to the suspicion that Fabry disease is under-diagnosed35.  This has led to both  newborn 
screening studies 29 and targeted screening studies of patient populations with evidence of 
organ dysfunction which can occur in FD (e.g. LVH42;211, dialysis43;212, stroke125;213).  A 
key driver behind these studies is that with the advent of ERT, the natural history of FD 
might potentially be altered. Whilst these studies have demonstrated that undiagnosed 
cases of FD can be found in these populations, they have also raised new questions as to 
the natural history of FD in this broader phenotypic population in whom disease 
manifestations may be milder or later in onset than classically described. 
A key aim of ERT is to prevent, or at least modify the progression of, critical organ 
dysfunction: renal, cardiovascular and cerebrovascular disease.  This chapter examines 
the importance of vascular disease manifestations in a large, single-centre contemporary 
cohort of FD patients.  The diagnostic pathways of index cases are examined and ways to 
improve this process discussed.  Use of baseline assessments of the cohort allows a cross-
sectional view of the disease manifestations of FD at different ages in both males and 
females.  The prevalence of vascular manifestations and their relation to mutation status 
and age is explored.  Particular attention is paid to cerebrovascular disease in FD.  Unlike 
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other disease manifestations, stroke occurs almost as frequently in females as males123 and 
has been described as occurring in the absence of other disease manifestations.  Whilst 
declines in renal function or risk for ventricular arrhythmias can, to a degree be predicted, 
there is currently no method for predicting stroke risk in FD and stroke can often have an 
instantaneous, life-changing impact.  Better understanding of the natural history of stroke 
in FD and potential risk factors may allow preventative intervention to reduce risk.  
4.1.1 Purpose of this chapter 
Whilst registry studies have proved valuable in advancing our knowledge of FD, they have 
limitations.  Datasets are often incomplete and there is a potential registration bias towards 
more severely affected patients.  The presence of a large specialist centre enables the study 
of a relatively large single cohort of patients.  This chapter describes the patient cohort of 
the RFH Fabry clinic with particular focus on vascular features affecting critical organ 
function (renal, cardiac and cerebrovascular) and comprises three sections: 
1. A cross-sectional description of the cohort:  
a) Prevalence of vascular disease in the presentation of index cases and incidence 
of vascular complications during their follow-up  
b) Prevalence of vascular complications at baseline and follow up in patients 
diagnosed on family screening. 
2. Incidence of stroke/TIA and its relationship to: 
a) Disease factors: mutation, enzyme activity, disease severity, other disease 
manifestations 
b) Cardiovascular risk factors 
c) Prognostic scores 
3. Abnormalities of plasma pro-coagulant factors and their relation to disease 
manifestations. 
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4.2 Hypotheses 
1. Patients presenting with FD may experience vascular events (e.g. stroke, arrhythmias) 
prior to diagnosis and experience long delays between those events and arrival at the 
correct diagnosis.  Rationale: FD is rare and therefore not commonly considered in 
the differential diagnosis of vascular events such as stroke. 
2. Cerebrovascular events are not predicted by other disease manifestations, enzyme 
activity or more common cardiovascular risk factors Rationale: strokes have been 
reported in patients without other disease manifestations and FD diagnosed in cohorts 
of patients with cryptogenic stroke 
3. Abnormalities of plasma procoagulant and anticoagulant factors are associated with 
vascular manifestations of FD Rationale: von Willebrand factor and anticoagulant 
pathways are controlled primarily by the endothelium and these disease 
manifestations have been hypothesised to be due to endothelial dysfunction.  
4.3 Methods 
Patients have been reviewed at the Royal Free since the late 1990s, when a number of 
males were enrolled in clinical trials of agalsidase alfa (Replagal), commencing in 1999.  
Replagal and Fabrazyme enzyme replacement therapies were both licensed by the 
European Medicines Agency on 3/8/2001 and services for the management of lysosomal 
storage disorders were nationally commissioned in 2005.  Decision making regarding 
institution of enzyme replacement therapy was undertaken according to national 
guidelines current at that time.  
4.3.1 Historical clinical record review 
The case records of families attending the Lysosomal Storage Disorders Unit since its 
inception until the end of August 2013 were reviewed.  
4.3.2 Baseline clinical assessment 
At baseline, patients had a full medical and family history taken.  A comprehensive family 
tree was constructed to include all known family members with FD.  Assessment of organ 
function included quantification of urinary albumin and protein, measurement of 
glomerular filtration rate (GFR) using radio-isotopes, brain magnetic resonance imaging 
(MRI) and review by a cardiologist including electrocardiogram (ECG) and 
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echocardiogram.  Left ventricular mass was calculated using the Devereux formula214 and 
adjusted for height; increased left ventricular mass was defined as ≥47g/m2.7 in females 
and ≥50g/m2.7 in males.  Dermatological review for angiokeratoma was undertaken by a 
dermatologist with a specialist interest in FD.   
The baseline assessment for the purposes of this study is the date of initial comprehensive 
assessment of disease status undertaken at a specialist centre.  Prior to the start of clinical 
trials of ERT in the UK few patients had had a comprehensive assessment of their disease 
status (e.g. cardiac, renal and cerebral) and therefore for patients diagnosed pre-1999 there 
is a lapse in time between date of diagnosis and baseline assessment.  All baseline 
assessments were undertaken prior to institution of therapy. 
All patients had measurements of enzyme activity and mutational analysis undertaken.  
The majority of enzyme activities were measured on plasma at the Royal Free or the 
Institute of Child Health (ICH), University College London using identical methodology 
(see Methods chapter) and reference ranges (4-21 nmol/ml/hour).  A small number of 
patients had enzyme activity assays performed by other laboratories with different 
methodologies and reference ranges; where no enzyme activity results from RFH/ICH are 
available, these patients are therefore excluded from analyses relating to enzyme activity.  
Mutations have been classified as nonsense, missense and deletions. Patients with 
missense mutations have been divided into three groups: the N215S mutation, mutations 
described as being associated with a mild/late onset phenotype (A143T, R301Q, R112C 
and R112H) and other missense mutations.  
4.3.3 Severity and prognostic scores 
All severity and prognostic scores were calculated by the researcher from the historical 
baseline data for the purpose of this study to ensure internal consistency across the data 
set.  Disease severity scores were calculated using the FOS-MSSI (severe disease 
manifestations.  
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Table 4-1), which scores disease features across four domains with the score weighted 
towards more severe disease manifestations.  
  
113 
 
Table 4-1: FOS-MSSI Severity Score for FD 
General  
(max = 15.5) 
Neurological  
(max = 15) 
Cardiovascular  
(max = 18) 
Renal  
(max = 18) 
Angiokeratoma (1.5) 
Oedema (1) 
Musculoskeletal pain 
(1) 
Cornea verticillata (1) 
Hypo/hyperhidrosis (1) 
or anydrosis (2) 
Abdominal pain (1) 
Diarrhoea/constipation 
(1) 
Haemarrhoids (1) 
Pulmonary involvement 
(2) 
NYHA classs (1/2/3/4) 
Tinnitus (1) 
Vertigo (1) 
Pain attacks (4) or 
chronic pain (6) 
TIA/PRIND (3) or 
stroke (6) or 
radiographic lesions 
only (1) 
Depression (1) 
ECG abnormalities (2) 
LVH (6) or 
cardiomyopathy (10) 
Pacemaker (4) 
Hypertension (1) 
Valve insufficiency (1) 
 
Proteinuria (4) or low 
GFR (8) or end stage 
renal failure (12) or 
dialysis (18) 
 
As severity increases with age, the score was adjusted for age by subtracting the calculated 
score from the predicted score for the patients age215: 
Males: predicted score = [2.29+ (0.05 * Age)]2 
Females: predicted score = [0.96 + (0.05 * Age)]2 
Prognostic scores were calculated using the Fabry International Prognostic Index (FIPI) 
(see Table 4-2) 216, a score developed to try to predict risk of developing clinically severe 
events: renal (ESRF, transplant or dialysis), neurological (stroke, TIA or PRIND), cardiac 
(stage III/IV heart failure, MI surgery or pacemaker/ICD insertion) or death. 
Table 4-2: Fabry International Prognostic Index (FIPI) 
Domain Score Risk 
Cardiac eGFR<60ml/min/m2.7) = 1.5 
Hearing impairment = 1 
LVMI ≥50g/m2.7 = 1 
Proteinuria (>300g/24hr) = 0.5 
Vertigo = 0.5 
Angiokeratoma/telangiectasia = 2 
Low 0-2 
Medium 3-4 
High 5-7 
Renal eGFR<60ml/min/m2.7) = 2 
Male gender = 1.5 
Proteinuria (>300g/24hr) = 1.5 
Angiokeratoma/telangiectasia = 2 
Low 0-2 
Medium 3-4 
High 5-7 
Neurological Hearing impairment = 2.5 
eGFR<60ml/min/m2.7) = 2 
Vertigo = 1.5 
Low 0-2 
Medium 3-4 
High 5-7 
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Anhydrosis/hypohydrosis = 1 
Death eGFR<60ml/min/m2.7) = 4 
Abnormal ECG =2 
 
Composite eGFR<60ml/min/m2.7) = 2 
Hearing impairment = 2 
Microalbuminuria = 1 
LVMI ≥50g/m2.7 = 1 
Anhydrosis/hypohydrosis = 1 
Low 0-3 
High 4-7 
 
4.3.4 Thrombophilia screening 
The thrombophilia assays were performed by the biomedical scientist staff of the 
haemophilia centre (Royal Free Hospital).  
Protein C (PC) activity: PC was activated by venom of Agkistodon coutartrix.  Activated 
protein C activity was measured using chromogenic substrate S2366 (HaemosIL). 
Protein S (PS) free activity: was measured using a latex agglutination assay.  Purified 
C4BP adsorbed onto latex beads reacts with free PS in the plasma.  A monoclonal antibody 
against PS is bound to a second latex reagent, resulting in agglutination by the adsorbed 
free PS. 
Anti-thrombin (AT) activity: plasma was incubated with an excess of bovine thrombin, in 
the presence of heparin, resulting in inhibition of the thrombin.   Residual thrombin was 
then measured using a chromogenic substrate, Tos-Gly-Pro-Arg-ANBA-IPA (HaemosIL). 
The residual thrombin is inversely proportional to the AT activity. 
FVL and prothrombin gene mutation: PCR-based mutational analysis was performed 
using the GeneXPERT ® system 
Lupus anticoagulant dilute Russel Viper Venom Test (DRVVT): the coagulation time 
following the activation of FX with Russel Viper Venom (American Diagnostica) was 
measured and ratio to normal plasma calculated.  If the ratio was >1.10, a neutralisation 
test performed by addition of a high concentration of phospholipid to demonstrate 
phospholipid dependence.  The test was positive if >10% correction occurred with 
addition of phospholipid.  If positive, the test was repeated after an interval of at least 12 
weeks to ascertain persistence.  
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FVIII activity: FVIII activity was measured using a standard APTT-based one stage assay, 
performed on an ACL TOP coagulometer (Instrumentation Laboratory). 
4.4 Results 
4.4.1 Overview of the RFH FD cohort 
233 patients, from 91 different family pedigrees were included in the cohort study, of 
whom 92 (39.5%) are male and 141 (60.5%) female.  65 patients (27.9% cohort, 44 male, 
21 female) were index cases and 168 patients (72.1%, 48 male, 120 female) were 
diagnosed on family screening.  In two pedigrees, two index cases were diagnosed 
independently within the same family due to lack of awareness of the diagnosis in different 
branches of the family. Of the index cases 36 males and 14 females were diagnosed 
following investigation of symptoms whilst 8 males and 6 females were diagnosed 
following further investigation of incidentally detected abnormalities (e.g. abnormal 
ECG).  For both index cases and those diagnosed on family screening, most cases were 
diagnosed within the last decade.  
Across 87 families the median number of affected family members was 3, range 1-31.  
Two index cases were adopted and one was estranged from the rest of their family.  One 
index case was from overseas and the rest of the family lived in a country where testing 
and treatment were not available.  
53 different mutations were found in 91 family pedigrees.  The recurrent mutations are 
shown in Table 4-3. 44 mutations were point mutations with 36 (67.9%) being missense 
mutations and 8 (15.1%) being nonsense mutations.  There were 8 short deletions and one 
pedigree had a deletion of exon 1.  The full list of different mutations is shown in Figure 
4-1; mutations were found in all exons. 
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Table 4-3: Recurrent mutations in FD 
Mutation Mutation type Exon No pedigrees No pt in cohort 
C52G Missense 1 2 2 
A143T Missense 3 3 10 
P205T Missense 4 3 13 
c.717del2 Deletion 4 2 2 
N215S Missense 5 29 84 
A257P Missense 5 2 2 
R301Q Missense 6 2 9 
I317T Missense 6 2 9 
R342Q Missense 7 2 3 
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Figure 4-1: Location of GLA mutations within the cohort.  GLA homodimer showing 
missense mutation sites (red) and nonsense mutation sites (pink); drawn using PyMol, 
based on crystal structure 1r46. 
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4.4.2 Causes of death 
Eleven patients in the cohort, all male, died during follow up.  Ages and causes of death 
are shown in Table 4-4. The median age at death was 53 years (range 34-81); cardiac 
complications were the most frequent cause of death.  All seven males who were 
diagnosed following family screening had significant manifestations of Fabry disease – 
either angiokeratoma/acroparasthesia in the three diagnosed in childhood/adolescence or 
cardiac/renal events for those diagnosed in the later decades.  
Table 4-4: Age and cause of death 
Age 
diagnosis 
Age 
death 
Cause of death Presenting feature Mutation ERT 
6 34 Cardiac Family screening – subsequent 
acroparasthesia & 
angiokeratoma 
A143T Age 21-34 
13 45 Cardiac Pain c.520delT Pre-ERT 
14 53 Stroke Family screen – acroparasthesia R227X Age 44-53 
15 43 Subarachnoid 
haemorrhage 
Family screen – acroparasthesia 
& angiokeratoma 
G361R Age 41-43 
29 58 Stroke & 
cardiac failure 
Stroke G361R Age 50-58 
38 41 Cardiac Rash c.466delG Age 38-41 
48 52 Cardiac Cardiac failure & syncope E338K Age 48-52 
65 66 Mesothelioma Family screen but stroke aged 
57 
A13P Age 65-66 
69 71 Cardiac  Family screen but MI and AVR 
aged 59 
N215S Age 71 
72 76 Cardiac Family screen – ICD for VT 
aged 70 
N215S Age 72-76 
73 81 Cardiac Family screen but diagnosed 
“HOCM” age 60 
N215S Age 73 
 
4.4.3 Vascular features in the presentation of index cases 
Presenting features 
Presenting features were defined as the primary clinical features, investigation of which 
led to the diagnosis of FD, whilst initial symptoms are the first symptoms related to FD 
which the patient experienced and in some cases differ from the presenting feature. 
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There were 44 index males, with a median age of diagnosis of 49.5 years (range 10-74) 
and 21 index females with a median age of diagnosis of 44 years (range 25-75).   The 
presenting features and median age of diagnosis for each presentation are shown in Table 
4-5. Cardiac manifestations were the commonest presentation, being the presenting 
feature in 66% of males and 33% females.  There was no difference in age at diagnosis 
between males and females presenting with cardiac features (58yr vs 54 yr, p =0.99).  
Symptoms related to arrhythmias (palpitations, syncope) were commonest with 
arrhythmias ranging from atrial fibrillation to ventricular fibrillation.   
Twenty five percent of males presented with a rash and/or acroparasthesia; these men 
presented at a significantly younger age than those with cardiac symptoms (median age 
19 yr vs 58yr, p<0.0001).  This was a rare presentation in females with only one female 
presenting with acroparasthesia.   In contrast, stroke was a common presentation in 
females, but was the presenting feature in only one male.  Four females were diagnosed 
following the finding of cornea verticillata on slit lamp examination of the eyes, but this 
presentation was not seen in men.    
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Table 4-5: Presenting symptoms and age at diagnosis of index cases 
Organ system Symptom No. (%) patients Age at diagnosis: median (range, years) 
  Male (N = 44) Female (N = 21) Male Female 
Cardiac All cardiac 29 (65.9) 7 (33.3) 58 (33-74) 54 (45-75) 
 Abnormal ECG/ LVH on 
imaging 
6 (13.6) - 49 (42-56) - 
 Syncope 7 (15.9) 1 (4.7) 59 (41-74) 46 
 Palpitations/ arrhythmia 5 (11.4) 2 (9.5) 59 (40-74) 54 (48-60) 
 Chest pain 5 (11.4) 1 (4.7) 55 (51-72) 45 
 Shortness of breath 4 (9.1) 2 (9.5) 56 (33-71) 71.5 (68-75) 
 Heart murmur 2 (4.5) - 57 (54-60) - 
 FH of sudden death - 1 (4.7) - 54 
Skin & pain All rash/ acroparsthesia 11 (25) 1 (4.7) 19 (10-33) 23 
 Rash 10 (22.7) - 21 (13-33) - 
 Acroparasthesia 1 (2.3) 1 (4.7) 16 23 
Neurological Stroke/TIA 1 (2.3) 5 (14.3) 29 43 (25-49) 
Renal All renal 3 (6.8) 3 (14.3) 25 (25-38) 27 (25-35) 
 Proteinuria 1 (2.3) 3 (14.3) 25 27 (25-35) 
 Haematuria 1 (2.3) - 25 - 
 Hypertension secondary to renal 
failure 
1 (2.3) - 38 - 
Opthalmological Corneal deposits on eye exam - 4 (19.0) - 33.5 (30-45) 
Gastrointestinal Abdominal pain/ diarrhoea - 1 (4.7) - 29 
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Table 4-6: Initial symptoms/ disease manifestations in index cases 
Organ system Symptom No. patients (%) Age at onset (years): median & 
range 
Time onset to diagnosis (years): 
median & range 
  Male 
(N=44) 
Female 
(N=21) 
Male Female Male Female 
Cardiac All cardiac 21 (47.7)) 5 (23.8) 54 (32-73) 59 (42-69) 2 (<1-18) 3 (<1-9) 
Syncope 6 (13.6) - 59 (45-73)  6.5 (1-15)  
Palpitations 3 (6.8) 1 (4.8) 59 (57-61) 48 1 (1-1) <1 
Incidental LVH 4 (9.1) - 50.5 (41-57)  10 (<1-18)  
Abnormal ECG 4 (9.1) 1 (4.8) 49 (44-54) 59 <1 (<1-4) 9 
Chest pain 2 (4.5) 2 (9.5) 44.5 (39-50) 51 (42-60) 8 (4-12) 1.5 (<1-3) 
SOB 2 (4.5) 1 (4.8) 47 (32-62) 69 1.5 (1-2) 6 
Skin & pain All rash/acroparasthesia 18 (40.9) 5 (23.8) 9 (5-16) 20 (7-26) 17 (1-53) 20 (2-29) 
Acroparasthesia 16 (36.4) 4 (19.0) 9 (5-16) 17 (7-21) 19 (6-53) 15 (2-29) 
Rash 2 (4.5) 1 (4.8) 12 (9-15) 26 1.5 (1-2) 20 
Neurological All neurological 0 5 (23.8) - 40 (24-46) - 6 (1-13) 
Stroke/TIA - 4 (19.0) - 39.5 (24-46) - 4 (1-13) 
Migraine with aura - 1 (4.8) - 40 - 9 
Renal All renal 3 (6.8) 2 (9.5) 29 (25-38) 27(25-29) 1 (1-27) 3 (<1-6) 
Proteinuria 2 (4.5) 2 (9.5) 27 (25-29) 27 (25-29) 14 (1-27) 3 (<1-6) 
Hypertension 1 (2.3) - 38 - 1 - 
Gastrointestinal Abdo pain/ IBS 2 (4.5) 1 (4.8) 45 (41-49) 18 18 (6-30) 11 
Eyes Asymptomatic cornea 
verticillata 
- 3 (14.3) - 37 (30-45) - - 
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Figure 4-2: Age at symptom onset and delay from symptom onset to diagnosis in 
male and female index cases. 
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Initial symptoms and diagnostic delays 
Acroparasthesia was the commonest single initial symptom in males, being the initial 
symptom in 41% of index males, see Table 4-6.  Males whose initial symptom was 
acroparasthesia or a rash had a significantly younger age of symptom onset than males 
whose initial symptom was cardiac-related (9yr vs 54yr, p<0.0001) and experienced 
significantly longer diagnostic delays (17yr vs 2 yr, p = 0.0001), see Figure 4-2.  In eight 
males and one female, the first awareness of disease manifestations was the finding of an 
abnormality on an ECG or chest radiograph performed for other reasons (e.g. pre-
operatively or as part of an insurance medical).   In four cases, further investigation of 
these findings yielded the correct diagnosis but in the other five patients, the correct 
diagnosis was not reached until development of overt cardiac symptoms a number of years 
later. 
Whilst acroparasthesia and cardiac symptoms were also common initial symptoms in 
females, cerebrovascular events, occurring in the absence of preceding FD symptoms 
were the initial disease manifestations in five females.  This contrasts to males where 
cerebrovascular events did not feature as the initial symptom in any index case.   
Most diagnostic delays appeared to be due to non-diagnosis rather than mis-diagnosis.  In 
some cases patients were labelled as having a clinical feature/ syndrome (e.g. hypertrophic 
cardiomyopathy or an arrhythmia) but the correct underlying diagnosis was not reached 
for a considerable period of time.  In other cases an erroneous diagnosis was assigned, but 
usually a diagnosis of exclusion, for which there is no concrete diagnostic test (e.g. 
irritable bowel syndrome).  These were most commonly rheumatological or cardiac (see 
Table 4-7).  
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  Table 4-7: Alternative diagnoses given prior to diagnosis of Fabry disease 
 Diagnosis Index cases Family 
screening 
Rheumatological All 3 7 
Rheumatic fever 1 2 
Rheumatoid arthritis 1 0 
Growing pains 1 5 
Cardiac All 5 6 
HOCM 2 4 
Sick sinus syndrome 1 1 
Wolf-Parkinson-White syndrome 1 1 
Long QT syndrome 1 0 
Other All 5 5 
Multiple sclerosis 1 0 
Irritable bowel syndrome 3 3 
Pre-eclampsia 1 0 
Hereditary haemorrhagic telangestcaisia 0 1 
Chronic fatigue syndrome 0 1 
 
In all patients the diagnosis of FD was confirmed by enzyme assay and mutational analysis 
but in all six patients presenting with renal manifestations, the diagnosis was originally 
suspected by the presence of storage material on renal biopsy.   In one male presenting 
with cardiac hypertrophy, an endomyocardial biopsy was performed pre-diagnosis which 
again showed storage material and led to confirmatory tests for FD. 
Change pattern of presentation of FD 
Over the past decade there has been a rapid increase in the number of both male and female 
index cases.  Amongst males this is attributable to a large number of males with the N215S 
mutation who are primarily presenting at an older age with cardiac manifestations, see 
Figure 4-3.  Almost all female index cases have been diagnosed within the last decade, 
presenting with a wider variety of clinical features and mutation types.  
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Figure 4-3:  Changing pattern presentation of FD index cases:  age of diagnosis by 
year of diagnosis; mutation type and year of diagnosis; and mutation type and 
initial symptoms. Open circles = incidental cases. 
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4.4.4 Vascular manifestations in index cases 
Vascular disease manifestations at both baseline and follow-up were analysed by mode of 
presentation, with a focus on cerebrovascular disease.  Data on PPM/ICD insertion and 
development of ESRF (GFR<15ml/min/m2.7) were also analysed both as an indication of 
severe disease in other organ systems and because these complications, similarly to stroke, 
can be life changing or limiting.   
Male index cases: 
The vascular complications experienced by male index cases are detailed in Table 4-8. 
One male had a stroke pre-diagnosis but five additional males suffered a stroke during 
follow up, two of whom are now deceased.  Strokes were commonest in those whose 
initial symptoms were “classical” features of acroparasthesia/angiokeratoma, despite the 
younger age of this group of patients.  One third of male index cases have developed WML 
on MRI in the absence of a clinical stroke/TIA.  PPM and ICD insertions occurred 
predominately in those with cardiac presentations, who were also older, and ESRF only 
occurred in the three males whose initial disease manifestations were renal.   
Table 4-8: Vascular complications in male index cases 
Initial 
symptom 
All Pain/ rash Cardiac Renal Other 
No.  44 18 21 3 2 
Median 
age at 
baseline 
51 (16-74) 40 (16-59) 58 (33-74) 47 (25-56) 62.5 (55-70) 
Median 
age latest 
FU/death 
58 (22-77) 43.5 (22-64) 61 (35-77) 58 (27-59) 67 (61-73) 
TIA/Strok
e pre-
diagnosis 
1 (2.3%) 1 0 0 0 
TIA/Strok
e at latest 
FU 
6 (13.6%) 4 2 0 0 
WML w/o 
stroke at 
baseline 
17 (38.6%) 6 7 2 2 
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WML w/o 
stroke on 
latest 
follow up  
17 (38.6%) 8 5 2 2 
PPM/ICD 
at baseline 
9 (20.4%) 0 8 0 1 
PPM/ICD 
at latest FU 
11 (25%) 1 9 0 1 
ESRF 3 (6.8%) 0 0 3 0 
Death 4 (9.1%) 3 1 0 0 
 
Female index cases: 
The vascular manifestations in female index cases are detailed in Table 4-9.  Six females 
had suffered a stroke/TIA pre-diagnosis, in five of whom stroke was the initial symptom 
of FD.  No further strokes/TIA have occurred during follow up.  One third of females have 
WML on MRI in the absence of a clinical event.  The incidence of stroke was higher in 
female index cases compared to males (28.5% vs. 13.6%) with a similar incidence of 
WML in both groups.  In contrast to males, no female index cases have developed end 
stage renal failure or required a cardiac defibrillator or pacemaker and there have been no 
deaths amongst females.    
Table 4-9: Vascular complications in female index cases 
Initial 
symptom 
All Pain/ rash Cardiac Stroke Renal Other 
No.  21 5 5 5 2 4 
Median 
age at 
baseline 
44 (24-75) 30 (24-46) 60 (46-75) 48 (25-53) 31.5 (28-35) 35.5 (29-49) 
Median 
age latest 
FU 
48 (26-77) 38 (28-51) 62 (48-77) 49 (26-54) 39 (29-49) 39.5 (30-57) 
TIA/Strok
e pre-
diagnosis 
6 (28.5%) 1 0 5 0 0 
TIA/Strok
e at latest 
FU 
6 (28.5%) 1 0 5 0 0 
WML w/o 
stroke at 
baseline 
6 (28.5%) 1 3 N/A 1 1 
WML w/o 
stroke on 
7 (33.3%) 1 3 N/A 2 1 
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latest 
follow up  
PPM/ICD 
at baseline 
0 0 0 0 0 0 
PPM/ICD 
at latest FU 
0 0 0 0 0 0 
 
4.4.5 Vascular manifestations in males diagnosed on family screening 
168 patients were diagnosed as part of family screening, comprising 48 males (median 
age diagnosis 24 years; range 6-72) and 120 females (median age diagnosis 34 years; 
range 7-78). Thirty two males (66.6%) had overt symptoms of FD at the time of diagnosis.  
The critical organ vascular complications encountered in males, both at baseline and 
subsequently are summarised in Table 4-10 and discussed in detail below. 
Table 4-10: Vascular complications in males diagnosed on family screening 
Symptoms 
at diagnosis 
All Pain/ 
rash 
Cardiac/ 
cerebrovasc. 
Other Asymp. 
organ 
involvement 
Features 
during 
follow up 
Asymptomati
c, untreated 
No. (%) 48 21 
(43.8%) 
8 (16.6) 3 (6.3) 8 (18.2) 4 (8.3) 4 (8.3) 
Age at 
diagnosis: 
median 
(range) 
24 (6-72) 20 (6-
39) 
65.5 (53-73) 28 (7-29) 39 (6-61) 10 (5-24) 14.5 (14-70) 
TIA/Stroke 
pre-
diagnosis 
2 (4.2%) 0 2 0 0 0 0 
TIA/Stroke 
at any time 
9 (18.7%) 3 3 2 0 1 0 
WML at 
baseline 
16 
(33.3%) 
9 6 0 0 1 0 
WML on 
latest follow 
up  
22 
(45.8%) 
12 6 2 0 2 0 
PPM/ICD at 
baseline 
2 (4.3%) 0 2 0 0 0 0 
PPM/ICD at 
any time 
4 (8.3%) 1 3 0 0 0 0 
ESRF 2 (4.3%) 1 1 0 0 0 0 
Death 7 (14.6%) 2 4 0 1 0 0 
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Males with acroparasthesia/ angiokeratoma pre-diagnosis 
Twenty one males reported pain and/or angiokeratoma as their first symptom with a 
median age of onset of 7 years (range 5-12) and a median age of diagnosis of 20 years 
(range 6-39); the median delay from symptom onset to diagnosis was 11.5 years (range 
<1-33 years).  In three patients the symptoms had been attributed to growing pains and 
one patient had been given an erroneous diagnosis of hereditary haemorrhagic 
telengectasia. None of these patients had suffered a stroke or required dialysis or a 
pacemaker/defibrillator prior to diagnosis. Full baseline assessments occurred at a median 
age of 35 years (range 16-51) by which time seven had LVH, seven proteinuria, four a 
GFR <60ml/min/m2.7and nine radiological evidence of white matter lesions.  Three have 
subsequently had strokes, one has required a pacemaker and one has developed end stage 
renal failure; two have died from complications of FD. Five of these men had deletions, 
seven nonsense mutations and nine missense mutations.  
Males with cardiac or cerebrovascular manifestations pre-diagnosis 
Six males had overt cardiac manifestations, for which they were under the care of 
cardiologists, prior to the diagnosis of FD being made on family screening.  The median 
age of symptom onset in these men was 58 years (range 52-64).  One man had had an 
aortic valve replacement and pacemaker insertion prior to diagnosis and both he and 
another male had been given an insufficient diagnosis of hypertrophic obstructive 
cardiomyopathy (HOCM).  Two further males had suffered a TIA as their initial FD 
related manifestation at the ages of 57 & 69 years.  Both had also developed cardiac 
manifestations prior to FD diagnosis with one requiring an ICD insertion for presyncopal 
VT and the other being investigated for possible cardiac amyloid after an abnormal 
echocardiogram.  The median time from symptom onset to diagnosis in these eight men 
was 3 years (range 1-14).  Baseline assessments in these eight men were performed at a 
median age of 65 years (range 52-73) at which point 7/8 had left ventricular hypertrophy, 
with the one patient without LVH having experienced VT; all had radiological evidence 
of cerebral WML and two had a GFR <60ml/min/m2.7, although one of these was diabetic 
and required dialysis.  Proteinuria was present in 3/8, all with concomitant diabetes.   
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Subsequently, two men have suffered strokes, one of whom had initially had a TIA.  Four 
are deceased, three from FD complications and one from mesothelioma.    The mutations 
found in these eight men were N215S (6) and other missense (2). 
Males with other symptoms pre-diagnosis 
Three other males were symptomatic at the time of diagnosis by family screening.  One 
was being investigated for growth failure at the age of seven, when his mother was 
diagnosed with FD, with a short deletion.  He subsequently developed acroparasthesia and 
at baseline assessment at the age of 17 he had ECG evidence of LVH and has subsequently 
suffered a TIA and declining renal function.  Another had developed symptoms of 
Raynaud phenomenon at the age of 24 and was diagnosed at the age of 29 (P205T 
mutation) by which time he had ECG evidence of LVH; he has not developed renal or 
cerebrovascular disease manifestations. The third man had developed gastrointestinal 
symptoms and vertigo in his 20s and on baseline assessment at the age of 27 had LVH 
and proteinuria and has subsequently suffered a TIA with declining renal function.  
Males asymptomatic at diagnosis 
Sixteen males were asymptomatic at the time of diagnosis, with a median age at diagnosis 
of 15 years (range 5-70).  Two males with nonsense mutations, both diagnosed age 5 years 
developed acroparasthesia at the ages of 7 and 12 years and have subsequently developed 
LVH, proteinuria and one has had a stroke. By the time of baseline assessment at a median 
age of 27 years (range 15-50), nine of the remainder had developed disease manifestations 
(2 acroparasthesia, 4 LVH and 3 LVH plus proteinuria) of whom one also had radiological 
evidence of WML but none have developed a stroke.  One died suddenly from a presumed 
cardiac arrhythmia aged 34 years.  Of the other five males one has proteinuria and renal 
impairment but has declined ERT and the other four are pauci-symptomatic and have also 
declined ERT presently. Other than the two patients with nonsense mutations, the 
mutations found in these patients were N215S (9) and those associated with a later onset 
phenotype (5).   
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Mutation type and changing pattern of presentation 
Similar to index cases, over the last decade there has been an emergence of male patients 
diagnosed on family screening in the later decades of life who predominately have the 
N215S mutation and cardiac disease (see Figure 4-4).  The number of deletions, nonsense 
and missense mutations has remained relatively stable and the majority of males with 
these mutations already had “classical” FD symptoms of acroparasthesia/ angiokeratoma 
pre-diagnosis.  Only four males remain untreated, three of whom are relatively young with 
the N215S mutation and one of whom has the A143T mutation but with a considerably 
higher residual enzyme activity than would be expected for an affected male. 
 
Figure 4-4: Disease manifestations at presentation of males diagnosed on family 
screening: age (blue = not receiving ERT) and mutation by initial symptoms.  
Increasing number of diagnoses with increased age at diagnosis and increased 
prevalence of N215S mutation in past decade. 
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4.4.6 Vascular manifestations in females diagnosed on family screening 
Forty (33.3%) of females had overt symptoms of FD at the time of diagnosis by family 
screening with another six (5%) developing symptoms post-diagnosis and 21 (17.5%) 
having evidence of FD-related organ dysfunction on baseline assessment.  Critical organ 
dysfunction is much less prevalent than in male with 53 females remaining asymptomatic 
and untreated and five of those with GI symptoms also not requiring ERT.  The main 
vascular complications experienced by these females are shown in Table 4-11.  Eleven 
females (9.2%) have suffered from a stroke/TIA, of whom four had the event pre-
diagnosis.  Over one third had WML on brain MRI without suffering a clinical stroke. 
Only 4 females (3.3%) required a PPM/ICD insertion and none developed ESRF.  
Table 4-11: Vascular complications in females diagnosed on family screening 
Symptoms 
at diagnosis 
All Pain/rash Cardiac/ 
cerebrovasc 
Other Asymp 
organ 
involvement 
Features 
during 
FU 
Asymptomatic, 
untreated 
No. (%) 120 19 (15.8%) 7 (5.8) 14 (11.7) 21 (17.5) 6 (5) 53 (44.2) 
Age at 
diagnosis: 
median 
(range) 
34 (7-
78) 
27 (8-53) 62.5 (34-78) 25 (14-
50) 
45 (10-72) 38.5 (7-
49) 
33 (8-65) 
Age at BL: 
median 
(range) 
37 
(11-
78) 
39 (13-2) 67 (51-78) 26 (14-
50) 
55 (32-72) 46.5 (35-
66) 
33 (11-68) 
TIA/Stroke 
pre-
diagnosis 
3 
(2.5) 
2  1 0 0 0 0 
TIA/Stroke 
at any time 
11 
(9.2) 
4 2 0 4 1 0 
WML at 
baseline 
37 
(30.8) 
4 5 2 14 4 8 
WML on 
latest follow 
up  
41 
(34.2) 
7 5 2 15 4 8 
PPM/ICD at 
baseline 
1 
(0.8) 
0 1 0 0 0 0 
PPM/ICD at 
any time 
4 
(3.3) 
1 2 0 1 0 0 
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Females with acroparasthesia pre-diagnosis 
Nineteen females had developed acroparasthesia prior to the diagnosis of FD, at a median 
age of 13 years (range 5-30).  The median delay from symptom onset to diagnosis was 12 
years (range 3-39).  In two females the symptoms had been attributed to growing pains 
and in another to rheumatic fever.  Prior to diagnosis two of these females had also 
suffered a TIA.  Median age at baseline assessment was 41 years (range 13-62) by which 
time 6/19 had LVH, 3/19 proteinuria and 2/19 had WML on MRI in the absence of a 
clinical event (stroke/TIA).  During follow up two further patients suffered a stroke (one 
of whom had WML at baseline) and one patient required an ICD insertion.  None have 
developed a GFR <60ml/min/m2.7.  Mutations identified in these patients were: deletions 
(5), nonsense (4), missense (7). 
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Figure 4-5: Presentation of females diagnosed on family screening. Age of onset and 
mutation type by initial symptoms.  There is an increasing rate of diagnosis of cases by 
family screening over the past decade.  
Females with cardiac or cerebrovascular manifestations pre-diagnosis 
Seven females had symptomatic cardiac disease prior to being diagnosed with FD, one of 
whom had been found to have hypertrophic cardiomyopathy on screening after her sister’s 
death but the underlying cause had not been identified.  The median age of onset was 64 
years (range 34-78) and the median time from symptom onset to diagnosis was 6 years 
(range 2-15).  One patient had a PPM for bradycardia prior to diagnosis and one patient 
had suffered a stroke pre-diagnosis.  At baseline assessment all except the patient with a 
PPM had LVH, one had proteinuria and 4/6 had WML.  One patient required an ICD 
during follow up but there have been no further cerebrovascular manifestations.  
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Additionally, one female with a missense mutation (L372P) had suffered a TIA pre-
diagnosis at the age of 47; on baseline assessment she also had LVH but no proteinuria. 
Females with other symptoms  
Thirteen females had IBS-type symptoms pre-diagnosis with a median age of onset of 16 
years (range 12-31), with three being given a formal diagnosis of IBS by gastroenterology.  
Of these 13 females, one had LVH at baseline and two had WML on MRI but there were 
no stroke/TIAs experienced during follow up and no evidence of renal disease.  
Additionally one female had been noted to have cornea verticillata on a routine eye 
examination five years pre-diagnosis but had not been investigated for an underlying cause.  
She is otherwise asymptomatic. 
Females asymptomatic at diagnosis 
Eighty females were asymptomatic at the time of diagnosis, of whom fifty three have 
remained asymptomatic and have not received ERT.  Eight of these have cerebral WML 
on MRI but, in the absence of other disease manifestations, have not been commenced on 
ERT.  Twenty one females had evidence of organ dysfunction of baseline assessment, 
performed at a median age of 55 years, four of whom have subsequently suffered a stroke.  
Six developed FD manifestations during follow up, one of whom has suffered a stroke.   
Changing pattern of diagnosis 
There has been a rapid increase in the number of females diagnosed with FD over the past 
decade.  Only twenty females were diagnosed prior to 2000, but since 2000 one hundred 
females have been diagnosed, averaging 7.7 new diagnoses per year.  Sixty (60%) of these 
have not required enzyme replacement therapy, 32 of whom have the N215S mutation. 
4.4.7 Cerebrovascular disease in FD 
Overall 15 males (16.3% male patients) and 17 females (12.1% female patients) suffered 
a stroke or TIA, with the event occurring prior to the diagnosis of FD in three males and 
nine females.  This almost equal incidence of cerebrovascular events between male and 
females with FD is in contrast to renal and cardiac events which are much commoner in 
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males than females (see Figure 4-6).  Asymptomatic WML on brain MRI were also 
almost as common in females as males.  Whether these arise due to the same pathological 
mechanism as stroke in FD and hence might be predictive of stroke in unknown.  Of those 
who had a brain MRI prior to their stroke/TIA, 8/12 (66.6%) of males and 6/8 (75%) 
females had WML; however, 32/76 (42.1%) of males and 33/119 (27.7%) of females had 
WML on brain imaging at baseline and have not suffered a stroke/TIA.  
 
Figure 4-6: Prevalence of critical organ complications in males and females with FD 
Relationship to age 
The median age at stroke/TIA was 46 years (range 19-74) in males and 47 years (range 
24-82) in females.  As shown in Figure 4-7 there is no difference in prevalence of 
stroke/TIA between males and females which gradually increases with age up to the age 
of 60 years, after which the rate of stroke increases. Similarly in those patients who have 
not suffered a stroke, there is no difference in the prevalence of white matter lesions at 
baseline between males and females, with a more rapid increase in both sexes after the 
age of 40.  In contrast, renal impairment and left ventricular hypertrophy are more 
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prevalent at baseline in males and occur at an earlier age.  In females, these complications 
were extremely rare below the age of 40 years, after which they increased rapidly with 
increasing age.  Correlations between baseline GFR/LVMI and age at baseline show that 
whilst both are significantly correlated with age in males and females (p<0.0001 in all 
cases), the correlations are stronger in females than males:  GFR – males: slope -1.00, r2 
= 0.29 vs. females: slope -0.88, r2= 0.42; LVMI – males: slope 0.57, r2= 0.21, females: 
slope 0.73, r2= 0.46. 
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Figure 4-7: Relationship between critical organ dysfunction and age in males and 
females. 
Relationship to other organ involvement and overall disease severity 
All males who had a stroke also have left ventricular hypertrophy with 7/15 (46.7%) 
having a PPM/ICD or arrhythmia and the rest having conduction delays/repolarisation 
abnormalities on ECG.  7/15 (46.7%) of males had a GFR<60ml/min/m2.7 and the same 
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number also had proteinuria.  In contrast, four females (23.5%) had no evidence of cardiac 
or renal involvement by FD and the prevalence of LVH, conduction abnormalities and 
renal disease was lower in females (see Figure 4-8). 
 
Figure 4-8: Prevalence of other organ involvement in FD patients with stroke/TIA 
(A).  Age-adjusted disease severity in patients with and without stroke/TIA (B). 
In males there was no difference in baseline age-adjusted severity score between males 
with a stroke and those without (6.48 vs. 2.47, p = 0.17), see Figure 4-8.  In females, those 
with stroke had higher baseline age-adjusted severity scores that those without (9.12 vs. 
1.01, p = 0.008), however this includes many females who are asymptomatic.  When 
compared to females requiring ERT for other disease manifestations, there is no 
significant difference in disease severity between the two groups (9.12 vs. 7.54, p = 0.93).  
Relationship to enzyme activity and mutation status 
Plasma GLA activity data, measured at either RFH/ICH prior to commencement of ERT, 
was available in 73 males and 129 females.  One male with the A143T mutation had 
plasma enzyme activity considerably higher than would be expected for an affected male, 
(1.5nmol/ml/hr), confirmed on repeated measurements, for reasons unknown; this male is 
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asymptomatic and has been excluded from the analyses related to enzyme activity.   The 
normal range for plasma enzyme activity is 4.0-21.0 nmol/ml/hr. 
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Figure 4-9: Relationship between enzyme activity, disease severity and mutation 
type.  
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In both males and females there was a correlation between baseline disease severity and 
plasma enzyme activity, see Figure 4-9.  In males this was a highly significant correlation 
(r2= 0.38, p<0.0001) but in females although the correlation was significant it was weak 
(r2= 0.04, p=0.02).  The median plasma activity for males was 0.1 nmol/ml/hr (range 0-
0.6), with patients with the N215S mutation having higher plasma enzyme activity than 
other patients, see Table 4-12.  This was concordant with a lower baseline disease severity 
in these patients.  Even though the 36 males with the N215S mutation have an identical 
mutation, there was a wide range of enzyme activity seen in these patients, with the 
enzyme activity correlated with disease severity (r2= 0.13, p = 0.02).   The median plasma 
enzyme activity for females was 4.07 nmol/ml/hr (range 0.4-12.6).  Females with the 
N215S mutation or “late onset” mutations had lower baseline severity scores than those 
with deletions or non-sense mutations.  Amongst those with the N215S mutation, plasma 
enzyme activity was correlated with disease severity (r2= 0.18, p=0.005). 
Table 4-12: Relationship between enzyme activity, severity & mutation type 
  Deletion Nonsense Missense “Late 
onset” 
N215S 
No (%) patients Males 8 (10.9) 6 (8.2) 17 (23.3) 6 (8.2) 36 (49.3) 
Females 13 (10.1) 18 (14.0) 46 (35.7) 10 (7.8) 42 (32.6) 
Plasma enzyme 
(nmol/ml/hr) 
median & rnage 
Males 0.1  
(0-0.11) 
0.1 
(0-.0.2) 
0.06 
(0-0.3) 
0.1 
(0.1-0.2) 
0.2 
(0-0.6) 
Females 2.9  
(2-8.1) 
3.45  
(0.4-7.9) 
3.3  
(1-10.3) 
5.3  
(2.7-12.6) 
4.2  
(1.9-7.4) 
Baseline age-
adjusted severity 
Males 11.8 
(2.3-17.8) 
9.0 
(2.6-14.7) 
8.8 
(0.1-18.7) 
-1.2 
(-9.5-11.3) 
-6.0 
(-14.0-6.5) 
Females 7.7  
(-4.5-18.5) 
2.7  
(-6.8-20.9) 
3.7  
(-6.1-16.3) 
1.59 
(-6.6-15.7) 
-2.6 
(-11.7-8.4) 
 
Whilst enzyme activity appears to be an important factor in overall disease severity in 
males, there was no difference in the median plasma activity for males with stroke/TIA 
compared to those without (0.1 vs. 0.1, p = 0.24).  Similarly, there was no difference in 
the median enzyme activity in females with stroke/TIA compared to those without (4.30 
vs. 4.07, p = 0.69).  Amongst males, strokes were commonest in those with deletions, 
nonsense or missense mutations and were uncommon in those with the N215S mutation, 
occurring only in old age in these patients, see Figure 4-10.  In males there was a 
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significant correlation between enzyme activity and age at stroke (r2= 0.476, p= 0.013).  
In females, strokes occurred in patients with all mutation types with no clear relationship 
between age at stroke and mutation type or plasma enzyme activity (r2= 0.098, p=0.24). 
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Figure 4-10: Relationship between stroke, mutation type and enzyme activity. 
Vascular risk factors 
Conventional risk factors for stroke include: smoking, diabetes and hypertension.  Obesity 
and a raised lipoprotein (a) are also considered to be risk factors for vascular disease by 
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some.  Amongst males there was no increase in cardiovascular risk factors amongst males 
with stroke compared to those without (see Figure 4-11).  All males with the N215S 
mutation had vascular risk factors.  Hypertension, diabetes, obesity and a raised Lp(a) 
were all at least twice as common amongst females who had suffered a stroke/TIA 
compared to those who had not.  Two females had no vascular risk factors for stroke and 
no other evidence of other organ involvement by FD; they have the mutations A143T and 
Q221P. 
Prognostic scores (FIPI) 
The FIPI neurological score was calculated based on data from baseline evaluation and 
outcome censored either at the time of stroke/TIA or at latest follow up.  There was no 
significant difference in events in patients with different prognostic scores (high, medium 
or low) in males (p = 0.48) or females (p = 0.45), see Figure 4-11. 
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Figure 4-11: Vascular risk factors and the FIPI prognostic score 
4.4.8 Plasma pro-thrombotic tendency 
Nineteen male and 22 female consecutive FD patients had plasma assays performed for 
protein C, protein S, anti-thrombin and FVIII activities and mutational analysis for the FV 
Leiden and PTG20210A prothrombin gene mutations. The median age of patients was 54 
years (range 19-84).  All males and 18 females were receiving ERT.  Seven (17.9%) 
patients had suffered a stroke/TIA and 61% had cerebral white matter lesions on MRI.  
One patient had a transient lupus anticoagulant, one patient was heterozygous for the FVL 
mutation and one patient heterozygous for the prothrombin gene mutation PTG20210A.  
One patient had a borderline reduced protein C activity (63 IU/dL); one female patient 
had a mildly reduced protein S activity (54 IU/dL) related to use of the oral contraceptive 
pill.  None of these patients had had a cerebrovascular event.  Five patients (12.2%) had 
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protein S levels above the normal range.  The rest of the patients had levels of PC and PS 
within the normal range and all patients had normal levels of anti-thrombin.  
FVIII activity was increased in 16 patients (39%, 9 male, 7 female).  FVIII activity 
increased with age in both males in females, Figure 4-12; in females this correlation was 
significant (slope 1.25, r2 = 0.263, p = 0.015); in males it was not (slope 0.91, r2 = 0.05, p 
= 0.35), due to four males with higher VWF levels than expected for their age.  Age 
adjusted severity scores were correlated with VWF levels, with a more significant 
correlation in females (slope 3.79, r2 = 0.471, p = 0.0004) than in males (slope = 3.591, r2 
= 0.316, p = 0.012).  The four males with higher VWF levels than expected for age also 
were outliers for severity, with higher age-adjusted severity scores.  Exclusion of these 
four men removed the correlation between severity and FVIII levels in males.  There was 
no difference in VWF levels between those with or without cerebrovascular disease. FVIII 
tended to increase as renal function declined, with a significant correlation between GFR 
and FVIII in females (slope -0.999, r2 = 0.334, p = 0.005) but not in males (slope -0.786, 
r2 = 0.137, p = 0.131). FVIII levels were strongly correlated with VWF levels in both 
sexes (males r2= 0.776, females r2 = 0.712, P <0.0001).   
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Figure 4-12: Relationship between FVIII and disease manifestations. 
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4.5 Discussion 
4.5.1 Vascular manifestations are important in the presentation of FD  
The data from the RFH demonstrates that vascular manifestations are important presenting 
features of FD in both males and females.  Cardiac manifestations, particularly 
arrhythmias, are common presenting symptoms in both males and females although more 
severe in males who also have a higher rate of pacemaker and ICD insertion.  Renal 
presentations with proteinuria occur in both genders, but progression to end stage renal 
failure did not occur in any female.  In contrast to cardiac and renal disease, stroke was a 
commoner presentation in females than males, being the initial symptom of FD in five 
females but no males.   
Early diagnosis offers the opportunity for initiation of ERT with the aim of preventing 
develop or progression of critical organ disease, although evidence of its efficacy in this 
respect is still lacking217;218. In addition to ERT, there is the opportunity to optimise 
supportive therapies, for example ACE inhibitors, blood pressure control and ICD 
insertion for primary prophylaxis of ventricular tachycardia211. Data from the cohort 
suggests that all males are at risk of these complications and therefore improving the 
diagnostic pathway in these patients would be beneficial.  
Many patients experienced long delays between symptom onset and the diagnosis of FD 
and this was true both of index cases and those diagnosed on family screening.  The 
number of patients diagnosed with FD on family screening who had already been 
investigated for manifestations of FD supports the notion that symptomatic FD remains 
un-diagnosed.  Those whose initial symptom was acroparasthesia experienced the longest 
delays, with a median delay of >10 years.  A number of factors may contribute to this: 
deducing the underlying cause of neuronopathic pain can be difficult, particularly when 
there may be few clues from physical examination or routine laboratory investigations219.  
Whilst the diagnosis was often made in males by dermatologists following the appearance 
of angiokeratoma, the rash often appears first in the bathing trunk region and may be 
missed unless directly asked about/ looked for by the consulted physician.   
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Delays were shorter in those patients who developed major organ involvement although a 
number of patients had been erroneously diagnosed with hypertrophic obstructive 
cardiomyopathy prior to arrival at the correct diagnosis. Awareness of the potential 
differential of FD amongst cardiologists, nephrologists and stroke physicians is likely to 
have been raised in recent years by a number of screening studies for FD conducted 
amongst these populations220. To date, no screening studies for FD in patients with 
neuronopathic pain have been published and it may be that awareness of the diagnosis 
amongst the diverse range of physicians to whom these patients present is lacking. 
4.5.2 Vascular complications are important clinical events during the follow up of 
patients of FD 
Eleven of the 91 males in the cohort (12.1%) have died and in all apart one case this was 
due to either cardiac or cerebrovascular complications, with a median age at death of 53 
years. Therefore, improving our understanding of how these complications arise and how 
they may best be prevented is vital to improving the prognosis of FD in men.  Despite the 
initiation of ERT, vascular complications continue to occur during follow up, particularly 
in those presenting with “classical” features of acroparasthesia and/or angiokeratoma.   
4.5.3 Stroke in FD – just another organ complication or different aetiology? 
Cerebrovascular disease stands out from other organ complications in having an almost 
identical prevalence in both male and female patients with FD.  In males, stroke arises in 
the setting of other disease manifestations.  It is more common in those with deletions or 
nonsense mutations and the age at first stroke is correlated with enzyme activity.  
Therefore, in males, stroke can be considered a direct complication of the disease process. 
The scenario in female patients is different.  Stroke can arise in the absence of disease 
manifestations in other organs.  Whilst the development of cardiac or renal disease appears 
to be strongly correlated with age, this is not the case for stroke which occurs most 
commonly in females in the fifth decade of life.  Whilst stroke is commoner in females 
with deletions, it occurs in all mutation types and there is no relationship between plasma 
enzyme activity and age at stroke.  Vascular risk factors seem to be more important in the 
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development of stroke in females than males. There are two females with a GLA mutation 
and stroke but no other disease manifestations or risk factors for stroke.  The fact that this 
scenario is not seen in male patients raises questions about the mechanisms which link a 
GLA mutation with the occurrence of stroke in these patients and whether it is truly 
causative or there are other, as yet unknown, factors to which the stroke might be 
attributable.  
4.5.4 Fabry disease in men – a spectrum or distinct subtypes? 
The incidence of FD has increased substantially in the past decade, mostly due to an 
increase in diagnoses of patients with the N215S mutation.  These patients have a higher 
residual enzyme activity and a significantly lower overall disease severity score with a 
predominance of cardiac involvement.  The “classical” phenotype of acroparasthesia and 
angiokeratoma in adolescence is rare in these men.  Although there are exceptions to this 
with two males with the N215S mutation presenting with proteinuria and end stage renal 
failure in their 20s/30s the N215S mutation potentially represents a distinct subtype of FD 
with different disease manifestations and prognosis to other patients.  This is potentially 
important for understanding prognosis in these patients – many of these patients are 
diagnosed at an age exceeding the expected life expectancy of males in FD reported in 
historical cohorts37 and are likely to have an improved prognosis.  This is also important 
for interpretation of clinical studies, particularly where comparisons to historical natural 
history cohorts are drawn221, as the natural history of these patients is likely to be 
significantly better than that of patients with more “classical” disease manifestations.  
Position 215 on the GLA enzyme represents an N-linked glycosylation site and 
glycosylation is important for the correct trafficking of proteins intracellularly.  
Understanding why a mutation at this site results in cardiac disease in later life may shed 
new insights in the pathogenesis of FD in different organ systems.  The range of enzyme 
activity seen in men with this mutation suggests that there are other factors which modify 
enzyme activity, either at the gene expression level or through a translational/post- 
translational mechanism.  The correlation between enzyme activity and disease severity 
would suggest that these factors are important modifiers of disease222. 
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4.5.5 Fabry disease in women – disease causing or disease predisposing? 
The GLA gene is located on the X chromosome and therefore historically females were 
considered carriers rather than affected heterozygotes.  Our cohort data is consistent with 
that of studies performed in the last 15 years which demonstrate that many females 
develop clinical manifestations of FD38;223.  On the other hand, many females remain 
asymptomatic throughout life.  Particularly in light of the large number of females 
diagnosed on family screening, understanding which females may go on to develop 
clinical manifestations of FD and why is of key importance both for counselling these 
women regarding genetic testing and understanding how best to manage them.   
Age appears to be an important factor in the development particularly of cardiac and renal 
disease with the incidence of these disease manifestations increasing rapidly after the age 
of 40 years (left ventricular hypertrophy) and 60 years (renal impairment).  The stronger 
correlations between age and LVMI and GFR in females than males suggests that age-
related factors have more of an impact on disease in females than males.  In the general 
population cardiovascular disease is unusual in pre-menopausal women224 with a 
significant increase being seen after the menopause, although this has been attributed in 
part to an increase in other cardiovascular risk factors225. Whether menopausal changes 
play a role in FD has not yet been investigated.  FVIII levels, which have also been 
associated with risk of vascular disease, increase with age in both males and females but 
are more closely correlated with age in females than males and are correlated with disease 
severity in females but not males.  This would support the hypothesis that age related 
changes in the vasculature in females impact on disease manifestations. 
Unlike men, conventional cardiovascular risk factors and obesity were much commoner 
in women with cerebrovascular disease than those without suggesting that in females 
additional risk factors may impact on the development of vascular disease.  Obesity has 
been demonstrated to be an additive risk factor in combination with other vascular risk 
factors226.  The importance of other risk factors is also supported by studies of 
polymorphisms in genes related to inflammation and coagulation where associations 
between polymorphisms and cerebrovascular disease were stronger in females than 
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males92;93.  We did not find an increase in the presence of the prothrombotic mutations or 
abnormalities of the anticoagulant system in our cohort. In both males and females a raised 
lipoprotein (a) was commoner in those with cerebrovascular disease than those without.  
Serum levels of Lp(a) are primarily genetically determined227 and increased Lp(a) is a risk 
factor for both cardiac228  and cerebrovascular disease229.  Potential mechanisms for this 
increased risk include up-regulation of the adhesion molecules ICAM-1 on leukocytes230 
and activation of coagulation231.  Lipoproteins are the carrier proteins for Gb3 in the 
circulation232 and therefore increased lp(a) may also exacerbate disease mechanisms 
mediated by increased Gb3. Investigation of lp(a) polymorphisms may reveal a new 
genetic modifier of FD.  
Taken together, these factors suggest that in females a GLA mutation, rather than being 
disease causing, may act to pre-dispose females to the development of cardiac, 
cerebrovascular or renal disease with additional factors required for complications to 
occur.  
4.6 Conclusions 
This study confirms that vascular disease is important not only in the clinical presentation 
but also the long term morbidity and mortality of patients with FD.  In male patients these 
complications become more prevalent with increasing age, with disease severity 
correlating with enzyme activity and mutation type.  The presence of an N215S mutation 
with a higher residual enzyme seems to limit the development of disease manifestations 
predominantly to the heart with cerebrovascular disease occurring only in the presence of 
additional risk factors.  Females have less severe disease with many remaining 
asymptomatic.  The onset of cardiac and renal disease occurs at a later age and to a lesser 
extent in females than males and it may be that in females additional events are required 
at the cellular/organ level for disease manifestations to develop.  In contrast, the 
pathophysiology of cerebrovascular disease would appear to be different, occurring at a 
similar age and prevalence in males and females. 
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The next two chapters explore potential disease processes at the cellular level, focussing 
on processes related to cellular adhesion and coagulation occurring at the blood-
endothelial interface to try to shed new insights onto the pathogenesis of these disease 
manifestations in patients with a GLA mutation. 
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Chapter 5 Cellular adhesion in Fabry and Gaucher 
5.1 Introduction 
The endothelium provides the critical interface between the blood and its constituents and 
tissues.  During steady state conditions there are resident populations of leucocytes, 
including lymphocytes (both B and T cells), dendritic cells and macrophages, in the 
tissues; these leucocytes have important roles in immune surveillance.  During activation 
of inflammation communications between the endothelium and circulating leukocytes 
enable the adhesion of leukocytes to the vessel wall and their egress from the circulation 
into the surrounding tissues.   This process has been implicated in a wide variety of 
diseases including vascular diseases (e.g. stroke)233;234, haematological malignancies235 
and disorders which affect the microcirculation (e.g. sickle cell disease)236;237.   
Abnormalities of leukocyte adhesion have been implicated in the vascular complications 
associated with FD126 including cardiovascular and cerebrovascular complications. The 
commonest abnormal findings to date are increased ICAM-1 and VCAM-1 (see 1.8.1), 
molecules central to firm leukocyte adhesion to the endothelium, in either the serum or in 
endothelial models.  A single study of monocytes in male FD patients showed increased 
expression of CD11b152.  Previous studies have concentrated on adhesion molecule 
expression and there is no data on whether these abnormalities result in increased adhesion 
activity or how they relate to clinical disease manifestations.  Studies of leukocyte 
adhesion in GD are limited; although endothelial adhesion is required for egress of 
monocytes from the circulation to become tissue macrophages, it is not known whether 
this process is abnormal in GD.  Additionally, the mechanisms underlying bone infarction, 
which bears some similarities to infarcts seen in sickle cell disease, and the increased risk 
of haematological malignancies in GD are poorly understood.  
Cellular adhesion is a closely regulated process and cytokines are the primary regulators.  
Increased levels of pro-inflammatory cytokines have been found in both FD and GD (see 
Table 1-6) which may up-regulate cellular adhesion in these patients.  Additionally the 
glycosphingolipids LacC and S1P can act to increase adhesion molecule expression10;142.  
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Gb3 has been shown to up-regulate endothelial VCAM1 and ICAM1 mRNA151 but the 
effect of other glycosphingolipids on endothelial-leukocyte adhesion is not known. 
5.2 Purpose of this chapter 
This chapter examines the expression and functional activity of adhesion molecules 
involved in leucocyte-endothelial adhesion, concentrating on firm adhesion using static 
adhesion experiments, as this is the part of adhesion where most abnormalities have been 
suggested in FD.  Utilising the ability of monocytes, but not lymphocytes, to adhere to 
tissue culture plastic238, the adhesion capacity of monocytes is assessed.  Monocytes are 
the key abnormal cells in GD and the leucocytes in which abnormalities of adhesion 
molecule expression have been found in FD. Expression of leucocyte adhesion molecules 
in subsets of mononuclear cells is examined by flow cytometry. 
5.2.1 Development of endothelial cell models of FD and GD 
In order to examine the role of decreased GLA and GBA activity on the expression and 
functional activity of adhesion molecules on the endothelial surface, an endothelial cell 
model was developed.  Endothelial cells perform a vast array of functions, which can vary 
according to their location, including active transport of small molecules, regulation of 
blood pressure, leucocyte adhesion and transmigration, angiogenesis and haemostasis.  
Whilst human umbilical vein cells (HUVEC) are the most studied primary endothelial cell 
isolate, they lose their phenotype after a small number, or even a single passage. For this 
work the EA.hy 926 endothelial cell line, which is a hybridoma of HUVEC and the human 
lung carcinoma cell line A549 was used. This cell line shows a number of endothelial cell 
characteristics including von Willebrand factor expression184 and, particularly pertinent to 
this project, up-regulation of ICAM-1 and VCAM-1 in response to TNFα239. 
Pharmacological inhibition 
Conduritol β epoxide (CBE) binds covalently to the active site of GBA, causing 
irreversible inhibition of enzyme activity240 and has been widely used in the study of GD.  
The search for a similarly efficacious inhibitor of GLA, including using high throughput 
screening technologies, has been less fruitful241.  1-deoxygalactonorijimycin (DGJ) is an 
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iminosugar, a small organic compound mimicking carbohydrates but which contains a 
nitrogen atom instead of an oxygen atom in the ring system242.  DGJ is biochemically 
selected to reversibly inhibit the active site of GLA but sufficiently distinct from 
carbohydrates to avoid processing by other carbohydrate-modifying systems. At low 
concentrations (upto 20μM) it acts as a chaperone and has been demonstrated to increase 
enzyme activity in FD fibroblasts243.  An inhibitory effect on enzyme activity, 
presumptively due to competitive inhibition, has been demonstrated at higher 
concentrations of 400-500μM244.   
Chloroquine hydrochloride is a lysosomotropic agent which has also been used to inhibit 
GLA.  It inhibits lysosomal enzymes to different degrees at different concentrations, with 
more inhibition of GLA than other lysosomal enzymes at low concentrations245.  
Chloroquine has a number of effects on the lysosomal system including increasing 
lysosomal pH, altering mannose-6-phosphate (M6P) receptor cycling and disrupting 
phagocytic pathways246. 
Amiodarone is another lysosomotropic drug but with no known direct effects on GLA or 
GBA activity and was used as a control for lysosomal dysfunction.  At physiological pH, 
amiodarone is un-ionised and passively diffuses across the lipid bilayers of intracellular 
organelles.  At acid pH, amiodarone becomes ionised and less able to diffuse out of the 
lysosome247 causing expansion of the lysosomal system.  Amiodarone impairs trafficking 
through the late endosomal pathway248 and alters M6P receptor recycling249.  It also 
inhibits lysosomal phospholipase A1 & A2 causing intralysosomal accumulation of 
phospholipids.   
RNA interference using small hairpin RNA 
Due to the lack of availability of an effective specific pharmacological inhibitor for GLA 
ribonucleic acid (RNA) interference (RNAi) was used as an additional method to reduce 
intracellular GLA activity.  RNAi results in sequence specific gene silencing at the 
messenger RNA (mRNA level).  Small interfering RNAs (siRNA) are short double 
stranded RNA oligonucleotides, 25 nucleotides in length, processed internally by the 
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enzyme DICER and then split into two separate strands.  One of these strands binds a 
complementary mRNA sequence on the target gene which is then cleaved and degraded 
by the RNA-induced silencing complex (RISC), preventing protein translation. siRNA 
sequences can either be introduced into cellular cytoplasm as pre-synthesised 
oligonucleotide strands using lipid-mediated transfection or using a viral vector DNA 
construct which integrates into cellular DNA (transduction).  The transcribed DNA 
encodes a short hairpin RNA (shRNA) which is then processed by DICER to siRNA.  As 
siRNA is inherently unstable and usually completely degraded within 48 hours, a shRNA 
approach using a lentiviral vector was used for this project to enable sustained suppression 
of GLA protein synthesis. 
5.3 Hypotheses 
1. Increased expression of leukocyte adhesion molecules occurs in FD and GD and is 
associated with vascular manifestations in FD and the presence of bleeding and 
gammopathies in GD. Rationale: FD and GD are associated with a pro-inflammatory 
state which results in up-regulation of adhesion molecules 
2. Lipid loading of endothelial cells, but not reduction in enzyme activity alone results 
in increased endothelial adhesion activity. Rationale: results to date suggest that Gb3 
rather than GLA deficiency is responsible for endothelial dysfunction.  
Glycosphingolipids LacC and S1P have been found to up-regulate adhesion molecule 
expression and other glycosphingolipids may also perform this function. 
5.4 Methods 
5.4.1 Monocyte adhesion assay 
This assay is investigates static adhesion processes and utilises the adhesion properties of 
monocytes whereby they are able to adhere to tissue culture plastic (TCP) surfaces.  This 
process is predominantly mediated by integrins and therefore calcium dependent, although 
monocytes may also adhere to TCP through scavenger receptors in a calcium-independent 
manner. Both monocytes and platelets adhere to TCP and therefore an iodixanol flotation 
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barrier was used to isolate monocytes resulting in a monocyte-enriched, platelet deplete 
mononuclear cell fraction. 
Adhesion of monocytes to TCP is time and concentration dependent, being linear over a 
range of 0.5-2x105 monocytes per well and is also serum dependent (see Figure 5-1), 
where adhesion molecules within serum adhere to TCP and then monocytes adhere to 
these.  10% serum was used for the assays; to assess solely the leucocyte component cells 
were suspended in pooled normal human serum (PHS) whereas to investigate the role of 
serum constituents, cells were suspended in heat inactivated autologous serum (AHS).  To 
account for differences in staining between assays, the results are expressed as the ratio of 
absorbance of the test well to the PHS serum blank well (see 2.7.1).   
The relationship between disease manifestations of GD/FD and adhesion ratio was 
evaluated by linear regression analysis.  The clinical data was obtained as described in the 
preceding chapters.  
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Figure 5-1: Development of monocyte adhesion assay. A: absorbance of solubilised 
Giemsa stain is dependent on cell concentration. B: time dependence of adhesion. C &D: 
dependence of adhesion on the presence of human serum. 
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5.4.2 Leukocyte adhesion marker expression 
Surface expression of adhesion molecules on mononuclear cells was assessed using flow 
cytometry.  The adhesion molecules investigated and the rationale for their selection is 
shown in Table 5-1.   
Table 5-1: Adhesion molecules assessed 
Antigen Leucocytes expressed on Reason selected 
 Mono CD14- Lymph  
CD11a Y Y Y Ligand for ICAMs 1-4; ICAM1 raised in some FD 
studies, other ICAMs not assessed 
CD11b Y X X Ligand for ICAM-1.  Up-regulated in monocytes on a 
previous study in FD 
CD11c Y Y X Shared β subunit with CD11a and CD11b but not 
ligand for ICAM-1 
CD50 Y Y Y Ligand for CD11a (LFA-1) 
CD54 Y Y X ICAM-1. Increased serum levels in FD 
CD102 Y Y Y Ligand for LFA-1 (CD11a) 
CD49d Y Y Y Ligand for VCAM-1 which is increased in some FD 
studies 
CD62L Y Y Y Predominant selectin on leukocytes – for rolling prior 
to firm adhesion 
CD36 Y X X Binds lipids; abnormal lipid profiles in FD/GD may 
cause upregulation 
 
Gating strategy and analysis 
Initial gating was performed on forward (FSC) and side scatter (SSC) characteristics.  This 
differentiates lymphocytes from cells which fall within the monocyte gate.  Within the 
monocyte gate, CD14+ monocytes were identified by gating on CD14+ strongly positive 
cells.  Within the FSC-SSC monocyte gate there is also a population of CD14 weak-
negative cells; whether these cells represent a sub-population of monocytes (e.g. 
CD14lowCD16high) or dendritic cells is not possible to establish from the cellular markers 
used. They have a different pattern of expression of adhesion molecules from the CD14+ 
monocytes and are therefore analysed as a separate cell population.  The median 
fluorescent intensity (MFI) of adhesion molecules on each cell population was measured 
using FlowJo analysis software (see 2.6).  CD62L is expressed on all mononuclear 
leukocytes but is more strongly expressed on a subpopulation of lymphocytes.  Therefore 
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the size of this subpopulation and the MFI of cells in this subpopulation was also 
calculated.  
5.4.3 Development of cellular models to look at endothelial adhesion 
The EA.hy 926 cell line was used to develop and endothelial model of FD and GD.  
Confocal imaging was performed to establish if uptake of DiI labelled acetylated low 
density lipoprotein (DiI-acLDL) occurred and whether von Willebrand factor was 
synthesised, both characteristics of endothelial cells.  Confluent monolayers of EAhy.926 
were stimulated with a range of doses of TNFα for 0-24 hours to assess for up-regulation 
of adhesion molecule expression.  This was assessed by two methods: 1) adhesion of DiI 
labelled murine monocytic cells (RAW 264.7) to the endothelial monolayer and 2) ICAM 
and VCAM expression by Western blot. 
For pharmacological inhibition, stock solutions of the four pharmacological inhibitors 
were made as detailed in the Methods chapter.  They were added to EAhy.926 cells at the 
concentrations indicated.  MTT assays were performed to measure the effect on cell 
viability.  To measure the effect of the drugs on enzyme activity, the cells were lysed and 
then activity assays performed.  The protein concentration of the lysate was measured and 
enzyme activity expressed as nmol/mg/hr. 
The UCL pGIPZ shRNA library was searched for sequences that target the GLA gene. 
Three sequences were selected: 
FD1 (V2LHS_82973):  antisense: ATAAAGAGGCCACTCACAG 
FD2 (V2LHS_82794): antisense: AAATCCCTAGCTTCAGTCC 
FD5 (V3LHS_391616): antisense: AGACATGAATAAAGGAGCA 
Analysis of the sequences using the bioinformatics tool, Basic Local Alignment Search 
Tool (BLAST, http://blast.ncbi.nlm.nih.gov) confirmed that each sequence targeted only 
the GLA gene with 100% alignment and that potential off-target effects for each sequence 
were different (see Table 5-2 ).   
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Table 5-2: Results of BLAST search for targets of the shRNA sequences 
Gene Query 
cover 
E 
value 
Function 
FD1 
Alpha galactosidase A 
(GLA) 
100% 0.02  
Mannose receptor C, type 1 
(MRC1) 
84% 0.11 Mediates endocytosis is glycoproteins by 
macrophages 
Zinc finger protein 552 
(ZNF552) 
78% 0.43 Unknown 
Family with sequence 
similarity 114 member A1 
(FAM114A1) 
73% 1.7 Unknown 
Leucine rich repeat 
containing 15 (LRRC15) 
73% 1.7 Unknown 
Polycystic kidney disease 1 
(PKD1) 
73% 1.7 Regulates calcium permeable cation channels and 
intracellular calcium homeostasis. 
FD2 
Alpha galactosidase A 
(GLA) 
100% 0.002  
Nitrogen fixation homolog 
(NFS1) 
73% 1.7 Supplies inorganic sulphur to iron-sulphur cluster 
(required by many cellular enzymes)  
Patain-like phospholipase 
domain containing 4 
(PNPLA4) 
68% 6.7 May be involved in triglyceride homeostasis 
Cyclic nucleotide gated 
channel beta 3 (CNGB3) 
68% 6.7 Encodes beta subunit of a cyclic nucleotide-gated ion 
channel.  Involved in function of cone photoreceptors 
Sulfatase modifying factor 2 
(SMF2) 
68% 607 Involved in post-translational generation of C-α-
formylglycine at catalytic site of sulphatases 
FD5 
Alpha galactosidase A 
(GLA) 
100% 0.002  
tRNA methyltransferase 1 
homolog (TRMT1L) 
78% 0.43 May be involved in neurological functions, including 
motor co-ordination & exploratory behaviour 
Ankyrin repeat domain 1 
(ANKRD1) 
73% 1.7 Localised to nucleus of endothelial cells and induced 
by IL-1 and TNFα. Likely to function as a transcription 
factor 
Dishevelled associated 
activator of morphogenesis 1 
(DAMM1) 
100% 6.7 Regulates cell growth through stabilisation of 
microtubules 
 
Sequencing confirmed the presence of the correct transcript (see Figure 5-2).  Restriction 
digest confirmed that the correct packing vectors were isolated (see Figure 5-3).  
EAhy.926 cells were infected with the lentiviral constructs and puromycin selection 
carried out, using a dose of 1μg/ml (derived from MTT assays – see Figure 5-4) to yield 
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a culture of GFP positive cells. Enzyme activity, using fluorimetry, and protein level, 
using Western blot, were assayed to confirm knockdown of GLA expression. 
 
Figure 5-2: shRNA sequences. A: target sites.  FD1 targets a sequence on exon 4 which 
forms part of the active site.  In addition to a target sequence on exon 3, FD2 also targets 
a short sequence on exon 7. B: confirmation of shRNA sequences from isolated plasmid 
DNA showing insertion of shRNA sequence in the GIPZ plasmid. 
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Figure 5-3: Confirmation of envelope and packaging vectors by restriction digest.  A: 
vector map for pMDG highlighting restriction sites for BamHI and EcoR1. B: vector map 
for p8.91 highlighting restriction sites for EcoR1 and BglIII. C: Restriction digest 
fragment sizes (1% agarose gel, 1V, 75 minutes). 
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Figure 5-4: GFP expression & puromycin toxicity. A: HEK293T cells producing 
lentivirus (x20); B: GFP expression in EAhy.926 cells 48 hours after infection (x20); 
C&D: GFP expression in EA.hy 926 cells after puromycin selection (x20,x40). E 
puromycin toxicity to EA.hy 926 cells (MTT assay), n=2, each experiment performed in 
triplicate. 
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5.4.4 Functional endothelial cell adhesion assay 
To measure the functional adhesion capacity of monocytic cells to the endothelial cell 
model, the murine monocyte-macrophage cell law RAW 264.7 was used.  The use of a 
cell line enabled the availability of a high number of cells of multiple experiments and a 
homogeneous cell population for use across assay.  As detailed in the methods chapter 
(see 2.7.2) , RAW cells were labelled with DiI, a fluorescent dye, and the fluorescence of 
RAW cells adherent after 1 hour incubation measured.  The results were expressed as the 
ratio of the fluorescence of test samples to the control samples. 
Adhesion of RAW, as determined by fluorescence, was dependent on a) the number of 
RAW cells added b) the density of the EAhy monolayer and c) activation of endothelial 
cells with TNFα (see Figure 5-5).  A concentration of 200 000 RAW per well was selected 
for the assays and a seeding density of 40 000 per well for EAhy.  TNFα was used at 2nM 
concentration for 8 hours, which allows up-regulation of both ICAM and VCAM and 
increased adhesion, whilst aiming to minimise the effects of prolonged TNFα on other 
cellular functions.  No decrease in viability or induction of apoptosis was seen at this 
concentration and duration. To enable delivery of lipids to cells, the lipids were dissolved 
in methanol.     
5.4.5 Western blot for VCAM/ ICAM expression 
Western blots were performed to measure the expression of ICAM-1 and VCAM-1 by 
endothelial cells, selected as being the most important adhesion molecules in static 
adhesion which is the aspect of adhesion assessed in the functional adhesion assays of this 
chapter.    
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Figure 5-5: Development of RAW to EAhy functional adhesion assay. Activated EAhy 
cells stimulated with 2nM TNFα for 8 hours.  RAW labelled with DiI fluorescent stain.  
A: fluorescent readout of RAW adhesion to activated EAhy is related to concentration up 
to 400 000 cells/well.  Beyond that spatial inhibition occurs, the cells clump and dislodge 
during washing of the plate. There is no adhesion to basal EAhy cells or in the presence 
of EDTA.  B: adhesion is also dependent on EAhy cell density, being increased when 
there is a confluent monolayer.  C: fluorescent microscopy images of adhesion of RAW 
to EAhy with addition of different numbers of RAW cells per well. 
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5.5 Results 
A summary of the demographics of patients recruited to the monocyte adhesion studies 
(flow cytometry and functional adhesion) is shown in Table 5-3.  The number of female 
GD patients recruited was small due to recruitment difficulties. 
Table 5-3: Patients/controls recruited to monocyte adhesion studies 
 Fabry  Gaucher  Control  
 M F M F M F 
No 10 19 15 5 9 12 
Age 46.1 
(20-73) 
45.5  
(19-77) 
47.8  
(18-78) 
36.8  
(22-48) 
34.2  
(27-54) 
44.9 
(26-68) 
ERT 10 (100%) 15 (79%) 15 (100%) 4 (80%) N/A N/A 
Mean 
adhesion 
ratio 
(PHS) 
1.91  
(1.09-2.96) 
2.35 
(1.10-5.77) 
1.69 
(1.04-2.76) 
1.64 
(1.18-2.29) 
1.62 
(0.87-2.84) 
1.43 
(0.75-2.09) 
Mean 
adhesion 
ratio 
(AHS) 
2.06 
(1.13-3.09) 
2.32 
(1.13-5.16) 
 
1.78 
(1.14-3.04) 
1.65 
(1.19-2.20) 
1.56 
(0.71-3.86) 
1.40 
(0.75-2.09) 
 
5.5.1 Monocyte adhesion to tissue culture plastic 
Adhesion in pooled human serum in Fabry patients was significantly greater than in 
controls (mean adhesion ratio 2.23 vs. 1.52, p = 0.0076) and Gaucher patients (mean 
adhesion ratio 2.23 vs. 1.68, p = 0.037) (see Figure 5-6).  There was no difference in 
adhesion between Gaucher patients and controls (mean adhesion ratio 1.68 vs. 1.52, p = 
0.30).  If the patients were separated into males and females, the adhesion ratio in Fabry 
men was slightly higher than in Gaucher or control, but the difference was not significant 
(p = 0.2), see Table 5-3; from means and standard deviations of the data a sample size 
>40 patients would be required for the observed differences to be significant.  In females, 
adhesion was significantly greater in Fabry patients than in controls (mean adhesion 2.35 
vs. 1.44, p = 0.023).  There was no difference between Gaucher patients and controls 
(mean 1.64 vs. 1.44, p = 0.23).  The sample size of female patients with Gaucher was 
small due to only a few patients consenting to blood sampling.  
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There was no visible adhesion on phase contrast microscope or with Geimsa staining in 
the presence of EDTA.  There was no difference in the ratio of adhesion in pooled serum 
to autologous serum between the patient groups, suggesting that the differences observed 
were due to an increased adhesion capacity of the monocytes rather than serum factors. 
The relationship between age and adhesion was analysed in all patient groups (see Figure 
5-7).  A significant correlation between increasing age and adhesion was found in females 
with FD but not in females with GD or female controls.  There was no correlation between 
age and adhesion in males. 
 
Figure 5-6: Adhesion of monocytes to tissue culture plastic. A: Overall adhesion in 
PHS.  B: ratio of adhesion in PHS to adhesion in autologous serum. C: adhesion ratio in 
males. D: adhesion ratio in females.  Lines indicate mean adhesion. 
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Figure 5-7: Relationship between age and adhesion. A: Males Fabry vs. control; B: 
Females – Fabry vs. control; C: Males – Gaucher vs. control; D: Females – Fabry vs. 
control. 
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5.5.2 Adhesion and disease features in Fabry disease 
To assess the relationship between monocyte adhesion and clinical manifestations of FD 
linear regression analyses were performed (see Table 5-4).  As well as disease 
manifestations, relationships between lipoprotein (a) and adhesion were examined as a 
raised Lp(a) was common amongst FD patients with cerebrovascular disease and has been 
demonstrated to increase expression of adhesion molecules230.  All male patients and most 
female patients were receiving ERT at the time of the study; the effect of exogenous 
enzyme on leucocyte adhesion is unknown.  Therefore both baseline and current disease 
parameters were analysed, with the baseline parameters serving as a surrogate for 
untreated disease severity in each of the assessed manifestations.  Within the female FD 
patients, the patient with the highest adhesion ratio was an outlier across all parameters 
except neurovascular disease and exclusion of this patient from analyses had a big impact 
on the significance of the results obtained.  It is uncertain why the adhesion ratio was so 
high is this patient and the ratio in this patient was >1 greater than the next highest result 
and almost three times the mean ratio.  It was therefore considered that it might be 
appropriate to exclude this patient from the analyses and the results with this exclusion 
are also shown in Table 5-4.  Exclusion of this one outlier resulted in increased strength 
and significance of correlation between adhesion and disease parameters in females. 
There was a significant relationship between age and severity in females but not in males 
based both on current severity score but also on baseline severity (see Figure 5-8).  As 
age is a key modifier of severity, age-adjusted severity scores were also assessed; the 
significant relationship was also found for age adjusted scores in females, but only after 
exclusion of the outlier and with a smaller r2 and p value.  
Table 5-4: Relationship between adhesion ratio and clinical FD parameters 
Parameter Time point Male/female Slope R2 P value 
FOS-MSSI Baseline Male 0.002 0.001 0.923 
Female  0.060 0.307 0.017 
F (excl outl.) 0.058 0.495 0.002 
Current Male -0.006 0.014 0.759 
Female 0.054 0.261 0.030 
F (excl. outl) 0.060 0.562 0.0005 
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Age-adjusted 
MSSI 
Baseline Male -0.056 0.330 0.083 
Female  0.064 0.150 0.112 
F (excl outl.) 0.073 0.339 0.014 
Current Male -0.015 0.143 0.316 
Female 0.051 0.103 0.194 
F (excl. outl) 0.073 0.358 0.011 
GFR Baseline Male -0.051 0.356 0.090 
Female  -0.059 0.220 0.050 
F (excl outl.) -0.050 0.375 0.009 
Current Male -0.006 0.061 0.522 
Female -0.021 0.171 0.089 
F (excl. outl) -0.024 0.358 0.011 
LVMI Baseline Male 0.005 0.088 0.439 
Female  0.070 0.320 0.018 
F (excl outl.) 0.061 0.419 0.007 
Lipoprotein (a) Current Male 0.507 0.156 0.259 
Female  1.464 0.306 0.017 
F (excl outl.) 1.079 0.269 0.033 
 
In both males and females there was a negative relationship between adhesion and 
glomerular filtration rate, with adhesion increasing with a decline in renal function.  The 
relationship, however, was only significant in females (see Figure 5-9).  The correlation 
between GFR and adhesion was stronger for baseline GFR results for both males and 
females.  Left ventricular mass index is also correlated with adhesion in females but not 
males.   
Cerebrovascular manifestations, stroke and the presence of white matter lesions, were also 
examined.  There was no difference in the adhesion ratios between patients with or without 
stroke or with or without white matter lesions either at baseline or currently (see Figure 
5-9). Serum Lp(a) was correlated with adhesion, in part due to the outlier, as significance 
was borderline if they were excluded (p = 0.033).  Three out of four patients with 
lipoprotein levels >1.0 were members of the same family. 
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Figure 5-8: Relationship between disease severity and adhesion. A: baseline FOS-
MSSI. B: baseline age-adjusted MSSI. C: current FOS-MSSI. D: Latest age-adjusted 
MSSI. Female outlier identified by black outline. 
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Figure 5-9: Relationship between age and organ function in FD. A: baseline GFR; B: 
current GFR; C: baseline LVMI; D: stroke/TIA; E: baseline WML; F: serum lipoprotein 
(a).  Female outlier identified by black outline. 
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Figure 5-10: Relationship between adhesion and GD complications.  A: presence of 
bone infarcts on MRI; B: bone marrow burden scores; C: presence of a gammopathy; D: 
presence of at least on N370S mutation; E: bleeding score; F: raised D-dimer. A, C, D,F: 
line = median; error bars = interquartile range. 
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5.5.3 Adhesion and disease features in Gaucher disease 
There was no difference in adhesion between patients with or without bone infarcts on 
latest MRI (median 1.693 vs. 1.455, p= 0.67) and no correlation between adhesion and 
total bone marrow burden scores on MRI (slope = 0.004, r2 = 0.002, p = 0.84). Adhesion 
was increased in those with a gammopathy but this difference was not significant (median 
1.79 vs. 1.40, p = 0.15, see Figure 5-10). There was no correlation between bleeding score 
and adhesion (slope = -0.022, r2 = 0.017, p = 0.58) nor was adhesion higher in those with 
a persistently raised D-dimer (median 1.37 vs. 1.76, p = 0.13).  The presence of at least 
one N370S mutation did not affect the adhesion ratio (median 1.455 vs. 1.693, p = 0.395). 
5.5.4 Expression of adhesion markers 
The MFI and standard deviations for adhesion molecules on the mononuclear cell subsets 
are shown in Table 5-5 and the significant findings are summarised in Table 5-6. 
Table 5-5: MFI of adhesion molecules on leukocytes (mean ±SD) 
CD CD14+ monocytes CD14- monocytes Lymphocytes 
 GD FD C GD FD C GD FD C 
CD11a 428 
±128 
441 
±117 
352 
±68 
576 
±162 
567 
±131 
381 
±129 
246 
±66 
226 
±54 
139 
±48 
CD11b 1638 
±579 
2019 
±542 
1697 
±784 
X x x x x X 
CD11c 159 
±70 
206 
±94 
175 
±71 
252 
±92 
298 
±102 
226 
±70 
x x X 
CD49D 404 
±127 
413 
±110 
424 
±100 
1033 
±181 
916 
±158 
1009 
±110 
283 
±77 
224 
±46 
202 
±49 
CD54 160 
±48 
185 
±41 
148 
±33 
196 
±50 
237 
±46 
197 
±42 
x x X 
CD102 710 
±155 
594 
±138 
768 
±209 
928 
±134 
865 
±102 
913 
±160 
354 
±107 
309 
±58 
304 
±56 
CD50 672 
±133 
654 
±132 
560 
±153 
450 
±76 
421 
±86 
364 
±76 
289 
±57 
257 
±45 
217 
±59 
CD36 2213 
±824 
2111 
±524 
2127 
±702 
341 
±419 
205 
±95 
318 
±296 
x x X 
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Figure 5-11: Median fluorescent intensity of the alpha subunits of the alpha-beta1 
integrins.  A: CD11a; B: CD11b; C: CD11c.  Lines indicate the mean; error bars, standard 
error of the mean. 
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Figure 5-12: A: Expression of CD49d, alpha subunit of VLA-4; B: expression of 
CD54 (ICAM-1); C: expression of scavenger receptor B (CD36). 
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Figure 5-13: Expression of CD102 (ICAM-2) and CD50 (ICAM-3) on mononuclear 
cell subsets. 
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Figure 5-14: CD62L expression. A: expression on CD14+ monocytes. B: expression on 
overall lymphocyte population. C: percentage of lymphocytes with high CD62L 
expression. D: MFI of CD62L on lymphocytes with high expression. 
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Integrins 
Expression of CD11a (the alpha subunit of LFA-1) was increased in FD and GD compared 
to controls across all leukocyte subsets, with the most significant differences seen in 
CD14- monocytes and lymphocytes (p<0.0001) rather than monocytes (p 0.004 for FD v 
C and p = 0.019 for GD vs. C), see Figure 5-11. There was no difference in the expression 
of CD11b.  There was an increase in expression of CD11c on CD14- monocytes in FD 
compared to controls (p = 0.013).  CD49d is significantly increased on lymphocytes in 
GD patients compared to both controls (p = 0.0002) and FD (p = 0.0049).  There is a slight 
reduction in expression of borderline significance in FD CD14- monocytes (p = 0.03). 
Immunoglobulin superfamily 
CD54 (ICAM1) expression is increased on FD CD14+ and CD14- monocytes relative to 
controls (p = 0.003 and 0.006), see Figure 5-12.  CD102 (ICAM2) expression was reduced 
in FD compared to GD or controls in CD14+ monocytes (p = 0.018 and 0.0034 
respectively), but not in CD14- monocytes, which overall had a higher MFI, or 
lymphocytes, see Figure 5-13. CD50 (ICAM3) expression was significantly increased in 
GD compared to controls on lymphocytes and CD14- monocytes (p = 0.0003 and p = 
0.0009 respectively), and also CD14+ monocytes (p = 0.017).  There was a slight increase 
in FD compared to controls across all subsets, most marked in lymphocytes (p = 0.019).   
L selectin 
CD62L is expressed at low levels on CD14+ monocytes and was decreased in FD 
compared to both GD (p = 0.0009) and controls (p= 0.009), see Figure 5-14.  Expression 
on CD14- monocytes was low and there were no differences between the conditions.  The 
percentage of strongly positive CD62L lymphocytes was slightly reduced in Gaucher 
disease, although the MFI of CD62L on these lymphocytes was increased in GD compared 
to FD (p = 0.0069). 
Scavenger receptor 
There was no difference in expression of CD36 on CD14+ or CD14- monocytes. 
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Table 5-6: Summary of changes in adhesion molecule expression (relative to 
controls) 
Adhesion molecule GD   FD   
 M+ M- L M+ M- L 
CD11a (LFA-1) ↑ ↑ ↑ ↑ ↑ ↑ 
CD11b (CR3) -   -   
CD11c (CR4) - -  - ↑  
CD49D (VLA-4) - - ↑ - ↓ - 
CD54 (ICAM1) - -  ↑ ↑  
CD102 (ICAM2) - - - ↓ - - 
CD50 (ICAM3) ↑ ↑ ↑ ↑ ↑ ↑ 
CD36 (SRB) -   -   
CD62L  - - ↑ ↓ - - 
 
Linear regression analysis of monocyte MFI for CD11a, CD54 and CD50 (the adhesion 
molecules where significant differences in expression on monocytes were found) did not 
show any correlation between MFI of the molecules and the adhesion ratio.  
Adhesion molecule expression and clinical disease manifestations 
Increased expression of CD50, 54 or 49d was not associated with GD complications of 
bone disease or gammopathies.  In FD CD11a and CD54 and CD50 MFI was not 
correlated with age-adjusted disease severity, renal function or left ventricular mass. 
5.5.5 Endothelial cell model 
Confocal microscopy confirmed uptake for DiI labelled acetylated LDL and synthesis of 
von Willebrand factor (see Figure 5-15); however, VWF did not form discrete Weibel 
Palade bodies as occurs in HUVEC cells.  EAhy.926 showed inducible expression of 
ICAM-1 and VCAM-1 in response to stimulation with TNFα with a dose and time 
dependent increase in adhesion of RAW cells to EAhy.926 (see Figure 5-16). 
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Figure 5-15: Endothelial characteristics of EAhy cells. A: Uptake of DiI-labelled 
acetylated LDL (x40); B: von Willebrand factor production (x40), but without forming 
classical Weibel Palade bodies; C & D: cobblestone morphology (x10 and x40). 
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Figure 5-16: Effect of TNFα on expression of adhesion molecules of EAhy.926 
monolayers. A: adhesion of DiI-labelled RAW to EA.hy926 monolayers activated with 
different doses of TNFα for different time periods.  B: toxicity of TNFα measured by MTT 
assay and by PARP cleavage on Western blot.  C: increase in ICAM-1 protein levels on 
activation of EA.hy with TNFα. D: increase in VCAM-1 protein levels on activation of 
EA.hy with TNFα. 
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Figure 5-17: Toxicity of inhibitors on EA.hy 926 cells assessed by MTT dye reduction 
assay. 
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Figure 5-18: Effect of pharmacological inhibitors on GBA and GLA activity after 
incubation of the cells with inhibitors for 7 days.  A range of concentrations were 
utilised to establish if there was a concentration dependent effect.  A: DGJ; B: CBE; C: 
chloroquine; D: amiodarone.  E: effect of inhibitors on GLA protein level after incubation 
for 7 days.  F: effect of inhibitors on alpha galactosidase B enzyme activity. 
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Development of pharmacological model 
MTT assay, showed a slight reduction in metabolic activity at higher (10μM) 
concentrations of chloroquine and amiodarone, implying reduced cell viability, but no 
reductions with DGJ or CBE (see Figure 5-17).  GBA activity was minimal after addition 
of CBE, with almost undetectable enzyme activity at 100 and 200μM. The other inhibitors 
had little effect on GBA activity.   
CBE had no effect on GLA activity.  Both amiodarone and chloroquine resulted a 
concentration dependent decrease in GLA activity, maximal with 6μM chloroquine with 
57% control activity and with 10μM amiodarone at 64% control activity.  Incubation with 
DGJ showed a slight increase in activity with 50μM DGJ and mild reduction in activity at 
higher concentrations, maximal with 200μM DGJ at 71% control activity (see Figure 
5-18).  Western blot for GLA protein levels showed an increase in GLA in cells treated 
with DGJ compared to other inhibitors.  Measurement of α galactosidase B activity 
showed a mild reduction in cells treated with DGJ and chloroquine but not amiodarone or 
CBE.  
For endothelial assays the doses of pharmacological inhibitors used were: chloroquine 
5μM, amiodarone 7.5μM, CBE 100μM and DGJ 200μM 
shRNA mediated knockdown of alpha galactosidase A 
Measurement of GLA enzyme activity showed a reduction in enzyme activity to 87.9% 
of control activity with the FD1 shRNA sequence, 26.4% with FD2 and 30.8% with FD5.  
Western blot confirmed marked reduction in GLA protein levels with FD2 and FD5 but 
not FD1.  FD1 was therefore not used for further experiments.  Interestingly treatment of 
FD2 and FD5 cells with DGJ 200μM resulted in partial restoration of enzyme activity and 
protein levels (see Figure 5-19).  The shRNA sequences had no effect on alpha 
galactosidase B activity, which shares >50% sequence homology with the GLA gene250. 
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Figure 5-19: Effect of shRNA knockdown. 
A: GLA activity expressed as percentage of the scrambled sequence enzyme activity; B: 
GLA protein levels in cell lysates; C: effect of shRNA knockdown of GLA on alpha 
galactosidase B activity; D: effect of treatment of cells with 200μM DGJ for 7 days on 
GLA protein levels (D,F) and enzyme activity (E). 
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5.5.6 Effect of altered glycosphingolipid metabolism on endothelial adhesion 
Reduction in GLA activity as the result of shRNA mediated gene silencing did not result 
in increased adhesion of RAW cells to the endothelial cell monolayer (see Figure 5-20).  
Cells treated with pharmacological inhibitors showed no difference in adhesion to 
untreated cells, except a slight reduction in adhesion to cells treated with CBE after 4hr of 
TNFα stimulation but not basally or after 8 hours. 
Western blots were performed to measure the protein levels of VCAM-1 and ICAM-1 in 
the shRNA cells to see if reduced GLA altered expression of these molecules.  EAhy cells 
do not express VCAM-1 basally; the increased expression of VCAM-1 in response to 
TNFα stimulation did not differ between cells with normal GLA activity (Scr) and those 
with reduced activity (FD2 & FD5), see Figure 5-20.  Basal expression of ICAM-1 was 
the same in all three cell types and there was no difference in responses to TNFα 
stimulation.  Minimal adhesion occurred in all cell types in the presence of the calcium 
chelator EDTA, confirming that adhesion is calcium dependent which is in keeping with 
integrins and members of the immunoglobulin superfamily being the principle mediators. 
5.5.7 Effect of glycosphingolipid addition on endothelial adhesion 
Wild-type EAhy cells were incubated with different glycosphingolipids at 10μM 
concentration and the effect of glycosphingolipid loading on adhesion evaluated.  There 
was no difference in functional adhesion activity following TNFα stimulation.  There was 
a minimal increase in basal adhesion with lactosylceramide, sphingosine-1-phosphate and 
lysoGb3.  Western blot for ICAM and VCAM did not reveal any differences in expression 
of these adhesion molecules with brief (8hr) or prolonged (72hr) incubation with 
glycosphingolipids or following TNFα activation of lipid loaded cells (see Figure 5-21). 
Adhesion of lipid-loaded RAW to endothelial monolayers 
Glycosphingolipid excess has been suggested as the mechanism for increased leukocyte 
adhesion.  RAW cells were incubated with glycosphingolipids at 10μM concentration or 
methanol vehicle control for 72 hours and their adhesion to EAhy cells, both normal EAhy 
and those treated with CBE/shRNA, assayed.  Amongst the lipids associated with GD 
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(S1P, GSP and LacC), there was an increase in adhesion RAW cells incubated with GSP 
compared to methanol vehicle to both normal EAhy and those treated with CBE following 
stimulation with TNFα.  LacC resulted in an increase in adhesion only to normal EAhy 
treated with TNFα.  Incubating RAW with lipids associated with FD (Gb3, S1P and 
lysoGb3) did not alter their adhesion properties compared to methanol vehicle, see Figure 
5-22. 
 
Figure 5-20: Effect of enzyme inhibition on endothelial adhesion. A: no increase in 
adhesion of RAW cells to monolayer in FD2 and FD5 compared to Scr (control). B: no 
differences in adhesion of RAW to cells treated with pharmacological inhibitors for 7 days.  
No difference in increase in expression of VCAM-1 (C) or ICAM (D) in response to TNFα 
stimulation in FD2 or FD5 compared to Scr.  
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Figure 5-21: Effect of glycosphingolipids on adhesion 
Effect of incubating EAhy cells with glycosphingolipids (10μM) for 72 hours on adhesion 
basally and following TNFα activation (2nM, 8 hours).  A: adhesion ratio to vehicle 
(methanol) treated EAhy basally and following TNFα activation. B: Western blot for 
ICAM-1 and VCAM-1 expression following 72 hour lipid incubation +/- TNFα activation 
or 8hr lipid incubation. 
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Figure 5-22: Effect of lipid-loading RAW on their adhesion to EAhy cells with 
reduced enzyme activity. 
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5.6 Discussion 
5.6.1 Leukocyte adhesion in FD 
Female patients with FD showed an age-dependent increase in monocyte adhesion not 
seen in males or in controls.  Adhesion in females, but not males, correlated with disease 
severity, left ventricular mass and Lp(a) concentration.  One significant outlier influenced 
the results – the reason for increased adhesion in this patient is uncertain.  Exclusion of 
this patient resulted in significant correlations also with GFR.  Unlike cardiac and renal 
disease, there was no relationship between adhesion and cerebrovascular disease.  As 
discussed in Chapter 4, ageing appears to be a much more important factor in the 
development of disease complications in females than males and these results suggest that 
an age-related increase in monocyte adhesion may contribute to some of these disease 
manifestations.  The processes that would underlie an age-dependent increase in adhesion, 
not seen in controls or male FD patients are uncertain.  In many males the onset of disease 
manifestations is considerably earlier than in females and therefore it might be that as 
similar age-dependent effect might be seen in males in childhood-adolescence.  
Dysfunction in lysosomal trafficking pathways has been reported with ageing, affecting 
both autophagy251 and endocytosis252.  ICAM1 and potentially other adhesion receptors 
are recycled through the endocytic pathway253.  One hypothesis would be that females 
with FD are more susceptible to age-related changes in the cellular trafficking pathways 
that are involved in the recycling of these adhesion molecules, leading to increased 
concentration of activated molecules on the cell surface  
Increase serum levels of adhesion molecules are associated with renal failure254 and 
therefore the negative relationship between GFR and monocyte adhesion seen in both 
males and females was expected, although it was only significant in females.  
The increase in ICAM1 expression on monocytes in FD suggests that the increased serum 
ICAM1 found in previous studies152 originates, at least in part, from leukocytes.  CD11a, 
the α-subunit of LFA-1, which is a ligand for both ICAM1 and ICAM3, which may 
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augment the interaction between LFA-1 and ICAM-1 was also increased, although to a 
lesser degree.  As well as playing a role in leukocyte adhesion, interactions between LFA-
1 and ICAM1 have other important roles including mediating B255 and T cell activation256.  
LFA-1 on mononuclear cells has also been shown to accelerate TGF-β induced renal 
epithelial-mesenchymal transition in renal cells257, a pathological process implicated in 
renal disease in FD62. 
5.6.2 Leukocyte adhesion in GD 
No differences were seen in monocyte adhesion in GD and only a slight increase in two 
adhesion molecules (CD11a and CD50) was seen on CD14+ monocytes in GD and CD49d 
(the α-subunit of VLA-4) and CD62L on lymphocytes.  Whilst GD has traditionally been 
considered a macrophage-centric disorder, recent studies of the bone marrow 
microenvironment258 as well as animal studies60 suggest that abnormalities also occur in 
other cell lineages.  The role of ICAM3 is less well defined than that of ICAM1 and it 
may be more important in signalling between leukocytes in inflammation than in cellular 
adhesion.  It is important in the activation of both lymphocytes259 and polymorphonuclear 
cells (e.g. granulocytes)260 but has also been implicated in macrophage phagocytosis of 
leukocytes261. VLA-4 is important in the homing of lymphocytes to lymph nodes and bone 
marrow.  It is also implicated in the pathogenesis of myeloma262 particularly of bone 
disease by promoting osteoclast activity263.  The pathogenesis of bone disease in GD and 
the mechanisms underlying the increased risk of myeloma are poorly understood.  The 
altered pattern of lymphocyte adhesion molecule expression seen in this study may 
contribute to these disease processes, although no differences were seen in expression of 
these molecules in GD patients with and without gammopathies or bone disease in this 
study. 
5.6.3 Endothelial adhesion 
Reductions in GBA or GLA activity did not alter adhesion capacity or the expression of 
ICAM1 or VCAM1; the increased ICAM1 seen on leukocytes was not seen in the 
endothelium.  Studies on endothelial cells in FD have suggested Gb3 loading of the 
endothelium, rather than GLA deficiency up-regulates ICAM1 and VCAM164;151.  We did 
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not replicate this finding which could be for a number of reasons.  These studies found 
increased mRNA levels, but in the study where protein levels were also measured by 
Western blot64 no difference was found.  Mode of delivery of lipids may also make a 
difference.  In vivo glycoproteins predominately circulate complexed to lipoproteins232 
and some studies have delivered lipids by complexing them to albumin, rather than 
dissolving them in methanol.  Lactosylceramide has been found to increase ICAM1 
expression on endothelial cells10, but we did not replicate this finding.   
Glucosylsphingosine increased RAW adhesion to activated endothelial cells and warrants 
further investigation.  
5.6.4 Experimental limitations 
Endothelial cell model 
Endothelial cells cover a vast surface area, lining all the blood vessels and lymphatics of 
the body, developing different characteristics depending on the vascular bed and the 
stimuli they received.  In addition to this heterogeneity, laboratory study of endothelial 
cells is challenging due to their tendency to de-differentiate and change phenotype in 
culture, even at a low passage numbers.  The use of a HUVEC-carcinoma hybridoma 
provided a more stable phenotype184, but the cells do lack some characteristics of HUVEC. 
Whilst they do express VWF, they do not form characteristic Weibel-Palade bodies; they 
do up-regulate ICAM1 and VCAM1in response to TNFα, the key adhesion phenotype 
being investigated in this study.  Additionally HUVEC are macrovascular, being sourced 
from the umbilical vein, whereas many of the disease manifestations of GD and FD occur 
in the microcirculation.  Sources of microvascular cells are limited, most commonly 
sourced from the dermis, and have similar phenotypic instability to other endothelial cells. 
A further limitation of the disease model was the effects of enzyme inhibition.  Whilst 
CBE almost completely inhibited GBA, it was not possible to achieve a similar level of 
inhibition for GLA either pharmacologically or using shRNA.  Additionally, these 
methods do not re-capitulate the disease state fully in vitro as there is no mutant enzyme 
present.  The GBA and GLA activity in endothelial cells of patients with GD/FD is not 
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known and therefore it is uncertain whether sufficient inhibition was achieved.  
Measurement of intracellular glycosphingolipids (e.g. Gb3) to see if accumulation occurs 
may be helpful.   The most promising strategy to overcome all these limitations would be 
the culture of primary endothelial cells from GD/FD patients and the relatively new 
techniques of culture of blood outgrowth endothelial cells and induced pluripotent stem 
cells may facilitate this.  
Leucocyte-endothelial adhesion 
Cellular adhesion is a complicated process with multiple modifiers including circulating 
cytokines and other molecules, blood cells (erythrocytes and platelets as well as 
leukocytes) and vascular tone.  The functional assays in this chapter look at mononuclear 
cells and endothelial cells in isolation, under conditions that may bear little resemblance 
to the in vitro process.  Only the functional adhesion of monocytes was examined although 
flow cytometry suggested more marked abnormalities within the lymphocytes. Static 
adhesion assays are commonly used in laboratory settings but the circulation is never static 
and flow rate is an important modifier of adhesion.  
Unavoidably, all GD patients and almost all FD patients had been commenced on ERT 
prior to entry into the study.  Samples were not collected whilst enzyme was being infused 
and the extent to which ERT might have affected the assay results is uncertain.  In GD, 
where treatment has been shown to be particularly efficacious for the visceral and 
haematological manifestations of the disease, this may have masked potential correlations 
with bleeding manifestations.  The effect of ERT on bone disease is less well established 
nor is it known if ERT reduces the risk of myeloma.  Recombinant GBA is targeted to 
cells via the mannose receptor which is expressed on cells of the monocyte-macrophage 
lineage but not lymphocytes which may explain in part why abnormalities in adhesion 
molecule expression in GD were most marked in lymphocytes.  The efficacy of ERT in 
FD remains to be established; patients continue to develop new disease complications (e.g. 
stroke) despite receiving ERT. 
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5.7 Conclusion 
Investigation of leukocyte adhesion revealed an age-dependent increase in monocyte 
adhesion in females with FD, with correlations with renal and cardiac but not 
cerebrovascular disease, but the main abnormalities found were in the expression of 
adhesion molecules on lymphocytes in both GD and FD. In both disorders, increased 
levels of the α-subunit of LFA-1 and ICAM3 were found with additional increases in 
ICAM1 in FD and the α-subunit of VLA-4 in GD.  These abnormalities may be implicated 
in organ involvement seen in these disorders, particularly bone disease in GD and renal 
abnormalities in FD.  Further investigation of lymphocytes within GD and FD, both to 
examine the mechanisms for the increased antigen expression (e.g. cytokine or lipid 
abnormalities) and to understand the functional impact of these abnormalities may shed 
new lights on to these disease processes.  No abnormality in endothelial function was 
found in these experiments, but there were marked limitations of the endothelial cell 
model and further exploration using either microvascular cells or primary endothelial cells 
from FD patients may be more fruitful. 
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Chapter 6 Cellular support of coagulation in Fabry and Gaucher 
6.1 Introduction 
Coagulation encompasses the pathways involved in blood clot formation and dissolution 
and their regulation.  Under normal physiological circumstances, these pathways are 
tightly regulated so that clot formation is rapid but localised to sites of vessel injury and 
that, once the vessel wall defect is repaired, clot dissolution occurs and normal vessel 
patency returns.  Abnormalities in any of these haemostatic pathways (procoagulant, 
anticoagulant or fibrinolytic) can result either in unintended bleeding or inappropriate 
thrombus formation.   
As demonstrated in Chapter 3, bleeding is a common symptom in the presentation of GD 
and is predominately mucocutaneous in nature.  Whilst bleeding maybe contributed to by 
thrombocytopenia, bleeding manifestations are often out of proportion to the reduction in 
platelet count.  Decreased platelet aggregation in response to low dose agonists has been 
reported in a number of studies172-174 but the mechanisms underlying this remain unknown.  
Coagulation factors have also been shown to be decreased (see Table 1-11), with variable 
decreases in coagulation factors found in different studies, and with abnormalities in 
anticoagulant pathways and fibrinolysis also being reported.  These findings point to a 
more global dysfunction across the coagulation pathways and it has been hypothesised 
that chronic activation of coagulation is responsible for this119.    
Conversely, some of the end organ complications of FD have been attributed to 
inappropriate microthrombus formation.  Whilst this is most obvious within the 
cerebrovascular system, microvascular disease akin to that seen in metabolic disorders 
such as diabetes and also sickle cell disease, might contribute to development of 
proteinuria and cardiac conduction defects.  These disease manifestations may be present 
at diagnosis but may also develop following institution of enzyme replacement therapy, 
particularly as patients age.  Investigations of a haemostatic defect within FD to date have 
predominately focused on the protein C anticoagulant pathway, but increased soluble 
tissue factor has been found in some studies (see Table 1-10). 
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6.1.1 Purpose of this chapter 
This chapter explores the role of cellular components of the blood (monocytes and 
platelets) and the endothelium in supporting generation of thrombin – the final effector 
enzyme of the coagulation cascade. As well as converting fibrinogen to fibrin, thrombin 
activates platelets and also activates the protein C anticoagulant pathway and stimulates 
release of pro-angiogenic cytokines264. 
Monocyte tissue factor expression and procoagulant activity 
Tissue factor (TF) is an important activator of thrombin formation.  Intravascular tissue 
factor is mostly expressed on myeloid cells, particularly monocytes265.  Much of the tissue 
factor expressed on the cell surface is thought to be encrypted – in an inactive form266, 
with activation (e.g. rise in cytosolic calcium) required for full activation267.  In this 
chapter the ability of monocytes to initiate coagulation is investigated by measuring 
expression of tissue factor on the cell surface and by a procoagulant activity assay to assess 
the ability of monocytes to initiate plasma coagulation.   
The platelet membrane in haemostasis 
Following vessel wall injury, macromolecules such as collagen become exposed on the 
sub-endothelial membrane allowing circulating platelets to adhere.  Following adhesion, 
platelets become activated and clump together (or aggregate) at the site of injury to form 
the primary platelet plug.  Platelet activation also results in exposure of anionic 
phospholipids, predominately phosphatidylserine, in the outer membrane of the platelet, 
on which the enzyme complexes of the coagulation cascade form.  Thrombin produced by 
the coagulation cascade acts as an additional platelet activator.  In quiescent platelets, 
phosopholipids are asymmetrically distributed over both leaflets of the plasma membrane, 
with PS almost exclusively located in the cytoplasmic leaflet.  On platelet activation, when 
intracellular calcium increases, a scramblase, which facilitates movement of 
phospholipids between the membrane leaflets is activated.  Concomitant inhibition of an 
aminophospholipid translocase prevents movement of surface PS back to the inner leaflet, 
resulting in accumulation of PS in the outer leaflet.  This process is called the platelet 
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procoagulant response, although the exact pathways leading to its activation are not fully 
understood. 
This fluidity of the phospholipid membrane depends on its lipid composition, including 
cholesterol content (cholesterol reduces movement), fatty acid composition and saturation 
of phospholipid.  Whether altered glycosphingolipid composition alters this membrane 
fluidity and activation of the platelet procoagulant response not known.  This chapter 
examines the ability of platelet to support thrombin generation in the presence of patient 
plasma, using platelet rich plasma and the platelet membrane procoagulant response using 
a prothrombinase assay in which phospholipid procoagulant activity is the rate-limiting 
factor for thrombin generation.   
The endothelial cell membrane in coagulation 
As well as its role in cellular adhesion, the endothelial cell membrane plays an important 
role in haemostasis, having both anticoagulant and procoagulant properties.  Quiescent 
endothelial cells provide an anticoagulant surface with additional procoagulant properties 
acquired on activation of the endothelium (e.g. by TNFα).  Activation of the anticoagulant 
protein C pathway takes place on the endothelial cell membrane, where the endothelial 
protein C receptor (EPCR) is the key receptor regulating the activity of activated protein 
C.  The APC pathway has been implicated in disease processes beyond thrombosis 
including inflammation268 and ischaemic stroke269.  Physiological activation of protein C 
by thrombin occurs on the surface of endothelial cells, involving two EC membrane 
receptors: EPCR and thrombomodulin270.  Thrombin binds to thrombomodulin which 
promotes activation of PC by thrombin.  Localisation of protein C to the EC surface by 
the EPCR enhances this reaction271.  APC inactivates FVa and FVIIIa effectively 
terminating thrombin generation.  Abnormalities of the APC pathway have been reported 
in both GD119 and FD152.  This chapter investigates whether endothelial dysfunction as a 
result of enzyme deficiency and/or lipid loading results in abnormal thrombin generation 
on the endothelial surface.  
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6.2 Hypotheses 
1. Monocytes from FD and GD have increased tissue factor expression and are 
procoagulant. Rationale: tissue factor expression is induced by pro-inflammatory 
cytokines.  FD is associated with a procoagulant state and laboratory studies in GD suggest 
that chronic activation of coagulation occurs. 
2. The platelet membrane in FD and GD has altered procoagulant capacity. 
Rationale: glycosphingolipid accumulation within lipid rafts in the platelet membrane 
may also membrane dynamics required for assembly of coagulation enzyme complexes 
(e.g. the prothrombinase complex). 
3. The endothelium in FD is procoagulant and supports increased thrombin 
generation. Rationale: microvascular lesions occur in FD and have been hypothesised to 
be due to impaired regulation of the procoagulant pathway. 
6.3 Methods and assay development 
6.3.1 Monocyte tissue factor procoagulant activity 
Monocytes express tissue factor on the cell surface, which is present at low levels in un-
stimulated cells.  This tissue factor can be used to initiate coagulation of citrated plasma 
following re-calcification.  A coagulation assay, sensitive to very low levels of tissue 
factor was developed whereby tissue factor is the rate-limiting factor and the source of the 
tissue factor is added cells; the methodology is detailed in 2.11.1.  This assay assesses the 
ability of cells to support thrombin generation via TF/FVIIa initiated coagulation.  The 
assay uses a KC4 coagulometer with a mechanical end point.  The reaction occurs in a 
cuvette containing a metal ball-bearing.  When the reaction mixture is fluid, a magnet 
holds the ball-bearing on its base point whilst the cuvette rotates.  As a fibrin clot forms, 
the fibrin stops the ball-bearing moving and it is moved away from the magnet as the 
cuvette rotates; this loss of contact stops the clock and gives the coagulation time. 
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Assay development and validity 
A standard curve was constructed using serial dilutions of a thromboplastin 
(Recombiplastin, Diapharma) to initiate coagulation.  Serial dilutions, down to a dilution 
of 1 in 64000 of Recombiplastin were made, using Tris-HCl-1%BSA buffer as the diluents, 
demonstrating the sensitivity of the assay to small amounts of tissue factor (see Figure 
6-1).  A standard curve was constructed with a 1 in 1000 dilution of Recombiplastin being 
allocated an arbitrary value of 100 units of tissue factor.  
Increasing concentrations of monocytes resulted in a decrease in the coagulation time, 
consistent with an increased amount of a procoagulant factor being present on the cells.  
Serial dilutions of RAW 274.1 did not initiate coagulation; whilst murine monocytes 
express tissue factor, murine tissue factor is unable to activate human FVII.  This 
demonstrates that it is a specific factor present on human monocytes which activates 
coagulation rather than just the presence of a large number of cells.  From the monocyte 
dilutions, a concentration of 1x105 per cuvette of monocytes was chosen for the assay, 
being on the slope of the curve.   
Surface expression of tissue factor was measured using flow cytometry, with the same 
gating strategy as described in 5.4.2.  This confirmed that tissue factor was only expressed 
on CD14+ monocytes and the mean fluorescent intensity of the bound tissue factor 
antibody was measured. 
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Figure 6-1: Development of tissue factor procoagulant activity. A: Effect of 
concentration of recombiplastin on coagulation time; 100% represents a 1:100 dilution of 
recombiplastin; B: Effect of monocyte concentration on coagulation time. C:Effect of use 
of EDTA for blood collection on coagulation time. D: Effect of RAW 264.7 cells on 
coagulation time. 
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Figure 6-2: The prothrombinase assay. A: the prothrombinase complex which forms on 
the surface of activated platelets, converting prothrombin to thrombin.  B & C: when FXa, 
FVa, calcium and prothrombin are added in excess, the rate of thrombin generation is 
dependent on the amount of phospholipid reagent added. 
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6.3.2 Platelet assays 
Patients who were known to be taking anti-platelet agents (e.g. aspirin, ibuprofen) were 
excluded from these assays.  Citrated whole blood was collected and centrifuged to yield 
platelet rich plasma (PRP).  As well as measuring the platelet count for the assays, the 
platelet size parameters were recorded: mean platelet volume (MPV), platelet distribution 
width (PDW) and platelet large cell ratio, see Figure 6-5.   
6.3.3 Platelet rich plasma thrombin generation 
Thrombin generation assays, using a calibrated automated thrombogram were performed 
using standard methodology as described in 2.11.2.  Thrombin generation is considered a 
global haemostatic assay which is affected by both the procoagulant and anticoagulant 
potential of a sample by measuring real time thrombin generation272.  The area under the 
curve gives the total amount of thrombin generated (endogenous thrombin potential) and 
the peak thrombin, the maximum thrombin at any time, are recorded.  Two time 
parameters are also measured: the lag time – the time period before measurable thrombin 
is generated and the time to reach peak thrombin generation.   
Utilising PRP, the platelets provide the phospholipid surface required for thrombin 
generation whilst the plasma contains the necessary coagulation factors with the reaction 
being initiated by the addition of 1pM tissue factor and calcium ions. PRP thrombin 
generation is reduced in patients with platelet function defects and has been found to be 
increased in over half of patients following a stroke273. In this study PRP thrombin 
generation was performed to see if there was a qualitative difference in the ability of 
platelet to support thrombin generation.  Therefore the platelet count was adjusted to be 
identical in all samples using platelet poor plasma.  Platelet counts of 150x109/ml and 
100x109/L were selected to see if thrombin generation was impaired at lower platelet 
counts as encountered in GD.  
6.3.4 Prothrombinase activity 
The prothrombinase assay is designed to assay the procoagulant activity of the platelet 
membrane. The prothrombinase complex consists of the serine protease FXa and its 
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cofactor FVa and calcium ions assembled on the phospholipid membrane of platelets and 
converts prothrombin to thrombin (see Figure 6-2).  When FXa, FVa, calcium and 
prothrombin are added in excess, phospholipid becomes the rate-limiting factor.  This was 
confirmed using a phospholipid reagent, Bell and Alton platelet substitute at a range of 
concentrations and the full method is described in 2.11.4. 
To remove plasma coagulation factors, platelets from PRP were washed, using an 
acidified buffer to prevent platelet activation274, and then re-suspended in Tris-HCl-0.1% 
BSA buffer at concentrations of 100x109/L and 50x109/L, selected to ensure that the 
platelet phospholipid membrane was the rate-limiting factor of the reaction (confirmed in 
Figure 6-7). 
6.3.5 Endothelial thrombin generation 
The EAhy endothelial model described in Chapter 5 was used to investigate thrombin 
generation on the endothelial surface.  This cell line has previously been used to study 
endothelial-dependent thrombin generation using the calibrated automated 
thrombogram275.  Under basal conditions EAhy cells express thrombomodulin and EPCR 
and activate protein C276; they also express low levels of tissue factor following TNFα 
stimulation277.  Increased levels of tissue factor serve to increase the rate of thrombin 
generation (increasing the amount of thrombin generated and speeding up the time course 
over which this occurs) whilst increased activation of APC has the opposite effect.   
Assay development and validity 
Under basal conditions, thrombin generation occurs slowly with a small endogenous 
thrombin potential and peak thrombin.  Activation of EAhy cells by TNFα increases 
thrombin generation, almost halving the lag time and doubling the endogenous thrombin 
potential (see Figure 6-3), supporting the presence of an inducible procoagulant response 
by endothelial cells.  There was little difference in thrombin generation over the range of 
doses of TNFα assessed in control studies suggesting that this procoagulant response is 
induced by relatively low concentrations of TNFα.   
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To assess the effect of excess glycosphingolipids and reduced enzyme activity on 
thrombin generation, cells (either normal EAhy or cells treated with CBE 100μM/ shRNA 
targeting GLA) were incubated with 10μM concentrations of lipids for seven days.  Lipids 
that are implicated in each disease were utilised: FD – S1P, Gb3, lysoGb3; GD – S1P, 
GSP and LC as described in 5.4.4 
 
Figure 6-3: Effect of TNFα and cell concentration on thrombin generation. Cells were 
seeded at 20 000 or 10 000 per well and cultured for 7 days.  They were activated with a 
range of concentrations of TNFα for 6 hours and thrombin generation measured. 
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6.4 Results 
6.4.1 Monocytes and tissue factor 
The monocyte tissue factor assays were performed on the same samples as the monocyte 
adhesion assays and the patient characteristics are detailed in Table 5-3.  The mean tissue 
factor expression and activity of the different patient populations is shown in Table 6-1. 
Table 6-1: Monocyte tissue factor expression and activity 
 Control Gaucher Fabry 
No. patients 21 20 29 
TF MFI 68.72 ±41.14 94.18 ±61.68 74.26 ±51.59 
TF activity (arbitrary 
units TF) 
12.70 ±5.38 10.26 ±5.03 12.23 ±6.67 
 
There was no difference in tissue factor expression, as measured by median fluorescent 
intensity, on monocytes between patients with GD, FD or healthy controls (p = 0.25).  
Two patients with GD and one patient with FD had much higher MFI than the others, for 
reasons that are unclear.  The two GD patients are brothers, one of whom presented with 
pancytopenia, splenomegaly and a paraprotein with a past history of avascular necrosis.  
The other brother was diagnosed following the diagnosis in his sibling and does not have 
bone infarcts or a paraprotein; both are receiving ERT.  The main disease manifestations 
in the FD patient relate to renal disease, but two other patients with lower GFRs had tissue 
factor MFI in keeping with those of the rest of the cohort.  All three patients had no history 
of thrombotic events (arterial or venous), a normal coagulation screen and normal D-
dimers; none of these had increased tissue factor procoagulant activity. 
There was no difference in the TF procoagulant activity of monocytes between different 
patient populations (p = 0.31).  There was no correlation between TF procoagulant activity 
and TF expression on monocytes (see Figure 6-4).   
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Figure 6-4: Monocytes and tissue factor. A: surface tissue factor expression. B: tissue 
factor coagulation activity. C: relationship between tissue factor expression and measured 
activity. 
  
211 
 
 
6.4.2 Platelets 
The demographics of the patients recruited for the platelet studies are shown in Table 6-2; 
all patients were receiving ERT.  Both PRP thrombin generation and the prothrombinase 
assay were performed on each sample.  There were no differences in platelet size 
parameters between the patients groups (see Figure 6-5).   
Table 6-2: Patients recruited to platelet studies and platelet parameters (mean ±SD) 
 Control Gaucher Fabry 
No. 8 7 8 
Age (years)  33.0 (22-52) 46.0 (22-63) 42.0 (24-53) 
M:F 4:4 3:4 5:3 
MPV (fl) 9.91 (±0.48) 10.3 (±1.02) 9.67 (±0.79) 
PDW (fl) 10.02 (±0.91) 11.94 (±2.12) 10.30 (±1.65) 
P-LCR (%) 23.66 (±4.10) 27.83 (±8.71) 21.21 (±7.49) 
 
Platelet rich plasma thrombin generation 
The results of PRP thrombin generation are shown in Table 6-3 .  There was no difference 
in thrombin generation parameters between the three patient groups (see Figure 6-6).  The 
lag time was longer in FD patients, which was of borderline significance, possibly due to 
the small sample size, which would suggest initiation of thrombin generation was slightly 
delayed in these patients but without alterations in the total amount of thrombin generated. 
Table 6-3: PRP thrombin generation parameters (mean±SD) 
Parameter Plt (x109/L) Control Gaucher Fabry One-way 
ANOVA p 
value 
Endogenous 
thrombin 
potential (nM) 
150 1395±591 1507±319.1 1727±516 0.41 
 100 1575±560 1247±267.8 1354±541.6 0.87 
Peak thrombin 
(nM) 
150 88.46±36.86 108.5±88.5 119.9±56.1 0.36 
 100 94.96±33.45 84.84±14.33 117.8±77.8 0.47 
Lag time (min) 150 9.23±2.24 8.78±2.71 11.62 ±2.47 0.08 
 100 9.50±2.42 8.56±3.68 12.32±4.0 0.12 
Time to peak 
(min) 
150 18.93±4.16 17.88±4.86 19.12±3.73 0.84 
 100 19.08±4.70 18.19±6.97 20.63±3.35 0.68 
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Prothrombinase activity 
The results of the prothrombinase assay are shown in Table 6-4 and Figure 6-7; as the 
results were not normally distributed the results are expressed as median with the 25-75 
percentile range stated; Mann-Whitney U tests were performed to establish the 
significance of differences between GD/FD groups and controls.  Across all parameters 
and platelet counts, the median prothrombinase activity was higher in FD patients than in 
controls or GD.  There was an increase in the rate of thrombin generation of borderline 
significance at both a platelet count of 100x109/L (p = 0.083) and 50x109/L (p = 0.049).  
The increase in amount of thrombin generated was significant at a platelet count of 
100x109/L (p = 0.01) but not 50x109/L (p = 0.43).  
Table 6-4: Prothrombinase assay results (median and 25-75% percentiles) 
Parameter Platelet count 
(x109/L) 
Control Gaucher Fabry 
Rate of 
thrombin 
generation 
(ΔOD/sec) 
100 1.24 (0.72-1.84) 1.26 (0.87-1.81) 2.27 (1.74-3.24) 
50 0.80 (0.58-0.94) 0.59 (0.45-0.82) 1.04 (0.76-1.68) 
Ratio 100:50 1.88 (1.33-2.27) 2.14 (1.95-2.35) 1.84 (1.54-2.76) 
Maximum 
thrombin 
generated 
(OD) 
100 522.5 (264.3-642.8) 508.0 (357.0-537.0) 690.0 (621.3-801.5) 
50 330.0 (236.3-426.8) 242.0 (172.0-281.0) 373.5 (336-572.0) 
Ratio 100:50 1.39 (1.10-1.80) 1.81 (1.29-2.86) 1.63 (1.10-2.05) 
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Figure 6-5: Platelet parameters of PRP. A: diagram indicating how platelet distribution 
width (PDW) and platelet large cell ratio (P-LCR) are derived. B: mean platelet volume; 
C: PDW; D: platelet LCR. 
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Figure 6-6: Thrombin generation of PRP. Activated with Innovin at platelet counts 
150x109/ml and 100x109/ml. Endogenous thrombin potential (A,B), peak thrombin (C,D), 
lag time (E,F) and time to peak (G,H). 
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Figure 6-7: Platelet prothrombinase activity. Measured at platelet counts of 100x109/ml 
and 50x109/ml. Rate of thrombin generation (A,C) and maximum thrombin generation 
(B,D). Platelet concentration dependence of both rate (E) and maximum thrombin 
generated. 
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6.4.3 Endothelial cell thrombin generation 
Gaucher endothelial model 
To establish whether enzyme deficiency, glycosphingolipid excess or the presence of both 
conditions alters the ability of endothelial cells to support thrombin generation in GD, 
cells were cultured with specific glycosphingolipids (S1P, GSP and LacCer) in the 
presence or absence of CBE.  The results are shown in Table 6-5 and Figure 6-8; due to 
the multiple comparisons performed a Bonferroni correction was applied so that results 
are considered significant if P<0.005.  Addition of glycosphingolipids to untreated EA.hy 
cells did not alter their ability to support thrombin generation.  Lipid loading with 
glucosylsphingosine of cells treated with CBE increased thrombin generation, particularly 
after TNFα activation – increasing the ETP and peak thrombin and the speed of thrombin 
generation.  Sphingosine-1-phosphate loading also had a similar effect on TNFα activated, 
CBE treated cells.  Lipid loading with lactosylceramide of CBE treated cells did not alter 
thrombin generation, except for an increase in peak thrombin after TNFα activation, 
although this increase was less than that seen with GSP or LacCer. 
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Table 6-5: Endothelial cell thrombin generation - Gaucher cell model 
Measured 
parameter 
EAhy 
activation 
Lipid 
addition 
WT CBE P values (t test) 
   Mean ±SD Mean ±SD Lipid vs. 
vehicle 
(WT) 
Lipid vs. 
vehicle 
(CBE) 
CBE vs. 
WT 
ETP (nM) Basal Vehicle 255±50 222.5±38.5 - - 0.42 
  S1P 165±31 214.5±0.5 0.06 0.74 0.06 
  GSP 349±17.5 331.0±11 0.04 0.009 0.20 
  LacC 210.5±53.5 176±83 0.35 0.43 0.58 
 TNFα Vehicle 477.5±9.5 522.5±34.5 - - 0.18 
  S1P 621±12.5 730±46 0.006 0.003 0.06 
  GSP 730±56 699.5±16.5 0.024 0.001 0.41 
  LacC 638.5±67.5 542±26 0.079 0.47 0.10 
Peak 
thrombin 
Basal Vehicle 16.73±2.51 15.45±2.43 - -  
  S1P 11.6±1.81 13.86±0.27 0.05 0.32 0.56 
  GSP 23.62±2.38 26.46±3.48 0.026 0.01 0.10 
  LacC 14.23±3.42 11.03±5.5 0.37 0.27 0.31 
 TNFα Vehicle 32.49±4.46 33.30±1.04 - - 0.44 
  S1P 44.08±4.18 51.30±1.71 0.030 <0.0001 0.77 
  GSP 44.02±5.47 56.82±0.15 0.047 <0.0001 0.05 
  LacC 43.42±2.77 43.52±0.13 0.022 <0.0001 0.95 
Lag time Basal Vehicle 38.5±4.83 36.5±1.83 - - 0.53 
  S1P 44.5±3.17 35.83±0.17 0.15 0.56 0.0091 
  GSP 24.67±2.83 26.33±1.67 0.01 0.002 0.43 
  LacC 43.33±3.33 29.00±2.33 0.23 0.11 0.0036 
 TNFα Vehicle 9.50±0.83 8.00±0.33 - - 0.04 
  S1P 7.67±0.67 6.50±0.17 0.04 0.002 0.04 
  GSP 8.17±0.5 7.67±0.33 0.08 0.29 0.22 
  LacC 7.67±1.67 7.50±0.17 0.16 0.08 0.87 
Time to 
peak 
Basal Vehicle 45.17±4.5 42.67±1.67 - - 0.42 
  S1P 52.17±2.83 43.0±0.67 0.08 0.77 0.006 
  GSP 31.33±2.50 31.83±0.5 0.01 0.0004 0.75 
  LacC 51.0±3.33 35.67±4.0 0.14 0.05 0.007 
 TNFα Vehicle 16.67±1 14.67±0.33 - - 0.03 
  S1P 14.33±0.5 13.0±0.33 0.02 0.003 0.02 
  GSP 15.17±0.5 13.17±0.17 0.08 0.002 0.002 
  LacC 14.0±2.33 13.33±0.33 0.14 0.008 0.65 
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Figure 6-8: Thrombin generation – GD endothelial cell model. Effect of the addition 
of S1P, GSP or LC to EA.hy, either wild-type or treated with 100μM CBE for 7 days. 
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Figure 6-9: Thrombin generation – FD endothelial cell model. Effect of the addition 
of S1P, lysoGb3 or Gb3 to EAhy transfected with shRNA targeting the GLA gene (FD2 
and FD5) or non-targeting control (Scr) for 7 days. 
220 
 
 
Fabry endothelial model 
Endothelial cells containing shRNA either targeting the GLA gene or a scrambled, non-
targeting control were cultured for seven days in the presence/absence of 
glycosphingolipids (S1P, Gb3 and lysoGb3).  Neither decreased GLA activity nor 
glycosphingolipid loading altered the ability of endothelial cells to support thrombin 
generation (see Table 6-6 and Figure 6-9).  Peak thrombin was increased in FD2 cells 
loaded with Gb3 compared to those cultured with methanol vehicle only, but there were 
no differences in other thrombin generation parameters or in the FD5 cells. 
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Table 6-6: Fabry endothelial cell model thrombin generation 
Parame
ter 
EAhy 
activation 
Lipid Scr FD2 FD5 P values     
   mean±SD mean±SD mean±SD Lipid vs. 
veh Scr 
Lipid 
vs. veh 
FD2 
Lipid 
vs. veh 
FD5 
FD2 vs. 
Scr 
FD5 
vs. Scr 
ETP 
(nM) 
Basal Vehicle 292.5±42.1 295.0±23.5 323.5±29.75 - - - 0.93 0.36 
  S1P 360.0±16.8 377.5±15.3 339±43.1 0.06 0.007 0.64 0.25 0.48 
  LysoGb3 279.0±23.4 327.1±63.5 345.5±16.2 0.65 0.46 0.32 0.28 0.02 
  Gb3 330.5±32.1 338.0±16.2 363.5±32.4 0.28 0.06 0.19 0.74 0.28 
 TNFα Vehicle 577.0±89.5 559.0±41.5 640.5±62.1 - - - 0.77 0.37 
  S1P 649.0±30 670.5±85.5 729.0±38.5 0.26 0.11 0.10 0.70 0.05 
  LysoGb3 746±22.5 707.0±27 614.5±42.0 0.03 0.007 0.73 0.13 0.02 
  Gb3 561.0±69.5 688±62.5 696.0±25 0.81 0.04 0.22 0.08 0.03 
Peak 
thrombi
n 
Basal Vehicle 11.97±1.75 10.96±0.39 10.91±1.01 - - - 0.38 0.41 
  S1P 12.20±0.4 11.09±1.63 14.98±3.07 0.83 0.89 0.09 0.32 0.19 
  LysoGb3 13.83±3.96 15.07±3.36 14.63±1.23 0.50 0.10 0.01 0.70 0.76 
  Gb3 10.88±1.59 10.58±1.06 13.32±0.34 0.46 0.59 0.02 0.80 0.06 
 TNFα Vehicle  27.39±0.65 32.90±5.24 - - - 0.93 0.17 
  S1P  37.64±3.61 33.99±0.83 0.001 0.008 0.74 0.68 0.005 
  LysoGb3  42.21±2.63 34.32±1.32 0.044 0.0007 0.67 0.009 0.39 
  Gb3  38.58±1.06 36.24±3.32 0.43 <0.000
1 
0.40 0.31 0.05 
Lag time Basal Vehicle 37.5±6.5 43.17±1.5 34.67±5.24 - - - 0.21 0.59 
  S1P 28.0±4.76 38.67±3.67 29.83±6.5 0.11 0.12 0.37 0.04 0.71 
  LysoGb3 34.33±2.33 39.71±2.33 28.88±3.0 0.47 0.09 0.17 0.05 0.07 
  Gb3 36.5±13.83 42.67±21.67 28.67±2.33 0.92 0.97 0.14 0.70 0.39 
 TNFα Vehicle 9.17±0.83 9.52±0.3 9.86±0.5 - - - 0.52 0.29 
  S1P 8.83±0.83 9.19±0.83 8.37±0.5 0.64 0.55 0.02 0.62 0.46 
  lysoGb3 8.5±1.13 9.36±1 8.19±0.3 0.45 0.80 0.008 0.38 0.67 
  Gb3 9.5±0.5 8.33±0.3 10.17±0.83 0.59 0.08 0.61 0.026 0.30 
Time to 
peak 
Basal Vehicle 31.39±0.65 37.39±1.5 32.23±2.51 - - - 0.003 0.60 
  S1P 33.71±0.23 34.72±4.01 33.22±3.84 0.004 0.34 0.73 0.69 0.84 
  LysoGb3 29.67±3 34.39±0.67 34.39±0.84 0.39 0.03 0.23 0.06 0.06 
  Gb3 31.13±0.83 32.88±2.17 31.39±0.67 0.74 0.04 0.61 0.27 0.74 
 TNFα Vehicle 14.17±0.83 15.70±0.67 15.37±0.67 - - - 0.07 0.12 
  S1P 14.17±1.50 16.87±0.84 14.39±0.33 0.99 0.13 0.09 0.05 0.82 
  LysoGb3 13.80±1.5 16.37±0.3 15.20±0.17 0.73 0.19 0.69 0.04 0.18 
  Gb3 15.17±0.83 16.87±0.84 14.53±0.84 0.21 0.13 0.25 0.06 0.40 
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6.5 Discussion 
6.5.1 Monocyte procoagulant activity 
No differences were found in tissue factor expression or procoagulant activity in patients 
with GD or FD compared to controls.  Tissue factor expression has not previously been 
studied in GD.  Whilst plasma coagulation abnormalities are common at baseline, as 
shown in Chapter 3, they improved markedly following enzyme replacement therapy.  The 
patients studied were all receiving ERT and therefore it may be possible that any 
abnormalities in monocyte procoagulant activity that are present in untreated disease 
respond to ERT.  Increased plasma soluble tissue factor was found in two studies of FD 
patients 88;170 but only in males and was associated with renal failure. 
Assay limitations 
There was no association found between tissue factor expression and monocyte 
procoagulant activity – which may be due to limitations of both the methodological 
approach and the procoagulant assay itself.  Freshly isolated monocytes were used for the 
procoagulant assay, which represent steady-state circulating monocytes.  Membrane tissue 
factor is predominately in an encrypted, inactive form.  Monocyte TF activation is induced 
by pro-inflammatory stimuli278 and therefore the procoagulant activity of circulating 
steady-state monocytes, is likely to be much less than their tissue factor expression would 
suggest.  Further assays could potentially be performed, activating monocytes with 
cytokines to assess if there were differences in TF activation between patient populations 
– although the no difference in surface expression of TF was found. 
The procoagulant activity assay may also be too insensitive to detect differences in 
procoagulant activity of steady-state monocytes.  The assay end point relies on fibrin clot 
formation and although the assay was sensitive to very low concentrations of 
thromboplastin, monocyte support for coagulation is more complex. As well as TF 
expression, monocytes can also support thrombin generation by direct activation of FXa.  
FX binds to the Mac-1 receptor (CD11b/CD18), triggering release of cathespin G which 
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directly activates FX to FXa.  Additionally, monocytes express tissue factor pathway 
inhibitor which binds and inactivates TF. 
6.5.2 Platelet support for thrombin generation 
There were no significant differences in platelet size parameters from which it was 
concluded that a similar amount of platelet phospholipid was available in sample for the 
functional platelet assays.   There was no difference in thrombin generation in PRP 
between the patients group, although there was considerable variation within all groups.  
The prothrombinase assay suggests that the procoagulant response may be increased in 
patients with Fabry disease in the small group of patients assessed.  Gb3 is synthesised by 
megakaryocytes and found in the membrane of platelets279.  Whether platelet membrane 
lipid composition is altered in platelets is not known and warrants further investigation.  
An increase in procoagulant activity should be confirmed on a larger sample size and by 
additional assessment by a tenase activity – assessing the ability of platelets to support 
FXa generation which is also dependent on phosphatidylserine exposure. 
Assay limitations 
The study of platelet function presents a number of challenges.  Platelet function can be 
affected by a wide range of drugs, especially aspirin280; this poses particular problems in 
the study of FD patients, many of whom take aspirin or other cardiovascular medications 
which can affect platelet function.  This limits the patients who can be studied and may 
bias towards more mildly affected patients.  Whilst attempts were made to exclude patients 
taking medications known to affect platelet function, it is possible that food substances or 
over the counter medication may have been taken which would affect platelet function.  
The manual sub-sampling method of the prothrombinase assay also limits the number of 
samples which can be tested on any one occasion. 
6.5.3 Endothelial cell thrombin generation 
Neither decreased GBA nor GLA activity on its own resulted in changes in thrombin 
generation.  Lipid loading of cells treated with CBE to inhibit GBA resulted in increased 
thrombin generation when cells were loaded glucosylsphingosine or sphingosine-1-
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phopshate, but only after endothelial activation of TNFα; no effect was seen with 
lactosylceramide.  Previous studies of the effect of glycosphingolipids on thrombin 
generation are limited.  A single study of platelets found that GSP inhibited platelet 
thrombin generation whilst S1P had no effect, but this study only incubated the platelets 
with the lipids for 5 minutes281.  The fact that thrombin generation is enhanced only in the 
presence of both lipid loading and CBE suggests that impaired lipid degradation is 
required for this effect and that this creates an environment in which the procoagulant 
properties of activated endothelial cells are enhanced.  This could be further investigated 
by investigating different aspects of thrombin generation in isolation (e.g using FXII 
deficient plasma to look at contact activation or an anti-TF antibody to look at the effect 
of tissue factor) to see if increased thrombin generation could be attributed to one part of 
haemostasis. 
Assay limitations 
The general limitations of the endothelial cell model have been discussed in 5.6.4.  Whilst 
EA.hy cells have been used to model thrombin generation and to detect abnormalities in 
contact activation275 and the protein C anticoagulant pathway282, being a hybridoma of 
HUVEC and lung adenocarcinoma they are likely to be difference in the haemostatic 
properties between these cells and the plethora of endothelial cells found in vivo.  In 
particular, further investigation utilising microvascular endothelial cells, likely to be the 
sites of inflammation within GD, may provide more physiologically relevant information. 
6.6 Conclusions 
No differences were found in tissue factor expression or the procoagulant activity of 
monocytes from patients with GD or FD, suggesting that monocyte tissue factor is 
unlikely to be important in vascular disease manifestations in these disorders.  FD but not 
GD is associated with an enhanced procoagulant response on the platelet membrane in the 
small sample studied to date.  This may be of particular importance as many of the vascular 
features of FD are thought to arise in the microvasculature where platelets play an 
important role in coagulation.  The potential contribution of platelets to the disease 
manifestations of FD is not well understood but clinically important.  Should the finding 
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of increased procoagulant response be confirmed in further studies then the next question 
would be whether this is modified by anti-platelet agents and, by implication, whether 
there is evidence to support their use in patients with FD as either primary or secondary 
prophylaxis.   
Increased thrombin generation by Gaucher-like endothelial cells following their activation 
would be consistent with the hypotheses from other studies that coagulation abnormalities 
are due consumptive consequent on chronic activation of coagulation119 and that some 
disease manifestations might be due to microvascular thrombosis183. 
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Chapter 7 Discussion 
This project has established the importance of vascular events in the pathology of both 
GD and FD and undertaken initial laboratory investigations into the potential mechanisms 
underlying these events.  Detailed description of the GD and FD cohorts at the Royal Free 
hospital highlights the complexity and heterogeneity of these disorders.  This chapter sets 
these findings in the broader context of research in the lysosomal storage disorders field, 
discussing new insights into and the pathogenesis of FD and GD and potential future 
investigative directions whilst also discussing the limitations of the methodological 
approach taken. 
7.1 Vascular features in the clinical presentation of FD and GD 
7.1.1 Vascular manifestations are important presenting features of FD and GD 
Within this project, the major vascular manifestations explored were bleeding symptoms 
in GD and, in FD, critical organ events that are believed to have at least in part an 
underlying vascular mechanism, namely stroke, renal disease and cardiac arrhythmias.   
Bleeding symptoms are common in the presentation of GD, being the primary presenting 
feature in 18.6% of patients (27.6% of symptomatic patients) and present in 54% of 
patients overall at baseline, including post-operative bleeding in 8%. Whilst platelet 
counts are reduced, the lack of correlation between platelet count and bleeding severity 
suggests other mechanisms come into play.  The presence of low FXI activity in a 
substantial number of patients at baseline, with significant improvements following ERT 
supports the presence of a disease related impairment of coagulation protein function.   
Whilst it had been hypothesised that bleeding severity in GD would be correlated with 
severity of disease manifestations in other organ systems, this was not the case with the 
methodological approach utilised in this study.  The disease severity scoring system used34 
was the one for which data was universally available for the cohort but this and the 
measures of bone disease (BMB score and presence/absence of infarcts) may not be 
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sensitive enough to detect a relationship between disease manifestations at a cellular/organ 
level in different organs and haemostatic defects. 
Vascular critical organ complications were common at presentation in both male and 
female index cases of FD, with cardiac manifestations being the commonest presenting 
features in both males and females. Stroke as a presenting feature was commoner in 
females than males.  The majority of FD patients were diagnosed following family 
screening.  Amongst males diagnosed in this way, 21% already had cardiac complications 
and 4% had suffered a stroke before diagnosis.  Amongst females, the prevalence of pre-
existing cardiac complications was lower (9%) than in males but the prevalence of stroke 
was similar (3%).  Whilst cerebrovascular disease in men occurred in the presence of other 
critical organ dysfunction in men, this was not the case in females.  In addition to mutation 
type, other cardiovascular risk factors appear important in the development of 
cerebrovascular disease in females.  There were two females with stroke with no risk 
factors and no other FD manifestations.  Whether these patients have some other, as yet 
unidentified, predisposing risk factor to stroke is unknown. 
7.1.2 Improvements in diagnostic pathways are needed to reduce delays between 
symptom onset and diagnosis 
In both GD and FD, index cases experienced substantial delays between symptom onset 
and arrival at the correct diagnosis.  In both disease, the main reason was failure to identify 
an underlying cause for the clinical feature (e.g. thrombocytopenia, neuropathic pain) 
rather than mis-diagnosis. The potential reasons for this are numerous and include: 
1. The wide differential diagnosis of presenting symptoms 
2. The rarity of FD and GD 
3. Lack of physician awareness of FD and GD 
4. Relative physical well-being of many patients at presentation 
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The differential diagnosis of underlying causes of many of the clinical manifestations with 
which patients with GD and FD present is broad; amongst these many causes the incidence 
of GD/FD is rare compared to more common conditions. How rare is unknown.  The true 
incidence of GD and FD is not known.  Newborn screening studies suggest that the true 
incidence of FD may be far higher than previously thought29, particularly for mutations 
associated predominately with disease manifestations in later life. This is supported by the 
data from the RFH cohort where there has been a marked increase in diagnosis of older 
patients with predominately cardiac manifestations in recent years.  Whilst diagnosis of 
GD is predominately fortuitous, usually being suspected following the finding of Gaucher 
cells on bone marrow biopsy, such opportunities for diagnosis are rare in FD where 
biopsies of affected organs are rarely performed.  The presenting features suggest that for 
FD, cardiologists, stroke physicians, dermatologists and paediatricians/paediatric 
neurologists are key physicians amongst whom awareness of FD should be increased.  The 
longest delays in diagnosis, on average of 22.5 years, were amongst FD patients whose 
first symptom was pain, beginning in childhood or adolescence. They present a particular 
diagnostic challenge and more research is needed on how best to improve the diagnosis 
of these patients amongst whom the physical and psychological consequences of delayed 
diagnosis can be substantial283.   
The availability of specific therapy in the form of ERT provides added impetus to reduce 
diagnostic delays in symptomatic patients.  Irreversible complications occur in both GD 
(e.g. avascular necrosis) and FD (e.g. cardiac fibrosis).  There is some evidence to support 
early initiation of therapy in reducing these complications in GD186 but this is not yet 
available in FD. 
7.2 Glycosphingolipids and enzyme defects: different effects in different cells? 
The heterogeneity of clinical manifestations within FD and GD and the marked 
differences in clinical manifestations between two disorders so closely linked on a 
metabolic pathway raise important questions about the roles of glycosphingolipids and 
their degradative enzymes within different cell types and organ systems.  
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Lysosomes are intracellular organelles, ubiquitous in eukaryotic cells. The vast majority 
of studies of cellular function in FD and GD have been performed on either fibroblasts or 
peripheral blood leucocytes and even basic knowledge regarding GLA and GBA 
expression and activity in other human cell types in lacking.  Whilst in type 1 GD 
macrophages are the key cell implicated in disease pathogenesis, the range of cell types 
thought to be important in the pathogenesis of FD is much broader, including podocytes, 
cardiomyocytes and neurons.  Perhaps further investigation of a broader range cell types 
might help answer some of the following unanswered questions in FD and GD, which are 
explored in further detail below: 
Why patients with FD and GD accumulate lipids in different cell types? 
Why do females develop clinical manifestations in FD? 
Why do different mutations cause clinical disease manifestations in different organ 
systems? 
Do the small number of recurrent mutations in FD and GD indicate a founder effect or 
survival advantage? 
7.2.1 Do different glycosphingolipids and their degradative enzymes function 
differently in different cells?  
In GD, the glycosphingolipid which accumulates in macrophages is thought to be derived 
predominately from phagocytosis of senescent erythrocyte membranes.  Globoside is the 
predominant glycosphingolipid in erythrocyte membranes284 and would be degraded by 
GLA before degradation by GBA.  It is therefore surprising that reticulo-endothelial 
manifestations do not occur in FD.  Alpha-N-acetylgalactosaminidase (also known as 
alpha galactosidase B) can remove the terminal α-galactose from Gb3 as well as the 
terminal α-N-acetylgalactosamine from sialoglycopeptides285.  Deficiency of this enzyme 
results in Schindler’s disease, the clinical manifestations of which include angiokeratoma, 
facial coarseness and neurodegeneration; lipid storage in endothelial cells is also reported. 
The first two of these clinical features are shared with FD, but neurodegeneration is not a 
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feature of FD, nor does FD unlike virtually all other LSDs have an infantile onset 
neurodegenerative subtype.  These observations raise the questions of a) whether 
degradation of glycosphingolipids occurs by a single identical pathway in all cell types b) 
whether excess of a particular glycosphingolipid has a different effect on different cell 
types?   
7.2.2 What is potential pathogenic role of the mutant protein? 
Our cohort data is in keeping with previous studies that clearly demonstrate that amongst 
females heterozygous for a GLA mutation, a substantial proportion develop clinical 
manifestations of FD, but equally others live to old age with no evidence of clinical disease. 
This raises the question as to why females develop clinical disease when their enzyme 
activity is normal or only slightly reduced.  Recently, it has been found that GBA mutation 
carriers have an increased risk of Parkinson disease. In both these scenarios there is the 
question as to whether the presence of mutant protein from transcription of the abnormal 
GBA/GLA gene is disease causing or disease predisposing.  Our clinical data from FD 
suggests that in females, age and cardiovascular risk factors may play and important role 
in the development of vascular manifestations. One hypothesis is that a GLA mutation 
predisposes to development of clinical manifestations (e.g. stroke, cardiac hypertrophy, 
and arrhythmia) but that further factors are required for development of overt disease.  
7.2.3 Are different mutations more pathogenic in different organs/ cell types?  
GD has classically been divided into distinct subtypes with type 2 and 3 associated with 
neurodegenerative disease.  Homozygosity for the L444P is associated with type 3 disease 
whilst the presence of at least one N370S mutation is considered protective.  The particular 
molecular significance of mutations at these sites is unknown.  Data from our cohort 
suggests that patients with the N215S mutation could be considered a distinct sub-type of 
FD, predominately presenting with cardiac disease in the later decades of life and having 
higher residual plasma enzyme activity. Why the heart, rather than other organs, is 
predominately affected in these patients is not known. The asparagine at position 215 in 
GLA is glycosylated and it may be that, as a result of alternative splicing mechanisms or 
other post-transcriptional modifications, this glycosylation is more important for structure 
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or activity of GLA in cardiac tissue than in other organ systems.  Little is known about 
the regulation of the gene promoter region or alternative splicing of GBA and GLA in 
different cell types and further exploration of this may help explain why some mutations 
predispose to particular disease manifestations.  The variation in enzyme activity, which 
correlates with disease severity, amongst patients with the N215S mutations points to 
additional factors other than the point mutation affecting enzyme level.  Additionally, the 
fact that a small number of patients with this mutation present with renal disease in the 
absence of cardiac disease, often at a young age, suggests that other variables may affect 
the cellular types in which the effects of the enzyme mutation clinically manifest.  
Understanding the effect of a particular mutation at the molecular level would also be 
particularly beneficial in FD where screening studies for FD have uncovered a high 
prevalence of GLA mutations of uncertain clinical significance48.  
7.2.4 Recurrent mutations: founder effect or survival advantage 
Most mutations within FD are private and occur within a single or small number of 
families. Within our cohort, 29 families, not known to be related, have the N215S mutation. 
This has yet to be reported in other cohorts but raises an important question.  Is this 
recurrence due to a founder effect, as has been proposed for recurrent mutations in GD 
within the Jewish population, or does this mutation confer a survival advantage?  Patients 
with the N215S mutation within our cohort overall have less severe disease than patients 
with other mutations but whether there is any survival advantage to heterozygotes to 
account for its frequency is not known. Cell membrane glycosphingolipids have important 
functional roles within the innate immune system286, with glycosphingolipid-enriched 
microdomains being important for phagocytosis.  Whether alterations in 
glycosphingolipid composition of cell membranes in “milder” mutations such as N215S 
in GLA or N370S in GBA results in improved functioning of the innate immune system 
has not to date been investigated.  
7.3 Abnormalities in blood-endothelial interactions 
Both bleeding events and thrombotic events arise due to abnormalities at the blood-
endothelial interface, caused by either abnormalities in components of the blood, 
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abnormalities in the vessel wall or by more complex alterations in the interactions between 
the two (e.g. blood flow pattern).  The methodological approach taken looked at aspects 
of these processes in isolation and under static conditions. 
7.3.1 Impact of ageing on abnormalities in FD 
Previous studies in FD had found increased levels of soluble adhesion molecules in the 
plasma of FD patients (see Table 1-9) and one study had reported increased expression of 
the adhesion molecule CD11b on the surface of monocytes in male patients152.  We did 
not replicate this finding but did find increased expression of CD11a, ICAM1 and ICAM3 
on monocytes in FD.  Level of expression of these molecules on monocytes was not 
however correlated with functional adhesion of monocytes to tissue culture plastic under 
static conditions, nor were they correlated with disease manifestations.  This may be 
because increased expression does not result in increased adhesion activity under basal 
conditions or because of the limitations of the methodology used.  Functional adhesion 
activity of monocytes was increased in FD with clinically significant correlations between 
adhesion and clinical parameters (disease severity, organ function and age) in females.  
These findings support the clinical data from the cohort where age had a bigger impact on 
organ dysfunction in females than males.  
One hypothesis for further exploration is that in females with FD age is an important 
modifier of disease manifestations.  Autophagy is the key pathway by which intracellular 
macromolecules and organelles are delivered to the lysosome for degradation and there is 
some evidence of autophagy dysfunction in FD73.  Autophagy also becomes impaired as 
differentiated cells age287;288. Although most studied in neurodegenerative diseases, there 
is evidence to support similar processes in other cell types including podocytes289.  
Therefore in females the additive effect of ageing on the presence of mutant GLA may 
result in cellular dysfunction. 
7.3.2 Abnormal lymphocyte adhesion molecule expression in GD 
Although cells of the monocyte-macrophage lineage are thought to be the primary 
abnormal cell in GD, increases in adhesion molecule expression were most marked in 
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lymphocytes.  This is a potentially important finding not only because it support the 
presence of abnormalities in cells other than those of the monocyte-macrophage lineage 
but also, as discussed in 5.6.2, of the potential role of these abnormalities in the 
pathogenesis of bone disease and myeloma. Whilst the efficacy of ERT in improving 
blood counts and decreasing visceral disease volume is well established, whether ERT 
fully ameliorates abnormalities within the bone microenvironment contributing to bone 
disease or increased myeloma risk is not established.  
No increases in functional monocyte adhesion were seen in GD and increases in monocyte 
adhesion molecule expression were modest compared to those seen in lymphocytes.  The 
finding of increased adhesion of RAW.274 murine monocytes loaded with 
glucosylsphingosine and lactosylceramide to EA.hy926 cells suggests that the findings in 
monocytes isolated from patients may be due to treatment effect.  Further investigation of 
monocytes from untreated patients is warranted, although the small number of patients 
available for such a study may limit sample size. 
7.3.3 Procoagulant defects in FD and GD require further investigation 
Initial investigations of the platelet membrane procoagulant response in this project 
suggest that the rate of thrombin generation on the platelet membrane is increased in FD.  
Platelets in FD remain under-investigated; confirmation a procoagulant platelet defect 
would be highly significant both in terms of furthering understanding of the pathogenesis 
of FD but more importantly in the potential therapeutic benefit of anti-platelet agents. 
Endothelial support for thrombin generation was increased in endothelial cells treated with 
CBE. Whilst at initial glance this may seem discordant with the bleeding phenotype noted 
in GD, deficiencies of anticoagulant proteins have been found in patients with GD (see 
Table 1-11) and implicated in the pathogenesis of bone infarcts. As activation of the 
protein C pathway occurs on the endothelial surface, defects in which would increase 
thrombin generation, this finding warrants further investigation in primary endothelial cell 
isolates from GD patients. 
234 
 
 
7.4 Study limitations 
7.4.1 Difficulties in studying rare inherited disorders 
Research into rare inherited disorders presents several difficulties, a number of which 
were encountered during the course of this project.  Although the patient cohorts at RFH 
are relatively large for FD and GD, they are still small, particularly when one considers 
the marked heterogeneity, especially within FD. Only small numbers of new patients are 
diagnosed each year and therefore, inevitably, virtually all laboratory investigations were 
performed in patients already receiving enzyme replacement therapy.  Collaborative 
studies between centres might increase availability of samples on newly diagnosed, 
untreated patients but the effects of transport time on some of the cell types studied, 
especially platelets are likely to be deleterious.  
7.4.2 Difficulties in undertaking mechanistic studies in FD and GD 
Attempting to recapitulate GD/FD within the laboratory environment is challenging.  
Whilst naturally occurring animal models exist for a number of LSDs, GD and FD are not 
amongst these.  Whilst murine models provide valuable insights into disease mechanisms, 
particularly at an organ level, the lack of disease features in the presence of storage 
material in some models raises questions about the comparability of glycosphingolipid 
and lysosomal biology in mice and humans. 
Whilst pharmacological inhibition and siRNA silencing can be used to develop disease 
models, they do not allow the effect to the presence of the mutant protein to be investigated. 
Additionally we do not currently know the normal GLA and GBA enzyme activity in 
different cell types and therefore it is difficult to establish the degree of reduction in 
enzyme activity needed to resemble that found in patients. Advances in cell culture 
techniques, particularly the ability to de-differentiate cells (e.g. fibroblasts) to pluripotent 
stem cells and then differentiate them to a wide variety of cell types, may open the door 
to more research on primary cell isolates.  Improved techniques in the isolation of 
endothelial progenitor cells from peripheral blood and podocytes from urine may provide 
an easier route for investigation of these cell types.  
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7.4.3 Laboratory investigation of blood-endothelial interactions 
Endothelial cells line all blood vessels and lymphatics and, in adult humans, number over 
one trillion, covering a surface area of greater than 3000 square metres290.  In addition to 
leucocyte adhesion and haemostasis, the endothelium fulfils many other roles including 
regulation of vascular tone and transfer of molecules across from plasma into surrounding 
tissues.  Endothelial cells adapt to their microenvironment such that the phenotype of cells 
varies between the microvasculature and large vessels.  Reducing this diversity to the level 
of a petri-dish comes with obvious limitations.  The cell line used in this study is of venous 
macrovascular origin (human umbilical vein) whereas many of the disease manifestations 
of FD and GD are more likely to be microvascular in origin, where obtaining cells is more 
challenging. 
In their in vivo state interactions between blood components and the endothelium occur in 
the presence of whole blood which is under a variable rate of flow depending on the 
anatomical site but is never static.  Whilst the methodological approach of investigating 
components of blood in isolation (e.g. platelets, monocytes) allows more specific study of 
those cells, it over-simplifies what is a highly complex in vivo physiological system. 
7.5 Further research avenues 
7.5.1 Disease heterogeneity and modifiers 
This thesis has better defined the vascular manifestations of GD and FD and their 
importance in the diagnosis of these disorders.  It has also highlighted the vast 
heterogeneity within both disorders, particularly FD. The wide range of GLA activity seen 
in male patients with the N215S mutation suggests that there are other factors either within 
the gene (e.g. polymorphisms) or affecting levels of gene expression which contribute 
overall enzyme activity.  The availability of high throughput genetic sequencing 
technologies facilitates the simultaneous investigation of a number of genes.  As well as 
full sequencing of the GLA gene, evaluation of other genes which may contribute to 
vascular disease, in particular the LPA gene, which accounts for >90% of the differences 
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seen in plasma lipoprotein (a) levels227 may be a potentially fruitful investigation as 
increased Lp(a) appeared to be a risk factor for cerebrovascular disease in FD patients. 
Greater evaluation of potential acquired disease modifiers (e.g. hypertension, obesity) is 
required in FD, ideally as a collaborative study with other centres.  Many females within 
the cohort were asymptomatic and diagnosed on family screening, but some had severe 
disease manifestations (e.g. stroke, cardiac arrhythmia). If the policy of family screening 
of females continues to be pursued then this must be coupled by concerted efforts to 
improve prognostic predictions and identify measures which might reduce risk of 
developing disease complications. 
7.5.2 Blood-endothelial interactions using primary cell models 
The limitations of the endothelial cell model and static adhesion have already been 
discussed.  Further investigations are required to confirm/ refute the preliminary findings 
from this thesis.  Ideally this would involve isolation of blood outgrowth endothelial cells 
from patients and measurement of adhesion of primary leucocytes (both lymphocytes and 
monocytes) to these endothelial cells under flow conditions.  Further investigation of 
thrombin generation could also be performed using primary cell isolates from patients 
with GD.   
Oxidative stress has been implicated in the pathogenesis of both FD64;89 and GD291;292.  
This has been more widely studied in FD than in GD and dysfunction of endothelial nitric 
oxide synthase, secondary to Gb3 accumulation, resulting in decreased nitric oxide 
availability has been proposed as the mechanism.  Measurement of eNOS activity and the 
end products of increased oxidative stress (e.g. lipid peroxidation) in FD and GD 
endothelial cells could provide a link between adhesion, coagulation and disease 
manifestations. Oxidative stress results in the up-regulation of a number of cellular 
adhesion molecules, particularly integrins and ICAM-1293. 
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7.5.3 Further exploration of platelet function and membrane composition 
Establishing whether platelets are procoagulant in FD is clinically important and warrants 
further investigation.  Platelet studies need to be performed on a larger sample size.  The 
current rate limiting step is the need for frequent manual subsampling during the 
prothrombinase assay.  Should the findings be replicated in a larger group of FD patients 
not receiving anti-platelet agents, then study of those patients taking anti-platelet agents 
would be important to see if anti-platelet agents reduce this effect.  
7.6 Conclusions 
This project has confirmed that vascular manifestations are an important part of the 
pathology of both GD and FD but are heterogeneous in their clinical manifestations.  Non-
disease related factors, including ageing and more conventional cardiac risk factors, are 
important contributors to this heterogeneity in FD females.  The mechanisms underlying 
these disease processes remain poorly understood.  Preliminary results from this project 
demonstrate abnormal expression of certain adhesion molecules in leucocyte subsets and 
further investigation using primary cells and more physiological flow systems is 
warranted. Understanding the mechanisms underlying vascular disease is of great clinical 
import as it may open up new therapeutic avenues.  This is particularly important in FD 
where the efficacy of ERT in preventing critical organ complications remains to be 
established.   
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Patient Information Leaflet 
Laboratory Investigation into changes in the coagulation system seen in patients 
with Gaucher disease and Anderson Fabry disease 
- Participant Information 
You are being invited to contribute to a clinical research study being co-ordinated by the 
Lysosomal Storage Disorders Unit and the Haemophilia Centre at the Royal Free 
Hospital. Please take time to read the following information carefully and take time to 
decide whether or not you wish to take part.  Please do not hesitate ask us if there is 
anything that is not clear or if you would like more information. 
 What is blood coagulation? 
Blood coagulation is a complex process by which blood forms clots, necessary to 
prevent excessive blood loss after injury. The bleeding and thrombotic disorders are due 
to under or over active coagulation factors and platelets. 
What is the purpose of this Study?   
The aim of this study is to investigate problems with bleeding or blood clotting in 
patients with Fabry and Gaucher Disease. It is known that patients with Gaucher disease 
may have a tendency to bleeding.  Conversely, patients with Fabry disease may have a 
tendency towards clotting, such as strokes. In both disorders, the extent of bleeding and 
clinical problems and the factors that contribute to these remain unclear. 
This study is in the form of: 
a) A questionnaire about bleeding problems and clotting problems you may have 
had and also asks about some factors which may be associated with blood clots 
in the general adult population 
b) Taking a blood sample for further tests to look at the proteins and platelets 
involved in the process of forming a blood clot and white blood cells that can 
activate clotting processes.  This will include looking for changes in the DNA of 
two proteins involved in the clotting process that can affect how well they 
function. 
Why have I been chosen?   
You have been invited to participate in this study because you have Gauchers disease or 
Fabry’s disease. You may or may not be on treatment for these disorders.  
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Do I have to take part?   
It is up to you to decide whether or not to take part.  If you decide to take part, you will 
be given this information sheet to keep and be asked to sign a consent form.  If you 
decide to take part, and if, at a later date you wish to withdraw, you are still free to do so 
anytime and without giving a reason.  This will not affect the care you receive. 
What will happen to me if I take part?   
If you do agree to take part, we do not anticipate any extra hospital visits .This study will 
NOT influence the care and the standard of treatment you receive.  If you agree to 
participate a member of the medical or nursing staff will go through the questionnaire 
with you when you next visit.  Two tablespoonfuls of extra blood will be taken when 
blood samples are being taken for your routine investigations or 
treatment.  Occasionally, it make not be possible to get an adequate blood sample on the 
first visit. If this is the case, we would invite you for a repeat blood test when you next 
attend an appointment. 
As a part of the research, we may also need to review your medical notes to correlate 
your medical condition with the laboratory test results. The notes will be only be 
reviewed by members of the Lysosomal Storage Disorders Unit.  
What will happen to the leftover samples?  
If there is any leftover blood samples, if agreeable to yourself, they will be transferred to 
the Katharine Dormandy Coagulation Research Plasma bank after completion of this 
study. This bank stores plasma samples from patients with a wide variety of possible 
bleeding or clotting disorders to enable future research in this area. Otherwise, samples 
will be destroyed at the end of the study. 
What are the possible benefits of taking part? 
We cannot promise the study will help you, but the information we get might help 
advance the treatment of people with coagulation abnormalities due to lysosomal storage 
disorders. Low levels of a clotting protein called Factor XI have been identified in some 
patients with Gaucher and can be associated with an increased risk of bleeding. Should 
this be detected, you will be offered an appointment at the Haemophilia Centre at the 
Royal Free for review by a clotting specialist. 
Who has reviewed the study? 
This research programme has been reviewed by the Research Ethics Committee. 
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Will my taking part in this study be kept confidential?   
All information which is collected about you during the course of the research will be 
kept strictly confidential.  If you consent to take part in the research, your data will be 
handled in a manner in accordance with the Data Protection Act 1998 and the rights you 
have under this act. The results will be published in various journals and international 
meetings in a way that you will not be identified.  
Representatives of regulatory authorities, research and development team at the Royal 
Free Hampstead NHS Trust or ethics committee will be allowed to see your medical 
notes as required to ensure the research is being properly conducted and that the data 
collected is accurate. Your privacy will be respected at all times.   
What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation in 
this study.  If you are harmed by taking part in the study there is no special 
compensation arrangement.  If you are harmed due to someone's negligence then you 
may have grounds for legal action, but you may have to pay your legal cost. Regardless 
of this, if you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this consent process, the 
normal National Health Service Complaints mechanism is available to you. If you have 
any concerns regarding the care you have received or as an initial point of contact if you 
have a complaint, please contact the Patient Advice and Liaison Service (PALS) at the 
address given below;  
PALS office: 020 7830 2174 , rfh.pals@nhs.net 
PALS, Royal Free Hospital, Pond Street, London, NW3 2QG  
Contact for further information?  
If you require any further information please do not hesitate to contact the Lysosomal 
Storage Disorders team on 0207 472 6409 Monday to Friday from 0900hrs to 1700hrs.  
Thank you for your patience in reading this leaflet. 
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Appendix 2 Solutions & Buffers 
General solutions 
Solutions used for tissue culture were autoclaved prior to use. 
TBE buffer 
Constituents: 1.1M Tris, 900mM borate, 25mM EDTA, pH 8.3 
A 5X stock solution was made by dissolving 54g of Tris base, 27.5g of boric acid and 4.7g 
of disodium EDTA in 1L of distilled water.  Stored at room temperature. 
Solutions for enzyme assays 
Red Cell lysis solution: 
To make 1L of x10 stock solution: 82.9g ammonium chloride (NH4Cl), 10g KHCO3, 
380mg EDTA (disodium), distilled water.  Stored at room temperature.  1:10 dilution to 
make x1 solution. 
4-methylumbelliferone standard 
A 1mM stock solution of 4-methylumbelliferone standard was made by dissolving 176mg 
of 4 methylumbelliferone (Sigma) in 1L of distilled water.  A working solution of standard 
was made by diluting 100μl of stock solution in 19.9ml of distilled water to give a working 
standard concentration of 1nM per 200μl. Stock and working solution stored at -20°C. 
Mcilvaine’s buffer 
Mcilvaine’s buffer comprises a mixture of 0.1M sodium citrate solution and 0.2 disodium 
phosphate solution with the quantities of each determined by the required pH. To make 
20ml of buffer the following volumes were added: 
pH 0.2M NaHPO4 0.1M citrate 
4.4 8.82 11.18 
4.7 9.6 10.4 
5.1 12.2 7.8 
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Glycine stopping buffer: 
1M glycine, pH 10.4.   
75g glycine and 58g sodium chloride dissolved in 1L of distilled water.  To 557ml of 
glycine-NaCl solution add 443ml of 1M sodium hydroxide.  The resultant solution in 1M 
glycine at pH 10.4. 
Solutions for Western blotting 
Whole cell lysis solution: 
Constituents: 20mM HEPES, 50mM NaCl, 2% nonyl phenoxypolyethoxylethanol (NP40), 
0.5% sodium deoxycholate, 0.2% sodium dodecyl sulphate (SDS), 1mM sodium 
orthovanadate, 1mM EGTA, 10mM sodium fluoride, 2.5mM sodium pyrophosphate, 
1mM β glycerophosphate. 
100mM sodium orthovanadate: dissolve 18.4g of sodium orthovanadate in 950ml of water.  
Adjust pH to 10.0 with concentrated hydrochloric acid.  Boil yellow solution until 
colourless, adjusting pH until there is a colourless solution with a pH of 10.0.  Make total 
volume up to 1 litre with water.  Aliquoted and stored at -20C. 
To make 500ml whole cell lysis solution, add together: 2.4g HEPES, 1.5g NaCl, 10g NP40, 
2.5g Na dooxycholate, 1g SDS, 5ml 100mM Na orthovanadate, 190mg EGTA, 210mg Na 
fluoride, 558mg Na pyrophosphate, 108mg β glycerophosphate and make up to 500ml in 
distilled water. Aliquoted and stored at -20°C. 
20X Transfer buffer 
Constituents: 500mM Bicine (Sigma), 500mM Bis Tris (Sigma), 20.5mM EDTA (BDH) 
To make 1L, 81.6g Bicine, 104.6g Bis Tris and 6g EDTA were dissolved in distilled water 
and the volume made up to 1L.  The solution was stored at 4°C. 
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TBS-Tween 
20x stock TBS solution: 20mM Tris, 137mM sodium chloride, pH 7.4-7.8.  To make 1L, 
48.4g  of Tris (Sigma) and 160g  of sodium chloride (BDH) were dissolved in 1L of 
distilled water and the pH adjusted to 7.4-7.8 with hydrochloric acid. Stored at 4°C 
1XTBS-Tween solution made by adding 2g of Tween 20 (Sigma) and 50ml of 20X TBS 
stock and making up to 1L in distilled water. The solution was stored at 4°C 
Blocking solution 
5% polyvinylpyrolidine in TBS-Tween.  25g of polyvinylpyrolidine (Sigma) was added 
to 500ml TBS-Tween and dissolved overnight using a magnetic stirrer. The solution was 
stored at 4°C 
Solutions for coagulation assays 
TrisHCl-NaCl buffer 
Constituents: 0.05M Tris-hydrochloride and 0.15M sodium chloride, pH 7.4 
7.88g of Tris-HCl (Sigma) and 8.76g NaCl (BDH) were added to 950ml of distilled water.  
The pH was adjusted to 7.4 with sodium hydroxide.  The volume was made up to 1L with 
distilled water.  The solution was stored at 4°C. 
To make Tris-HCl-1%BSA buffer, 200mg of bovine serum albumin was added to 20ml 
of Tris-HCl and dissolved with gentle agitation.  The solution was stored at 4°C and 
discarded after 2 weeks. 
HEPES buffer for PRP thrombin generation 
Constituents: 20mM HEPES, 6% bovine serum albumin, pH 7.35 
476mg of HEPES and 6g of bovine serum albumin were dissolved in 100ml of distilled 
water. The solution was aliquoted and stored at -80°C. 
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Krebs Ringer buffer 
Constituents: 4mM potassium chloride, 107mM sodium chloride, 20mM sodium 
bicarbonate, 2mM sodium sulphate, pH 5.0. 
To make 1L: 298mg KCl, 6.25g NaCl, 1.68g NaHCO3 and 284mg NaSO4 were dissolved 
in 950ml of distilled water.  The pH was adjusted to 5.0 with hydrochloric acid and the 
volume made up to 1L with distilled water.  The solution was stored at 4°C. 
Krebs Ringer buffer 0.9g/L glucose, pH 6.0.  500ml of Krebs Ringer buffer was 
supplemented with 450mg of glucose (Sigma) and the pH adjusted to 6.0.  The solution 
was stored at 4°C and discarded after 1 month. 
Stopping buffer for prothrombinase assay 
Constituents: 0.05M Tris-HCl, 0.12M sodium chloride, 2mM EDTA, pH 7.5 
To make 1L, 7.88g of Tris-HCl, 7.008g of NaCl and 2.33g of EDTA were dissolved in a 
final volume of 1L distilled water.  The solution was stored at 4°C. 
High salt wash buffer for VWF ELISA 
1L of 10X stock solution was made by dissolving 3.9g sodium dihydrogen orthophosphate 
dehydrate, 26.8g disodium hydrogen orthophosphate 12 hydrate and 282.2g of sodium 
chloride in 800ml of distilled water.  The volume was made up to a total of 1L with 
distilled water.  The stock solution was stored at room temperature. 
Working strength wash buffer was made by adding 100ml of 10X stock and 2ml of Tween 
20 to 900ml of distilled water.  The working solution was stored at 4°C for 1 month 
ELISA coating buffer 
500ml of coating buffer was made by dissolving 790mg of sodium carbonate and 1.47g 
of sodium hydrogen carbonate in distilled water. The pH of the resultant solution should 
be pH9.6 and the solution was re-made if outside the range of pH 9.4-9.8.  The solution 
was stored at 4°C 
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ELISA dilution buffer 
Dilution buffer was made by adding 3% polyethylene glycol (PEG) to working strength 
wash buffer.  15g of PEG 8000 was added to 500ml of wash buffer.  The solution was 
stored at 4°C. 
ELISA substrate buffer 
500ml of substrate buffer was made by dissolving 3.65g of citric acid and 11.94g of 
disodium hydrogen orthophosphate.12 hydrate in 500ml of distilled water.  The resultant 
solution should be pH 5.0.  The solution was stored at 4°C. 
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